



MAKING ALL THE DIFFERENCE

REPORT
2009
including over 250 company
profiles and contact addresses

See you in Munich

November 15-17, 2010



BIO-EUROPE
16TH ANNUAL INTERNATIONAL
PARTNERING CONFERENCE
2010

www.ebdgroup.com/bioeurope

► *more information on page 24-25*



www.biotech-bavaria.de



Biotechnology in Bavaria 2009

Imprint

Editorial staff: Petra Burgstaller, Christina Enke-Stolle,
Georg Käab, Bianca Reuter

Data collection: Petra Burgstaller, Sabine Jordan
Company Profiles: Ivonne Wagner, Lina Paulenz

Layout-Design: aimcom, Munich, www.aimcom.de
Illustration: Birgitta von Glass

Contact

Prof. Dr. Horst Domdey, Managing Director
Spokesman of the Bavarian Biotechnology Cluster
Nicola Schumacher and Mathias Lamparter,
Cluster Manager

The Bavarian and the Munich Biotechnology Cluster
are managed by:

Bio^M Biotech Cluster Development GmbH
Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0)89-89 96 79-0
Fax: +49 (0)89-89 96 79-79
E-Mail: info@bio-m.org
Internet: www.biotech-bavaria.de



The layout, graphics and other contents of this brochure
of the Bavarian Biotechnology Cluster are protected by
copyright law.

Content

Preface	06-07
■ Prof. Dr. Horst Domdey – Spokesman, Bavarian Biotechnology Cluster	
Biotechnology in Bavaria in 2009 – Making all the Difference	09
The Companies in the Bavarian Biotechnology Cluster	10-11
■ Current Status	
Employment	12
■ Jobs in Biotechnology Companies	
The Bavarian Biotech SMEs	13
■ More about Employment	
Products and Pipeline	14-15
■ Drug Development	
Deals, Cooperations, Mergers, Financing	17-19
■ Big Deals and Cooperations 17	
■ M&A Activities 18	
■ Financing 18	
■ Revenues 19	
Two Bavarian Awardees in Germany's "Top Cluster Contest"	21-23
BIO-Europe in Munich in November	24-25
Company Profiles	27-105
in alphabetical order	

About this survey:

For the following report, a biotechnology company has been defined as a company, which develops and/or manufactures products on the basis of state-of-the-art molecular biological methods. But as "conventional" pharmaceutical companies are increasingly also using such methods, it is often difficult to differentiate between biotech and pharma. Traditional phytopharmaceutical companies and manufacturers of homeopathic products are however not included in this compilation. We distinguished the parameters specific to each sector and conducted separate surveys for biotech companies, pharmaceutical companies, contract research organizations (CROs), contract manufacturing organizations (CMOs), suppliers and others with activities in the biotechnology sector. In the case of the biotech companies, a distinction was once again made between small and medium-sized companies (SME) having their headquarters in Bavaria, and branch offices and subsidiaries of national and international biotech companies (biotechnology companies, non-SMEs). The term "non-SME" therefore does not say anything about the actual size of this branch office.

The data forming the basis of this report are based on the evaluation of a written survey carried out by BioM Biotech Cluster Development GmbH at the beginning of 2010 of approx. 342 Life Science companies throughout Bavaria. Based on the questionnaires returned and intensive followup telephone calls it was possible to achieve a response rate of almost 77%. Possible deviations from previously published figures are the result of additional data obtained in this survey that also may refer to previous years. The period under review for this report is the year 2009.

published in April 2010



Dear Reader,

PROF. DR.
HORST DOMDEY
Spokesman, Bavarian
Biotechnology Cluster



A well known phenomenon of the European Soccer Champions League is that you can be a winner although you have just lost a match. Especially the fans of Germany's most renowned soccer club Bayern München have become very familiar with this experience. This experience is also true for championships in general: Becoming the number one does not mean that you have to win each single match; you might (and will) loose a number of matches which usually happens when you meet your most feared opponent.

A similar situation can be observed when you take a view on the development of the Bavarian Biotech Industry in the year 2009. The bottom line is: Biotech in Bavaria is a winner again. Even in a year as difficult as 2009, the Bavarian biotechnology industry has been able to keep its positive momentum which it had gained in the years before. I have to admit that I was afraid, for example, that the number of employees might have dropped considerably over the past months. We indeed could see some of these "adjustments" which obviously had to be made in some companies, however, the singularly observed losses could be completely compensated by other companies which were even forced to increase their personnel in the past months.

On the other hand, 2009 has not been the year to solve all those problems that have accompanied our biotech industry already in the years before. One of these is the dramatic downturn of the creation and set-up of new companies which aim at the research and development of new drugs. I assume that this decline is directly connected to the high intelligence of those who indeed have new and innovative ideas and concepts in this field but have at the same time realized that the market is currently not providing any capital for these – eventually very expensive – developments. Whereas the venture capital industry has stayed firm with their portfolio companies, it did more or less not invest in new start-ups. The gap between seed and early stage financing is wider than ever.

With a new concept that has been developed within the scope of Munich's new "Spitzencluster" strategy, biotech in Bavaria might, however, have a real chance to overcome this problem (see pages 21-23). The Bavarian Ministry of Economic Affairs, a constant and loyal supporter of our local biotech industry, has committed itself within the Spitzencluster concept to foster wise and meaningful business concepts in the field of drug development; they have, however, to be leading edge. This kind of support is absolutely needed because the process to turn an invention into an innovation is the most difficult one and it is at the same time – unfortunately – the least funded one. What we then need is a stronger and sustainable (seed-) financing of the drug development start-ups to bridge the gap between seed and early stage.

In the past years Bavaria has recognized the huge potential in the field of industrial biotechnology and has set up a specific program to support new upcoming ideas in this area. I am very positive that with Bavaria's strong commitment in the field of drug development we will be able to feed our drug pipeline also in the coming years and continue to be a winner in this field – again and again.



Biotechnology in Bavaria in 2009 – Making all the Difference

2009 started as 2008 had ended: the financial and world economic crisis was still the main topic in business, politics and the public. The year seemed not to be easy for the biotechnology sector, an highly selective “Darwinian” year was proclaimed by some experts. But the wave of redundancies and/or bankruptcies still feared by many at the beginning of 2009 has mercifully not materialised, and yet German biotechnology in particular managed to get through this difficult year relatively unhurt. True, financing from outside, which is so important to a sector still deeply involved in hightech product development in the health sector, has definitely taken a dive, and the long, dry stretch in investment cash put even many familiar names to the US-Biotech graveyard. Only since late summer 2009 a turn around – starting mainly in the U.S. – in share prices developed as a bet on a better future to come.

Fortunately the Bavarian companies have been able to stabilise themselves in troubled water and to produce quite some positive news, for example, the increase in capital achieved by Micromet AG in Munich (€ 56 million) or 4SC AG in Martinsried (€ 30 million) and Wilex AG, from Munich, which set itself up for the next development phases with around € 10 million. Nationwide only the “Alzheimer’s company”, ProBioDrug, in Halle (Saxony-Anhalt) made a similar financing and successfully raised € 36 million.

It has become a lot more difficult, however, for biotechnology companies to land really big deals with Big Pharma. After a number of mergers and takeovers worth billions, the pharmaceutical industry seems to be very much preoccupied with itself at the moment and definitely needs to consider very carefully where the money is going to come from for the investments it intends or can afford to make, in innovative, promising partnerships that will only yield returns in the long term. The imponderables of the reform of the US health system are a further reason for expecting the pharmaceutical industry to be even more cautious this year.

It is obvious on the other hand that the pharmaceutical industry is on the road for the biologics future now reorganising its R&D structure and creating more partnerships in which the biotech companies are becoming the early-stage research arms of the multinationals, as Marc Cluzel, senior vice president R&D of Sanofi-aventis stated: “Tomorrow’s research will be carried out through networks”.

Beside direct financing the ability to cooperate becomes the main theme for Biotech companies, also in Bavaria. Thus it is pleasing to see that our companies focus on their business models and reduce their cash burn rate by strengthening their product portfolios. Straight focus for quality in their assets is the key lesson the companies had to learn during the financial crisis. When hopefully the emerging good news at the end of 2009 and beginning of 2010 will continue, the Bavarian Biotech industry has shown how to survive the Darwinian struggle – and what nice and very special fruits can be found there by investors or industry partners.

The Companies in the Bavarian Biotechnology Cluster

Current Status

Below, we present the current results of the company survey for the Bavarian Biotechnology industry in 2009. We take a look back to the turbulent times, when the global crisis peaked within the first half of 2009 and only slowly recovered in the year's last months.

Biotech SMEs and non-SMEs:


In 2009, there were 165 active biotech SMEs in Bavaria. In addition to the SMEs, there are 31 branch offices and subsidiaries of national and international biotechnology companies. The term "non-SME" therefore does not say anything about the actual size of the branch office; it varies from less than ten employees to several thousand employees (non-SME biotech, see page 5 for definitions). An example for the latter is Roche Diagnostics in Penzberg south of Munich.

119 SMEs and 22 non-SME biotech companies are located in the Greater Munich Area.

Regensburg has the second-largest cluster of companies in Bavaria, with 23 biotech companies (SMEs and non-SMEs) and additionally some 17 companies working in MedTech, biomaterials and other fields like industrial biotechnology. In the whole of Bavaria there were 4 newly established companies in total and 4 close-downs or mergers. For the last few years, the majority of the newly established companies is offering services in order to earn money right from the start. For early business ideas irrefutably requiring

seed financing, because no other revenue can be generated, the situation is still difficult even in Bavaria. The chart shows the distribution of specialisations, i. e. the fields of business, on which individual SMEs have decided to concentrate. The two main fields of the business in which Bavarian biotechnology companies are active are: therapeutics / diagnostics and manufacturing of devices and reagents. More detailed descriptions of the profiles of these and all the other Bavarian Life Science companies can be found in the extensive Appendix (s. pages 27-105).

BIOTECH/PHARMA COMPANIES IN BAVARIA




CROs and Pharma:

The number of contract research organisations (CROs, 60 in 2008), and pharmaceutical companies (Pharma, 35 in 2008) has not changed compared to 2008.

CMOs, Suppliers, others:

Suppliers like contract manufacturing organisations (CMOs) play a significant role for the biotech industry and were therefore included in this survey. Thirty of them are located in Bavaria.

BAVARIAN BIOTECH SMES IN 2009



COMPANY FOUNDATIONS

COMPANY	CATEGORY	ORIGIN
Genewake GmbH	Therapeutics & Diagnostics	n.d.
Lisando GmbH	Agriculture, Food, Environment	n.d.
Prosalix GmbH	Therapeutics & Diagnostics	n.d.
XL-Protein GmbH	Therapeutics & Diagnostics	TU München

Employment

Jobs in biotechnology companies

Compared to last year, the number of employees in all biotechnology companies has increased by 340 to about 9.300 (+ 3.9%). Bavarian biotech SMEs alone currently employ 3.420 people (previous year: 3210; +6.5%) of which around 2740 work in the greater Munich area. Since 2006, the number of employees in SMEs has increased by 20%. At the end of 2009, there were 869 people employed in the biotech sector in the Regensburg region (2008: 1040).


In addition to the 3.420 employees in the small and medium-sized biotechnology companies there are more than 5.900 people working in the branches and subsidiaries of international biotechnology companies; nearly 4.500 alone are working for Roche in Penzberg. Since 2006, the number of employees has increased by 14%.

In addition, there are a good 9.600 employees working for national and international pharmaceutical companies. Apart from this, a not inconsiderable percentage of local life science jobs are offered by CROs. Approximately another 2.000 people are employed in this sector. Compared to last year the number of employees has increased by 5%.

When we look at the group of suppliers, production plants and other service companies in the life science sector, the number of employees did not change significantly and sums up to about 1.900.

The total number of employees in the Bavarian Life Science industry in 2009 amounts to 22.800. However, this number does not include employees from specialised consulting firms, finance, patent, marketing and communications companies, which also play an important role in the Bavarian life science landscape.

NUMBER OF EMPLOYEES IN THE BAVARIAN BIOTECH CLUSTER




The Bavarian Biotech SMEs

More about Employment


Looking at the Biotech SMEs in Bavaria, the majority of employees work for companies which focus on the development and marketing of therapeutic and diagnostic products. More than 50% of all employees are working for these companies. In addition, another 768 people work for companies which produce reagents and devices for the Life Science industry.

The Bavarian Biotech industry, which started with a few innovative companies in the early nineties, today represents a dynamic "Centre of Innovation" with more than 30 newly established companies only since 2006. The majority of companies is still very young. 58% of them employ between 1-10 persons (2008: 61%); and 29% employ in the range of 11-50 persons (2008: 27%), thus showing an – although small – positive maturation trend.


DEVELOPMENT OF STAFF NUMBERS IN BIOTECH COMPANIES



SIZE OF BIOTECH SMES BY NUMBER OF EMPLOYEES IN 2009



NUMBER OF EMPLOYEES IN THE BIOTECH SMES IN BAVARIA (2009)



Products and Pipeline

Drug development


Bavaria still goes strong in accelerating the development and commercialization of therapeutics and diagnostics – remaining in the top position in Germany as just recently published in the survey "Biotechnology in Germany 2010" by Biocom/biotechnologie.de.

During the last year, two drug candidates developed by Bavarian SMEs gained marketing approval, one being an entirely novel class of therapeutics. In addition, a number of companies successfully moved their clinical candidates forward on the drug development pipeline.

In April 2009, TRION Pharma GmbH announced that the European Commission had approved its trifunctional antibody Removab® for the intraperitoneal treatment of malignant ascites in patients with EpCAM-positive carcinomas. Removab® is the first approved treatment for malignant ascites worldwide, the first approved bispecific, trifunctional antibody, and the first approved therapeutic antibody invented, developed and produced in Germany. Removab® is marketed by Fresenius Biotech GmbH and produced by TRION Pharma GmbH.

DRUG PIPELINE IN BAVARIA

number of drug candidates



Also last year, MediGene AG received German marketing authorization for Veregen® for the treatment of genital warts. MediGene acquired the basic rights for Veregen®, which contains a defined extract from green tea leaves, from Epitome Pharmaceuticals, Inc., in 1999 and was solely responsible for the drug's successful preclinical and clinical development, as well as for the approval process. In the US, marketing approval was granted to Veregen® in 2006. In Europe, marketing authorization applications under the decentralized procedure had been filed in Germany, Austria, and Spain, and received a positive decision in all three countries. The marketing authorization in Germany, the reference member state in this decentralized procedure, forms the base for further marketing authorization applications in other states in the EU.

In addition to these successful developments, several other Bavarian biotech SMEs made considerable progress in clinical development of their candidates. Antisense Pharma

GmbH, for example, started a Phase III trial with its key candidate Trabedersen in aggressive brain tumours in the beginning of 2009. In September, FDA and EMEA granted orphan drug designation to Trabedersen for the treatment of pancreatic carcinoma. Additionally, Trabedersen received patent protection by the European Patent Office until 2026.

Wilex AG finished patient recruitment in its Phase III trial of Redectane®. Furthermore, preliminary Phase II data with Mesupron® administered to patients with pancreatic cancer showed impressive improvement in overall survival. 4SC AG started a clinical Phase II trial for vidofludimus in Inflammatory Bowel Disease, as well as a clinical Phase II trial for resminostat on Hepatocellular Carcinoma.

At present (April 2010), clinical development programmes of the Bavarian SMEs encompass the fields of indication listed in more detail below.

PHASE II	PHASE III	APPROVED
4SC: Rheumatoid Arthritis, chronic gut disease, hepatocellular cancer, Hodgkin Lymphoma Affectis: Depression Avontec: Asthma, Psoriasis Bavarian Nordic: Smallpox IDEA: Onychomycosis, Skin pain and Inflammation MediGene: Pancreatic Cancer, Breast Cancer, Rheumatoid Arthritis Micromet: Colorectal Cancer, Acute Lymphoblastic Leukemia MorphoSys (with Centocor): Immunology Scil: Periodontitis Fresenius Biotech/ TRION Pharma: Breast Cancer Vasopharm: Closed Head Injury Wilex: Pancreatic Cancer, Breast Cancer	Antisense Pharma: Glioblastoma Curacyte: Hemoximer®, Sepsis GPC Biotech: Satraplatin®, Prostate Cancer (under evaluation) IDEA: Diractin®, Osteoarthritis Wilex: Redectane®, PET-Imaging Wilex: Rencarex®, Kidney Cancer	MediGene: Eligard®, Prostate Cancer (Europe) MediGene: Veregen® Genital Warts (USA, Europe) MediGene: Oracea™, Rosacea (Europe, sold) Fresenius Biotech/TRION Pharma: Removab®, Malignant Ascites (Europe)



Deals, Cooperations, Mergers, Financing

Big Deals and Cooperations

Bavarian biotechnology companies provide a unique product pipeline and excellent mature technology platforms, which attract industry partners and investors from all over the world. We can only give a small excerpt of all the cooperations that have been entered in 2009.

In January 2009, Wilex AG (Munich) and UCB Pharma S.A. entered into strategic partnership. Wilex acquired UCB's preclinical oncology portfolio of five programmes, comprising two small molecule programmes and three antibody programmes. In addition to that, UCB invested € 10 million in Wilex upon closing and will also make a milestone payment of € 10 million.

Proteros biostructures GmbH (Martinsried), focusing on X-ray protein structure analysis, has also entered into a collaboration with UCB in of March 2009. The company has signed a research services agreement with UCB for the support of structure-based discovery of small molecule drugs. The financial terms of the fixed research fees and milestones have not been disclosed.

Micromet AG (Munich) entered into an option, license and collaboration agreement with Bayer Schering Pharma AG. The two companies started a collaboration on the development of a BiTE antibody against an undisclosed solid tumor target through the completion of the clinical phase I trials. BiTE antibodies are designed to direct the body's cell-destroying T cells against tumor cells, and represent a new therapeutic approach to cancer therapy. Bayer Schering Pharma AG exercised the option in December 2009 and Micromet received an option exercise fee of € 5 million in January 2010. According to the agreement, Micromet will be eligible for milestone payments of up to € 285 million in total and up to double-digit royalties based on tiered net sales of the product. Again Micromet hit the headlines by announcing a cooperation with Sanofi-aventis in October 2009, being worth up to € 320 million.

In April 2009, Affectis Pharmaceuticals AG (Martinsried) and Mitsubishi Tanabe Pharma Corporation (MTPC) entered into a drug discovery collaboration. Under the terms of agreement, Affectis will receive research fees and development milestones for the common discovery of new anti-depressants of MTPC.

Within the industrial biotechnology sector, Sloning Biotechnology GmbH (Puchheim) has entered into a cooperation with the multinational consumer chemicals company Henkel KGaA to provide its proprietary protein engineering platform for their laundry and home care enzyme development.

In September 2009, Pieris AG (Freising-Weihenstephan) and Allergan Inc. decided to start a partnership to strengthen their expertise in drug delivery and ophthalmic drug development. Pieris AG will provide its proprietary Anticalin technology. Allergan will be solely responsible for all discovery, development, and commercialization costs and will be responsible for clinical development and related activities and commercialization. Pieris has granted Allergan a worldwide and exclusive license for specific Anticalins to be used in the field and in return has received an upfront payment of € 7.5 million. Further financial terms were not disclosed.

Furthermore, MorphoSys AG (Martinsried) and Daiichi Sankyo have expanded their collaboration. Daiichi Sankyo agreed to fund the development of certain infectious-disease-specific technologies of MorphoSys. Daiichi Sankyo has become the first collaboration partner for HuCAL PLATINUM® based drug discovery in infectious diseases.

Moreover, Medigene AG (Martinsried) has signed an agreement with Solvay Arzneimittel GmbH for the commercialization of Veregen® in Germany, Austria and Switzerland.

Kinaxo Biotechnologies GmbH (Martinsried) succeeded in closing collaborations with Bayer Vital GmbH as well as with Roche Diagnostics GmbH (Penzberg) to use its quantitative phosphoproteomics technology PhosphoScout® for the identification of novel biomarkers.

M&A Activities

In January 2009, MWG-Biotech AG acquired 100% shares of the Cologne based biotechnology company Operon Biotechnologies GmbH. Since November 2007, both companies have started a partnership to create a new worldwide leader in the customized oligonucleotide market and to device further additional services in the genomic field services for the whole Eurofins Group the company belongs to.

GPC Biotech AG, Martinsried and Agennix Inc., Princeton, NJ announced their merger in February 2009. Diefenbach Hopp BioTech GmbH & Co KG Holding, an investment company of

Dietmar Hopp, co-founder of SAP AG invested another € 15 million in Agennix to combine GPC Biotech's and Agennix's oncology pipelines. Now Agennix AG is a publicly traded biopharmaceutical company focussing on developing novel anti-cancer therapies. The company's most advanced program is Talactoferrin, an oral targeted therapy that has demonstrated activity in randomized, double-blinded, placebo-controlled Phase II studies in non-small cell lung cancer as well as in severe sepsis.

Financing

Despite the terrifying situation of venture capital investments in 2009 concerning all industry sectors, the US biotech industry remained the single largest investment area in terms of funding raised (\$3.5 billion into 406 deals, according to National Venture Capital Association) in comparison to other industries. In Germany, the latest overview by BIOCOM/biotechnologie.de showed a total volume of financing by venture, public and private investors of about € 300 million for whole Germany in 2009. Almost 50% of these financings went to Bavaria:

Taking private and public financing together, € 146 million have been raised by Bavarian biotech companies in 2009, an increase of 32% compared to last year. The amount of money raised through public or private placements by listed companies recovered in 2009 and reached almost the value as in 2007.

Venture capital financing including silent partnerships dropped down to € 30.1 million, which represents a loss of 48% compared to 2008.

Successful financing rounds were completed by Intana Bioscience GmbH (€ 0.65 million), Kinaxo Biotechnologies GmbH (€ n.d.), Lipofit GmbH (€ 4.0 million), Sloning BioTechnology GmbH (€ n.d.), Vasopharm GmbH (€ 4.5 million) and some other companies which are summarised in total in the graph.

Revenues


The figure on the right shows the revenues of Bavarian biotechnology companies quoted on the stock exchange.

These are **4SC, Agennix, Geneart, MediGene, Micromet, MorphoSys, and Wilex.**

The sales revenues for 2009 of the listed companies were down by only 3.8%, to € 185 million. The R&D investments of the listed companies reached € 141 million, which is nearly the same range as in 2008 and shows that the companies are keen to put every effort in developing their pipeline.


51% of all the other biotech SMEs answered our questionnaire concerning their revenues and reported about € 119 million in 2009. In total and including the revenues of the listed companies earnings amount to more than € 400 million – as in 2008.

REVENUES TOTAL IN MIO. €, LISTED COMPANIES



EXTERNAL FINANCING AND DEALS

Mio. €





Two Bavarian Awardees in Germany's "Top Cluster Contest"

The year 2010 started with good news: In January, two Bavarian applications won the second round of the "Top Cluster Contest" (Spitzencluster-Wettbewerb) launched by the German Federal Ministry of Education and Research (BMBF) in 2007 to boost Germany's innovative strengths and economic success. Over a period of five years, each high-performance cluster will receive up to € 40 million, matched by similar amounts of capital from businesses or private investors, to implement strategic action plans jointly developed by regional key players from industry, science and other institutions. The plan is to hold three rounds of competitions some eighteen months apart. In each round, five excellence clusters are selected by an independent jury with an emphasis on innovative approaches to a long-term cluster strategy that draws on the respective strengths of the cluster and aims to fully utilise so far unused potential. This requires that the entire innovation chain – from idea to commercial exploitation – be taken into account. In selection of the applications attention was paid to both the development potential and the creativity and innovativeness of the approach.

A New Dimension in Drug Development in the Greater Munich Area

With its joint strategy "m⁴ – personalised medicine and targeted therapies – a new dimension in drug development", the biotechnology and pharmaceutical companies, the clinics and research institutions of the greater Munich area have aligned with the cluster management organisation BioM Biotech Cluster Development GmbH to overcome the central challenges of today's drug development: Insufficient drug safety and efficacy, a lack of efficiency in the process of drug development due to long development cycles, extensive costs and high attrition rates. The long-term plan of m⁴ is based on the existing strengths of the Munich Biotech cluster and targets the improvement of the development process and the optimisation of the individual effectiveness and safety of new therapeutics by implementation of personalised and targeted medicine along the entire value chain.

Whether a drug can treat a patient successfully varies considerably between individuals on account of specific characteristics in the genome, in other words the genotype. A drug that cures one person may have no effect on another or may even lead to serious side effects. The aim of personalised medicine is to counteract the lack of efficacy and safety of many drugs currently on the market by developing "customised therapies" for certain groups of patients and to make that development more efficient and cost-effective.

Backed by the excellence cluster funding, the Munich Biotech Cluster is now lined up to make targeted drug development along the entire value chain more efficient by closely linking all players involved as early in the process as possible. To achieve this, the Cluster is using the local excellence in research and preclinical and clinical development to boost

its success rate in obtaining marketing approval for molecules that can be used for targeted therapies aimed at specific patient populations. This is a unique opportunity for Munich to develop into an internationally acknowledged Center of Excellence for Personalised Medicine.

Over 40 project ideas from the Munich conurbation, with its more than 100 partners from science and industry, went into the joint application, including an especially large number of projects in which small and medium-sized biotech companies are cooperating with research institutes in the region. As a second mainstay, starting from basic research and going right through to marketing approval, structural improvements in the Munich region will help make value creation in drug development faster and more efficient. With this in mind, it is planned, for example, to establish the m⁴ Clinical Trial Service Center, a new and central service organisation integrating and supporting early clinical development. The identification and validation of individual disease markers will be facilitated by setting up the m⁴ Biobank Alliance, a consortium of tissue banks with standardised procedures and a large pool of biological samples. An extensive IT structure, the m⁴ Data Integration System will be established to help deal with the huge masses of data and to integrate all relevant partners along the entire value chain. In addition, the new m⁴ eAcademy will train the skilled personnel specifically required in LifeSciences by new online eLearning degree courses. The program m⁴ Scouting & Incubation shall secure a constant supply of innovations in the future markets of the m⁴ cluster by targeted identification and advancement of promising academic research projects by grants and a professional project management.

Funds of around € 40 million granted by the BMBF will be topped up by at least the same amount by participating partners from industry, using their own resources, to a total volume of € 80 million. In addition, the State of Bavaria contributes around € 14 million for the implementation of the new cluster strategy. The sum is intended to develop further the cluster management, for start-ups and the interim financing of projects that look particularly promising. Part of the funding by the Bavarian Government is meant to be used as the basis for a special "sidecar"-seed fund that will integrate further capital from investors. In other words, the total volume of the Munich project currently amounts to almost € 100 million!

The joint vision of the Munich application is to develop the cluster to an internationally renowned excellence- and model region in personalised and targeted medicine until the year 2020. In particular small and medium-sized companies that are specialised in the area of therapeutics and diagnostics shall secure innovation, attractiveness and sustainable

growth. In the next decade, their number shall grow to at least 200 to create 6000 new jobs and to attract international investors, global acting companies and specialised staff.

The spokesman of the initiative and coordinator of the joint application, Prof. Dr. Horst Domdey (BioM), is extremely pleased. "We are really thrilled that the tremendous commitment of science and industry that we encounter in the Munich region, has earned its reward by winning this challenging competition. I should therefore like to thank all fellow campaigners who have shown unprecedented staying power in developing this forward-looking and sustainable strategic concept for our location. And we are really pleased for our Bavarian colleagues in Erlangen/Nuremberg that their concept has also received distinction as a top-class cluster. There are, in part, definite thematic correspondences between this concept and the Munich approaches, so that we can perfectly well imagine working together in future even more closely than today."

Medical Technology for the Future in Erlangen-Nuremberg

The second Bavarian winner initiative, the "Center of Excellence for Medical Technology" of the "Medical Valley EMN" cluster located in Erlangen/Nuremberg, was launched in 2007 by influential players in the area of business, science, politics and healthcare and is focused on the growth market of medical technology, a field that contributes substantially to the image of the entire region. Common goal of the high technology cluster is to create only products, services and solutions which verifiably contribute to effectiveness and efficiency in healthcare.

Medical Valley EMN develops interdisciplinary technologies to improve the quality of healthcare in a sustainable way and to contribute to a reduction of healthcare costs in an overaged society. In more than 40 projects, over 70 partners from industry, science and healthcare are targeting the topics of "Imaging Diagnostics" (optimized therapy through

early diagnosis), "Intelligent Sensor Systems" (miniaturised modules for mobile applications), "Therapy Systems" (improvement of drug therapy control) and "Ophthalmology" (age-related eye diseases). Examples are "Breast-CT/Integrated Breast Care" – a concept for gentle and highly sensitive breast diagnostics, "Barrier-free Healthcare-assistance" – new services based on intelligent sensor systems and radio communication to facilitate self-containment of age-demented patients and "Osteofit 2030" – the development of improved orthopedic implants with a reduced risk of infections. The members of the jury of the excellence cluster competition valued the close network between science, industry, hospitals and patient care organisations and the innovation of the medium-sized enterprises as a particular strength of the region. As an "anchor"-company, Siemens HealthCare participates with a range of projects in the area of imaging diagnostics.

In total, € 80 million will support the economic development of the excellence cluster, thereof 40 million awarded by the German Federal Ministry of Education and Research. The Bavarian ministry of economics also contributes to the initiative. In the long term, the area aims to become a model region for optimal healthcare, with 2.500 new jobs and sales of € 2.5 billion until the year 2020. Currently, around 180 companies in the area of medical technology with 16.000 employees are located in the cluster.

"Our success in the Top Cluster Contest is a great honor for the region and in particular for the University of Erlangen-Nuremberg, as medical technology is the main focus of research and education. Over 60 chairs and professorships in various fields are working on questions related to medical technology" comments Prof. Dr. Karl-Dieter-Grüske, Vice Chancellor of the University Erlangen-Nuremberg.

Also Dr. Ulrich May, Chairman of the EMN and mayor of the city of Nuremberg, is very pleased about the success: "We are undisputable playing in the champions league of medical technology. With the victory in the Top Cluster Contest, the region has won an important game. What applies to the success in the excellence cluster of medical technology also applies to the economic development of the metropolitan area: The bundling of the regional forces and cooperation are essential prerequisites for success."



Simon Moroney (MorphoSys), Horst Domdey (BioM[®]), Ania Muntau (University Munich, LMU), Günther Wess (Helmholtz Centre Munich), Georg Käab (BioM[®]), Christian Peschel (Technical University Munich, TUM)



Minister Annette Schavan congratulates Christian Peschel and Horst Domdey



www.m4.de · www.bio-m.org



www.medical-valley-emn.de

Munich to become the capital of biotech dealmaking in November

For the first time in ten years BIO-Europe, Europe's largest partnering event for the life science industry, returns to Munich. From November 15–17, 2010 Munich will be the center of dealmaking activity for over 2,500 biotech, pharmaceutical and financial executives from around the world who will engage in an unprecedented level of partnering.

The hosts for the 2010 event, the Bavarian Ministry of Economic Affairs, Infrastructure, Transport and Technology, the BioM Biotech Cluster Development GmbH and Bavarian Cluster Biotechnology, will showcase their historical and culturally rich city and the diversity of institutions, global players and maturing companies powering the success of biotechnology in the Southern German region.

Munich is home to one of the largest and most vibrant biotech clusters in Europe. Featuring 180 life science companies, the biotech cluster employs 8,800 people. Munich's success as a biotech region can be attributed to a rapidly developing commercial biotechnology industry, world-class scientific research institutions, excellent infrastructure, efficient access to capital, and highly qualified employees.

Even though BIO-Europe 2010 is still six months away, preparations are proceeding at full speed. Firms from around the world have already circled the dates in their calendar. Complementing the intellectually stimulating daytime programs and productive partnering sessions, anticipation is running high for evening events featuring receptions at the historic and beautiful Munich Residenz, LoewenbraeuKeller and Munich Old Town Hall.

"The top big pharma companies will arrive in force for the 16th annual BIO-Europe partnering meeting in Munich. Dealmaking will be at a fever pitch as upwards of 2,000 projects will be the focus of intense discussion," said Carola Schropp, President of EBD Group, the organizer of BIO-Europe.

The BIO-Europe event was last held in Munich in 2001, and in the intervening years it has grown into the premier biotechnology business exchange in Europe. Horst Domdey, Managing Director, Bavarian Biotechnology Cluster, said he is looking forward to welcoming the event back to Munich.

"We were just a baby biocluster, not even a cluster really, when this event was last held in Munich in 2001. It has been

a busy time for us, launching successful companies, drugs that have been approved, as well as new development programs."

The Munich life science industry today is made up of 43 pharmaceutical companies and 136 biotechnology companies, 8 of which have successfully been listed as public companies. Among the biotechs, 118 are SMEs between them employing 2,600 employees of which 60 percent are dedicated to development projects for therapeutics and diagnostic agents. "Our focus is drug development," said Domdey, "this is where we have scored points quickly and have developed as a major player."

"There is a very good story here for people interested in targeted therapies as we have a number of companies working in that area and several university-based projects," he said.

Of note, BIO-Europe will help to illuminate the impressive array of opportunities for partnering with innovative local firms as well as experience Munich as an ideal hub to base operations.

The Power of Productive Partnering

BIO-Europe is a conference that is designed to build value through partnerships. As the financial crisis gripped the globe in 2008/09, partnering further emerged as the primary strategy for biotech companies to progress drug development and raise capital. For big pharma, partnering has emerged as the strategy for stocking emptying drug pipelines with potential new medicines. "The lesson we have learnt over the past few years is clear: Partnering is here

to stay. Partnering, in all of its manifestations not only provides a lifeline for many biotech companies, but is also a structural means for moving experimental drugs ever closer to commercialization," added Schropp.

At BIO-Europe, attendees utilize specialized partneringONE® software to screen through the thousands of unique partnering opportunities, and automatically generate a calendar of mutually agreed one-to-one meetings. As a result, over three days a typical delegate at BIO-Europe will have on average 12 pre-arranged one-to-one meetings, while a few will have as many as 45! This is in addition to the well attended evening events that further encourage networking.

The conference program that serves as backdrop to the partnering meetings on the first day of the 2009 event featured 17 workshops and panel discussions with 70 leading life science executives, venture capitalists, academic researchers and consultants participating as speakers.

This November, when biotech dealmakers from around the world attend BIO-Europe 2010, Munich will be the capital of productive partnering.



November 15–17, 2010 in Munich, Germany

www.ebdgroup.com/bioeurope

Venue:

International Congress Centre Munich (ICM)
Messegelaende, 81823 Munich, Germany
www.icm-muenchen.de/link/en/15496488

CONTACT

Thomas Voigt, EBD Group
Phone: +1 (0)760 930 0500
E-Mail: tvoigt@ebdgroup.com
Internet: www.ebdgroup.com/bioeurope





Company Profiles



Contact:
Yvonne Alexander

Am Klopferspitz 19a
D-82152 Martinsried/München
Phone: +49 (0) 89 700763 0
Fax: +49 (0) 89 700763 29
E-Mail: yvonne.alexander@4sc.com
Internet: www.4sc.com

4SC AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Autoimmune Diseases, Rheumatology, Oncology, Hepatocellular Cancer, Hodgkin's Lymphoma, Acute Myeloid Leukemia, Small Molecules, HDAC-Inhibitors, Molecular Modelling, Medicinal Chemistry, Drug Development

4SC AG is a drug discovery and development company focused on autoimmune and cancer indications. Vidofludimus (4SC-101), a small molecule, is currently in a Phase IIb study in rheumatoid arthritis and a Phase Ila exploratory study in inflammatory bowel disease. The company's lead oncology compound, resminostat (4SC-201), a pan histone deacetylase (HDAC) inhibitor, is in Phase II trials in hepatocellular carcinoma and Hodgkin's lymphoma. Two further oncology compounds, 4SC-203 and 4SC-205, are in Phase I studies. 4SC develops drug candidates until proof-of-concept in order to generate value creating partnerships with the pharmaceutical industry in return for advance and milestone payments as well as royalties. 4SC was founded in 1997, has 91 employees, and is listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005.



Contact:
Dr. Mihaly Juhasz

Hammersbacher Fußweg 24
D-82467 Garmisch-Partenkirchen
Phone: +49 (0) 8821 9430 271
Fax: +49 (0) 8821 9430 272
E-Mail: M.Juhasz@accelsiors.com
Internet: www.accelsiors.com

Accelsiors Group International

CRO

Accelsiors International headquartered in Europe, is composed of an international CRO, drug development consulting and a biopharma development group. With offices in Germany, Hungary, the United States and a partnership in China, India and Latin America, Accelsiors conducts cost effective, time efficient large multi-centric international trials.

Accelsiors' comprehensive project experience developed for multinational and US companies, provides reliable data and regulatory support for the filing of products with EMEA and FDA, while counseling clients through all project phases, from planning to implementation, from cloning to filing. Accelsiors intimate involvement with biologics (Peptides, EPO, Ifn-beta, Ifn-alpha, hGH, SR-Forms) and small molecules (GnRH) contributes proven experience to complicated drug development programs.



Contact:
Dr. Jörg Scheidle

Am Windfeld 35
D-83714 Miesbach
Phone: +49 (0) 8025 2867-0
Fax: +49 (0) 8025 2867-28
E-Mail: info@acino-pharma.com
Internet: www.acino-pharma.com

Acino AG

PHARMA & CHEMICAL INDUSTRY

Keywords: Medicinal Chemistry, Drug Delivery, Clinical Research, Pharmacology

Acino has specialised in the development, registration and manufacture of generic and innovative pharmaceutical products using sophisticated formulation technologies, for which Acino also holds patents. By focusing on solid oral dosage forms with modified release as well as therapeutic systems for transdermal drug delivery such as patches and biodegradable, subcutaneous implants, Acino supplies the leading companies in the European drug markets. Acino offers the pharmaceutical industry a comprehensive range of services from product development and registration through procurement and contract manufacturing to packaging and logistics. Headquartered in Basel, the Acino Group currently employs a staff of close on 350. In 2007, it generated a total sales revenue of over CHF 180 million. Acino Holding AG is quoted on the SIX Swiss Exchange (SIX: ACIN).

Active Motif Chromeon GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Microscopy, Nanobiotechnology, Fine Chemicals / Reagents

Active Motif Chromeon provides innovative fluorescent reagents for Life Science research applications including several lines of fluorescent chromophores™ the Chromeo™ Dyes, RuLabels and Py-Dyes. Chromeo Dye excitation and emission properties match common excitation sources and filter sets, ideal for microscopy and plate-based assays. RuLabels are phosphorescent ruthenium probes that emit strongly polarized light with a long decay time, which enhances sensitivity and reduces background. The Py-Dyes possess unique physical and spectral properties that make conjugation simple, while greatly reducing background. As alternative to organic dyes, a set of bright and biocompatible fluorescent nanoparticles is offered. They represent excellent tools for increasing the sensitivity of your assays.



Contact:

Dr. Jörg Plümpe

Von-Heyden-Str. 12
D-93105 Tegernheim
Phone: +49 (0) 9403 95449-10
Fax: +49 (0) 9403 95449-15
E-Mail: chromeonsales@activemotif.com
Internet: www.activemotif.com

Affectis Pharmaceuticals AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Inflammation, Antibody, CNS, Small Molecules, Drug Development

Affectis is a biopharmaceutical company implementing novel concepts for the treatment of psychiatric disorders, especially depression. Affectis has unique capabilities to discover and develop drugs based on pioneering findings in the field of psychiatric disorders. The Company's drug discovery programme targets two interrelated pathways so far unknown in the context of depression and schizophrenia.

The Company started operations in November 2003 as spin-off of the Max-Planck-Institute of Psychiatry (MPI) in Munich, Germany.



Contact:

Dr. Luc St-Onge

Fraunhoferstr. 13/4.OG
D-82152 Martinsried
Phone: +49 (0) 89 8932811-100
Fax: +49 (0) 89 8932811-111
E-Mail: info@affectis.com
Internet: www.affectis.com

Agennix AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Dermatology, Immune Therapy, Infectious Diseases, Drug Development, Peptide/Protein, Small Molecules, Oncology

Agennix AG is a publicly traded biopharmaceutical company that is developing novel therapies in areas of major unmet medical need to improve the length and quality of life of seriously ill patients. The Company's most advanced program is talactoferrin, an oral targeted therapy that has demonstrated activity in Phase 2 studies in non-small cell lung cancer as well as in severe sepsis.

Talactoferrin is currently in Phase 3 clinical trials in non-small cell lung cancer. Other clinical development programs include RGB-286638, a multi-targeted kinase inhibitor in Phase 1 testing; the oral platinum-based compound satraplatin; and a topical gel form of talactoferrin for diabetic foot ulcers.



Contact:

Barbara Müller

Fraunhoferstr. 20
D-82152 Martinsried
Phone: +49 (0) 89 8565-2665
Fax: +49 (0) 89 8565-2610
E-Mail: ir@agennix.com
Internet: www.agennix.com



Contact:
Prof. Dr. Gottfried Brem

Larezhausen 2-3
D-86567 Hilgertshausen
Phone: +49 (0) 8250 9279040
Fax: +49 (0) 8250 9279049
E-Mail: labor@agrobiogen.de
Internet: www.agrobiogen.de

Agrobiogen GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Automation, Xenotransplantation, Genomics, Gene Transfer, Transgenic Animals, Agrobiotechnology

Agrobiogen focuses on and is experienced in the application of molecular genetic techniques in livestock animals (especially moleculargenetic diagnosis and gene transfer). Many transgenic rabbit lines and several cattle clones have been established. As a service for other biotech companies transgenic farm animals are generated using conventional microinjection procedures and nucleus transfer. Gene diagnosis of microorganismus toxic to livestock like BVD, as well as parentage control of animals, scrapie resistance genotyping and analysis of DNA markers are offered as a service for breeders, veterinarians and companies. Agrobiogen has developed a simple labour-saving system for collection of tissue samples and extraction of DNA from millions of animals for automatically controlled analyses.



Contact:
Dr. Karl Fehnle

Münchner Str. 11
D-85540 Haar
Phone: +49 (0) 89 613727-0
Fax: +49 (0) 89 613727-20
E-Mail: cro@algora.de
Internet: www.algora.de

ALGORA Gesellschaft für Medizinstatistik und Vertriebssysteme mbH

CRO

Keywords: Clinical Research, Monitoring, Oncology, Infectious Diseases

Algora is a niche CRO successfully operating on clinical trials in Germany. Services include phase II-IV trials as well as large observational studies and range from protocol development to final study reports. Algora manages complete study projects or delivers individual services, such as clinical monitoring, data management or statistical analysis. Experienced in oncology since the first days of the company in 1989, Algora always had a focus on innovative therapies, leading to close relationships to university hospitals and medical societies. Since 1995 another focus developed in large pediatric studies. Customers are pharmaceutical and medical device companies, independent research groups, and other CROs.



Contact:
Dr. Karl-Heinz Grajer

Hanauerstr. 1
D-80992 München
Phone: +49 (0) 89 149096-1600
Fax: +49 (0) 89 149096-2600
E-Mail: karl-heinz.grajer@amgen.com
Internet: www.amgen.de

AMGEN GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, please visit www.amgen.com or www.amgen.de.

Amgen Research GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Drug Development, Small Molecules, Hematology, Inflammation, Neurology, Oncology, Metabolic Diseases

AMGEN, (Applied Molecular Genetics Inc.) was founded in 1980 as one of the pioneers of industrial biotechnology. The company develops, produces and sells biopharmaceutical products that are produced through recombinant DNA technologies as well as small molecule therapeutics.

AMGEN Research GmbH was founded in Regensburg in 2000. Basic research is conducted with the aim of identifying new pharmaceutical lead structures for the development of innovative drugs. Low molecular weight compounds are identified by high throughput screening (HTS) procedures. Over 10 million compounds are analyzed every year.



Contact:
Mirko Stemmler

Josef-Engert-Str. 11
D-93053 Regensburg
Phone: +49 (0) 941 465-20000
Fax: +49 (0) 941 465-20100
E-Mail: Mirko.Stemmler@amgen.com
Internet: www.amgen.de

AmplexDiagnostics GmbH – Gesellschaft für molekularbiologische Diagnostik

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Clinical Diagnostics, PCR, Infectious Diseases

AmplexDiagnostics GmbH is a privately held company for the development and production of In Vitro Diagnostics. Our aim is the improvement of the potential of the PCR-technology by implementing the main advantages of this technology into the diagnosis of bacterial infections. Founded in 2002 - Amplex developed its first product (hyplex StaphyloResist) and entered the market already in 2003. Additional systems (hyplex STD ID for detection of sexually transmitted mycoplasmas; hyplex EHEC for detection of EHEC/EPEC and hyplex EnterotoResist for characterisation of VRE) followed in 2006. Additionally, we developed the first PCR-system (hyplex ESBL ID) for the direct detection of ESBL producing bacteria direct from patient material. For further information please visit www.hyplex.info or contact us.



Contact:
Dr. Lars Wassill

Werkstr. 2
D-83555 Gars-Bahnhof
Phone: +49 (0) 8073 91693-0
Fax: +49 (0) 8073 91693-33
E-Mail: info@amplexdiagnostics.de
Internet: www.amplexdiagnostics.de

AMS Advanced Medical Services

CRO

Keywords: Analysis, Pharmacology, Medical Writing, Monitoring, Clinical Research,

AMS Advanced Medical Services GmbH is a privately owned independent European mid-size CRO founded in 1997 in Mannheim by 6 partners, 4 of whom are medical doctors. AMS has also offices in London, Vienna and Munich. AMS has an overall staff of 350 people, approx. half of them are in clinical research, the other half in Marketing and Sales services. AMS invented the 1. Internet-Pharmaschool (1.IPS) with trainers and techniques offering tailor-made training concepts for staff in both clinical research and sales. AMS is a full service CRO with significant experience in multiple therapeutic areas and strong medical expertise covering Phase I to Phase IV, non-interventional programs, pharmaco-epidemiology and -economics. Our staff includes 60 CRAs and more than 50 people in DM and Stats.



Contact:
Gerlinde Jänel

Werner-Eckert-Straße 10
D-81829 München
Phone: +49 (0) 89 2000074-11
Fax: +49 (0) 89 2000074-40
E-Mail: gerlinde.jaenel@ams-europe.com
Internet: www.ams-europe.com



Contact:
Axel Leimer

Martin-Empl-Ring 32
D-81829 München
Phone: +49 (0) 69 24242-117
Fax: +49 (0) 69 24242-150
E-Mail: info@amsilk.com
Internet: www.amsilk.com

AMSilk GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: New Materials, Fine Chemicals / Reagents, Tissue Engineering / Cell Culture, Drug Delivery

The AMSilk®-Technology enables the production of tailor-made materials which are unrivaled by most common synthetic materials. AMSilk addresses many applications and industry sectors with new materials enabling new products with previously unachievable features.

AMSilk has developed a unique process to produce biopolymers like spider silk at an industrial scale. These materials form the basis for coatings, films, non-wovens and monofilament fibers. The resulting products are being developed medical, pharmaceutical and industrial applications.

The name AMSilk and the AMSilk Logo are registered trademarks of AMSilk GmbH; Munich.



Contact:
Dr. Marian Wiegand

Lochhamer Str. 29
D-82152 Martinsried
Phone: +49 (0) 151 11511155
Fax: +49 (0) 89 85782909
E-Mail: wiegand@amvac-research.de
Internet: www.amvac-research.de

AmVac Research GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, ELISA / ELA, Gene Transfer, Microscopy, PCR, Vaccines

Founded in 2008, AmVac Research is a biotech company developing highly innovative and multifunctional vaccines.

The company is using a novel viral vector technology – licensed from the Max-Planck-Society – that combines the immunogenic characteristics of live viral vaccines with the high safety profile of inactivated vaccines. This technology serves as a platform for the development of several tailor-made vaccines. One main focus of the company is the development of vaccines against respiratory tract diseases caused by viral agents such as RSV or hPIV3 against which there is no effective therapeutic or preventive means – despite their high worldwide incidence. Related to vaccination, AmVac Research will make use of its MALP-2-derivative platform based on a novel proprietary class of adjuvants; in order to not only enhance the efficacy and protective ability of vaccines but also to allow their mucosal delivery.



Contact:
Prof. Dr. med. Reinhold P. Linke

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 52012638
Fax: +49 (0) 89 52389013
E-Mail: linke@amymed.de
Internet: www.amymed.de

amYmed GmbH – Referenzzentrum für Amyloidkrankheiten

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Antibody Production Service, Devices, Antibody

We provide high precision immunohistochemical classification of the diverse amyloid diseases with respect to specific and causal treatment as a service for patients and physicians.

We are in the process of extending this service by producing and offering test kits in order to enable clinics and institutes of pathology to perform this classification by themselves.

AntiProt

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Antibody Production Service, Agrobiotechnology, Fine Chemicals / Reagents, Allergy

AntiProt produces and distributes antibodies raised against various proteins especially against plant proteins for scientific purposes. AntiProt helps scientists to produce monoclonal and polyclonal antibodies and supports them individually on the whole way from peptides till purified antibodies. AntiProt concentrates its research on production of antibodies-markers for photosynthesis, stress responses, pathogen resistance, toxins, allergenic reactions and other processes.



Contact:
Dr. Anna Niebling

Waldstr. 22
D-82049 Pullach
Phone: +49 (0) 89 7444270-0
Fax: +49 (0) 89 7444270-1
E-Mail: info@antiprot.com
Internet: www.antiprot.com

apoGene GmbH & Co. KG

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Tissue Engineering / Cell Culture, Knock Out, Xenotransplantation

apoGene is focused on the field of xenotransplantation. Rabbits and pigs are genetically modified (transfer, knock out and recombination of endogenous genes) for influencing the different steps of the rejection process after xenotransplantation of animals tissues and organs. We are also investigating the expression of endogenous retroviral sequences after xenogenetic transfer. For the development of knock out animals we have developed and patented an alternative strategy, the so called screen-out of hemozygote carriers of functional defects in natural or mutagenized populations. The technique will also be very interesting for the establishment of animal models for basic and applied research.



Contact:
Prof. Dr. Gottfried Brem

Thalmannsdorf 25, Larezhausen
D-86567 Hilgerthausen
Phone: +49 (0) 8250 928466
Fax: +49 (0) 8250 7166
E-Mail: gbremabg@apogene-gmbh.de
Internet: www.apogene-gmbh.de

ARTHROGEN GmbH

PHARMA & CHEMICAL INDUSTRY

Arthrogen combines scientific and clinical know-how in order to successfully develop innovative gene therapeutic approaches for the treatment of patients with rheumatic diseases. Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by persistent joint swelling and progressive destruction of cartilage and bone. Among the connective diseases RA is the commonest and the most important in socioeconomic terms. Biologicals targeting specific cytokines and their receptors have been proven useful as systemic therapies for RA and provide proof of principle of targeted therapies. Gene therapy can provide stable, regulated production of anti-inflammatory molecules and might provide a more efficient system to deliver therapeutic compounds at the site of inflammation. Local gene therapy for chronic diseases such as RA could permit long-term production of therapeutic molecules in the inflamed compartment.

ARTHROGEN GmbH

Contact:
Dr. Ulrich Schneider

Wiesseerstr. 103
D-83707 Ringsee
Phone: +49 (0) 8022 187978
Fax: +49 (0) 8022 187978
E-Mail: info@arthrogen.de
Internet: www.arthrogen.de



Contact:
Yvonne Deppert

Moosstraße 7
D-82319 Starnberg
Phone: +49 (0) 8151 44690-22
Fax: +49 (0) 8151 44690-30
E-Mail: kontakt@prostrakan.com
Internet: www.arzneimittel-prostrakan.de

Arzneimittel ProStrakan GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Drug Development, Drug Delivery, Cardiovascular Diseases, Endocrinology, Metabolic Diseases, Oncology, Pain

Arzneimittel ProStrakan GmbH is the German affiliate of the Scottish ProStrakan plc, a pan-European pharmaceutical company. ProStrakan is engaged in the development and commercialisation of speciality prescription medicines for the treatment of unmet therapeutic needs.

In Germany the core products are in the field of postoperative nausea and vomiting and cancer pain. Further innovative products are for the treatment of anal fissures and testosterone deficiency.



Contact:
Dr. Martin Marhoefer

Georg-Brauchle-Ring 64-66
D-80992 München
Phone: +49 (0) 89 4544-1440
Fax: +49 (0) 89 4544-5440
E-Mail: info@de.astellas.com
Internet: www.astellas.de

Astellas Pharma GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Drug Development, Antibiotics, Allergy, Autoimmune Diseases, Immune Therapy, Infectious Diseases, Inflammation

Astellas Pharma Inc. was formed in April 2005 from a merger with Yamanouchi and Fujisawa. Astellas Pharma is Japan's second largest pharmaceutical company and is headquartered in Tokio. It has operations in Europe, Asia, North America and Japan. Astellas is focused on four key therapy areas: Transplantation, urology, dermatology, and anti-infectives. Astellas employs approximately 3,300 people in Europe across Sales and Marketing, Research & Development and Manufacturing. Astellas has 19 Sales and Marketing Affiliates, 3 plants and 1 R&D site in Europe. Astellas Europe is headquartered just outside London in Staines. The German headquarters are based in Munich. Located here are Sales, Marketing and Medical. The product portfolio includes therapies in transplantation, urology, dermatology, asthma/COPD, cardiology, antibiotics and gastroenterology. Astellas Pharma GmbH Munich employs approximately 350 people including 225 sales representatives.



Contact:
Dr. Gundel Hager

Bahnhofstr. 9-15
D-82327 Tutzing
Phone: +49 (0) 8158 2597-30
Fax: +49 (0) 8158 2597-31
E-Mail: info@aurigon.de
Internet: www.aurigon.de

Aurigon Life Science GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Drug Development, Pharmacology, Toxicology

Aurigon is an independent GLP/GMP certified CRO, dedicated to preclinical testing of small molecules/chemicals, biologicals including peptides, antibodies, herbal extracts, food additives, cell therapy and biosimilars. We offer a comprehensive range of services in (bio)-analytics, pharmacology and toxicology. With personalized and flexible services we support achievement of our customer's needs in expected timelines, investment and efforts.

With its headquarter in the south of Munich, Aurigon Life Science operates in state of the art GLP respectively GMP compliant facilities with subsidiary and affiliated laboratories located near Budapest.

We are a trusted outsourcing partner for multinational pharmaceutical and chemical groups, food producers and innovative biotechnology companies. We feel committed to life.

baseclick GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Clinical Diagnostics, Fine Chemicals / Reagents, New Materials, Chip / Array Technology, Nanobiotechnology, PCR

Baseclick GmbH is a young and dynamic start-up company located in Tutzing, south of Munich, close to the biotech campus in Munich-Martinsried. The baseclick IP was generated at the University of Munich in the group of Prof. Thomas Carell. Core technology of our company is the modification of oligonucleotides with click chemistry. Using this method, nucleic acids can be easily labeled with various molecules, amongst them dyes and quenchers, biotin, and more. Multiple modifications with different labels can be done at any position within the DNA/RNA strand, including the termini. Our second expertise covers the direct detection of DNA or RNA by photographic methods (DNA-Photography). The procedure is inexpensive, fast, and reliable. It enables simple and sensitive detection even in complex biological samples.

baseclick

Contact:
Dr. Wolfgang Höckh

Bahnhofstr. 9-15
D-82327 Tutzing
Phone: +49 (0) 8158 903867
Fax: +49 (0) 8158 903894
E-Mail: info@baseclick.eu
Internet: www.baseclick.eu



BAVARIAN NORDIC

Bavarian Nordic GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Vaccines, Infectious Diseases

Bavarian Nordic (BN) is a leading international biopharmaceutical company developing innovative vaccines to prevent and treat infectious diseases. The company is capable to meet the growing demand for safe 3rd generation smallpox vaccines due to its proprietary vaccine technology MVA-BN®. BN was founded in 1994 and is headquartered in Kvistgaard, Denmark with subsidiary operations in Martinsried and Berlin, Germany. BN recently founded in the US an operating company, BN ImmunoTherapeutics Inc., for research and development of cancer vaccines. The company employs about 180 people and is listed on the Copenhagen Stock Exchange.

More than 450 healthy and immune compromised subjects so far vaccinated with MVA-BN®, suggest an excellent safety and efficacy profile of the vector.

Contact:
Derek Beggs

Fraunhoferstr. 13
D-82152 Martinsried
Phone: +49 (0) 89 8565 0030
Fax: +49 (0) 89 8565 1333
E-Mail: derek.beggs@bavarian-nordic.com
Internet: www.bavarian-nordic.com

Baxter Deutschland GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Tissue Engineering / Cell Culture, Devices, Antibody, Vaccines, Immune Therapy, Pain, Oncology

The Bioscience business of Baxter produces therapeutic proteins from plasma and through recombinant methods to treat hemophilia, immune deficiencies and other blood-related disorders. These include coagulation factors, immune globulins, albumin, wound-management products and vaccines. The Hospital Care business manufactures products used to deliver fluids and drugs to patients, anesthesia gas and parenteral nutrition. Renal provides renal dialysis products and services to support patients with kidney failure. The focus of Baxter Germany is sales and marketing. In Halle / Westfalen chemotherapeutic products are manufactured. Research capacities of Baxter Europe are located in Switzerland and Austria. Current R&D projects aim at new therapeutic proteins and regenerative medicine. Baxter also co-operates with a number of European and US based Biotech companies.

Baxter

Contact:
Jutta Brenn-Vogt

Edisonstr. 4
D-85716 Unterschleißheim
Phone: +49 (0) 89 31701-0
Fax: +49 (0) 89 31701-720
E-Mail: info_de@baxter.com
Internet: www.baxter.de



Contact:

Dr. Markus Helfrich

Universitätsstr. 30
D-95447 Bayreuth

Phone: +49 (0) 921 554309

Fax: +49 (0) 921 552710

E-Mail: markus.helfrich@baygenetics.com
Internet: www.baygenetics.com

BayGenetics GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Fine Chemicals / Reagents, Peptide/Protein, Vaccines

The biotechnology company BayGenetics GmbH was founded in May 2008 as a spin-off from the University of Bayreuth. The company is active in the area of the micro organism *Bacillus subtilis*. The aim of the company is to develop and commercialise new technology platforms for protein production, enzyme catalysis and vaccine development based on *B. subtilis*. BayGenetics has already identified interesting applications in the areas of protein synthesis and enzyme catalysts including an efficient intracellular protein expression system which is being further developed in a secretion system. Applications in the development of oral vaccines are planned in the medium to long term.



Contact:

Dr. Gerhard Gunzer

Sauerbruchstr. 50
D-81377 München
Phone: +49 (0) 89 579589-0

Fax: +49 (0) 89 579589-3503

E-Mail: info@beckman.com

Internet: www.beckmangenomics.com

Beckman Coulter Biomedical GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Nanobiotechnology, Devices, Automation, PCR

Beckman Coulter Genomics GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Genomics, Drug Development, Clinical Diagnostics, Pharmacogenomics, Pharmacogenetics

Beckman Coulter develops, manufactures and markets products that simplify, automate and innovate complex biomedical testing. Our diagnostic systems are found in hospitals and other critical care settings around the world and produce information used by physicians to diagnose disease, make treatment decisions and monitor patients. Scientists use our life science research instruments to study complex biological problems including causes of disease and potential new therapies or drugs.

Hospital laboratories are our core clinical diagnostic customers. Our life science customers include pharmaceutical and biotechnology companies, universities, medical schools and research institutions. Beckman Coulter has an installed base of more than 200,000 clinical and research systems operating in laboratories around the world.

Beckman Coulter has a leading position in Laboratory Automation. Research & Development as well as Production of our stand alone automation systems, the AutoMate 2500 Family (formerly known as OLA 2500), are located in Munich, Germany.

Bernina Plus GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Nanobiotechnology, Liposomes, Drug Delivery

Bernina develops smart oral drug delivery systems for therapeutic peptides. The proprietary technology is based on artificial envelopes created by lipids. In addition, these nano-particulate natural and synthetic lipids are used in coating and drug elution processes.



Bernina Plus

Contact:
Dr. Felix Groppe

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 52388740
Fax: +49 (0) 89 52388333
E-Mail: gropp@berninaplus.de
Internet: www.berninaplus.de

Bicoll GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Infectious Diseases, Drug Development, Medicinal Chemistry, Small Molecules, Oncology, Natural Compounds, Nutraceuticals

Bicoll is a biopharmaceutical company, offering pre-clinical support in the area of Drug Discovery from Natural Products and Medicinal Chemistry. To speed up drug discovery processes, Bicoll offers its drug like compound library BILOBAC N, consisting of already fractionated extracts, to global clients in drug discovery and related innovative fields. BILOBAC N provides enhanced probability of biological activity and reduced complexity of fine fractions, thus ready to use in client's screening systems. With innovative strategies and a proprietary technology platform, Bicoll is able to rapidly select only the best leads with superior drug-like profiles for further development. Subsequent medicinal chemistry and custom synthesis complete Bicoll's seamless substantial services.



Contact:
Dr. Kai Lamottke

Richard-Riemerschmid-Allee 27
D-81241 München
Phone: +49 (0) 89 82072564
Fax: +49 (0) 89 529178
E-Mail: lamottke@bicoll-group.com
Internet: www.bicoll-group.com

BIOCAM GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

BIOCAM as an medical engineering company acts since 2001 and has 28 employees. The company develops, produces and sells hard - and software imaging systems and guided imaging therapy systems. They are applied for early diagnoses, differential diagnoses and for the screening and the treatment of cancer and inflammation diseases *in vivo* on the patient. Anatomical and physiological information displayed simultaneously and are overlayable. The products which are already on the market apply to the skin sector; the current developments will enter the market sectors endoscopy, neurosurgery and plastic surgery.



Contact:
Dr. Thomas Plän

Friedenstr. 30
D-93053 Regensburg
Phone: +49 (0) 941 785398-0
Fax: +49 (0) 941 785398-10
E-Mail: marketing@biocam.de
Internet: www.biocam.de,
www.dermogenius.com



Contact:
Dr. Martina Reiter

Lise-Meitner-Str. 30
D-85354 Freising
Phone: +49 (0) 8161 53369-82
Fax: +49 (0) 8161 53369-84
E-Mail: info@bioeps.com
Internet: www.bioeps.com

BioEPS GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: PCR, RNAi & Antisense, Analysis, Clinical Research

BioEPS is doing trainings, event organization and project oriented research within the field of Life Science. The company is focused on molecular biology, especially qPCR technology, including experimental design, applications and biostatistics.

- Training: In cooperation with TATAA Biocenter Sweden, BioEPS offers in-house and customer specific hands-on courses which cover the latest aspects of qPCR technologies and biostatistics.
- Event Organisation: BioEPS is organizing bioscience events within the life science sector. Together with partners from industry and university a wide range of events can be organized.
- Project oriented research: BioEPS is supporting companies or universities in research projects and is doing design, optimisation and performance of qPCR experiments.



Contact:
Dr. Shannon Frances

Lochhamer Str. 9
D-82152 Martinsried
Phone: +49 (0) 89 895574-0
Fax: +49 (0) 89 895574-825
E-Mail: info@biomax.com
Internet: www.biomax.com

Biomax Informatics AG

BIOTECH BIOINFORMATICS

Keywords: Genomics, Proteomics

Biomax offers an innovative and powerful solution to accelerate knowledge-driven research processes in the life sciences. We support our customers with a platform that combines software products with knowledge resources, including oncology, nutrigenomics, plant research and functional genomics. Biomax provides computational solutions for better decision making and knowledge management in the life science industry.

Our flexible and comprehensive solutions provide access to relevant knowledge at the right time and in the right context. Biomax helps customers generate value from proprietary and public resources by extracting the knowledge indispensable for efficient data exploration and interpretation. Biomax focuses on integrating information to enable a knowledge-based approach to develop innovative life science products.



Contact:
Eugen Dahlmann

Bruckmannring 32
D-85764 Oberschleißheim
Phone: +49 (0) 89 3157000
Fax: +49 (0) 89 3153242
E-Mail: info@biomed.de
Internet: www.biomed.de

Biomed Labordiagnostik GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

The product range of BIOMED Labordiagnostik GmbH focuses on proven reagents for the in vitro diagnostic since 1976. BIOMED offers system reagents together with calibrators and controls. The reagents are stable, long-lasting, ready-to-use, a guarantee of reliable test results due to maximum test signals, linearity and correlation and available in economical sizes of pack. BIOMED system reagents have a favourable serum-reagent ratio and offer economically relevant benefits which ultimately bring about a quantifiable reduction in costs: 1. Reduced amount of time spent loading the machine, 2. Two to seven additional spaces on the R1 plate, 3. More methods possible on the device, 4. Analysis time shortened by up to 30 minutes. Using the lyophilised or ready-to-use calibrators and controls achieves reliable control results which conform to RiliBÄK and meet the most demanding requirements.

BIONORICA AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Fine Chemicals / Reagents, Bone / Joint Diseases, Cardiovascular Diseases, Respiratory Diseases, Medical Writing

Bionorica AG is one of the most successful manufacturers of phytotherapeutics in Germany. The product range focuses on diseases of the respiratory tract, gynaecological disorders and medications for the treatment of pain. As an essential Bionorica follows the principle of phytoneering as gold standard in modern phytotherapy. Phytoneering stands for deciphering the active principle in botanicals (PHYTO) using innovative technologies (engiNEERING) to develop and manufacture the most effective phytopharmaceuticals. Our expressed goal is to discover new active substances in order to develop effective drugs with minimized side effects.



Contact:
Sabine Kohl

Kerschensteiner Str. 11-15
D-92318 Neumarkt
Phone: +49 (0) 9181 23 19 0
Fax: +49 (0) 9181 23 12 65
Internet: www.bionorica.de

Biontex Laboratories GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Nanobiotechnology, RNAi & Antisense, Gene Transfer, Liposomes, Gene Therapy, Fine Chemicals / Reagents, Microscopy

Biontex is a genetic engineering company offering comprehensive range of products in field of transfection technology. Our new development METAFECTENE EASY is a GLOBAL INNOVATION in this product sector eliminating need for time-consuming optimization, while METAFECTENE SI is a reagent designed for efficient siRNA transfection. A major alternative is the direct transport of proteins into cells; a purpose for which the new reagents in the PROTEOfectene series were specifically developed. Our groundbreaking new Microfection product series enables the outstanding optical properties of μ -Slides in live-cell imaging to enhance the versatility and efficiency of nucleic acid and protein transfection applications. The product portfolio is completed by mycoplasma detection and removal kits.



Contact:
Dr. Stephan König

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 324799-50
Fax: +49 (0) 89 324799-52
E-Mail: contact@biontex.com
Internet: www.biontex.com

BioProof AG

CRO

BioProof offers high standard analytics of small molecules and biologicals (LC-MS/MS, HPLC, ELISA, bioassays) according to GLP, pharmacokinetic evaluation and support as well as medical writing (IDB, IMPD, IND etc.). Its multidisciplinary team has excellent expertise in registration-oriented project management at the intersections of chemistry, analytics, formulation, manufacturing, preclinical and clinical development, throughout the whole product-driven development process. BioProof is a privately owned and independent CRO, founded in 2001. Focusing on development until proof of concept, BioProof is continuously expanding its potential through partnering and networking.



Contact:
Dr. Alexander von Nieciecki

Weihenstephaner Str. 28
D-81673 München
Phone: +49 (0) 89 2444129-33
Fax: +49 (0) 89 2444129-30
E-Mail: info@bioproof.de
Internet: www.bioproof.de



Contact:
Dr. Martina Fuß

Heidemannstr. 164
D-80939 München
Phone: +49 (0) 89 31884-121
Fax: +49 (0) 89 31884-123
E-Mail: martina_fuss@bio-rad.com
Internet: www.biorad.com

Bio-Rad Laboratories GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Chip / Array Technology, PCR, Peptide/Protein, Proteomics, Genomics, Gene Transfer, Clinical Diagnostics

Bio-Rad Laboratories GmbH is a subsidiary of the Bio-Rad Group, one of the leading companies in the field of Life Science and Diagnostics with more than 6,500 employees throughout the world. Bio-Rad Laboratories develops, produces and distributes apparatus and consumables for molecular biological and biochemical research in Life Science and for Clinical Diagnostics.



Contact:
Dr. Günter Bertholdt

Boltzmannstr. 11a
D-85748 Garching
Phone: +49 (0) 89 28910-916
Fax: +49 (0) 89 28910-933
E-Mail: mail@bioregeneration.eu
Internet: www.bioregeneration.eu

bioregeneration™ GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

bioregeneration™ GmbH works in the field of tissue engineering using a proprietary technology. The technology comprises of the newly developed biomaterial "Xellulin", which can be individually shaped and causes no graft-reaction in the human body.



Contact:
Dr. Ralf Bäuerle

Obere Hauptstr. 10b
D-85386 Eching
Phone: +49 (0) 89 3799666-6
Fax: +49 (0) 89 3799666-99
E-Mail: info@biozol.de
Internet: www.biozol.de

BIOZOL Diagnostica Vertrieb GmbH

BIOTECH DEVICES & REAGENTS

Keywords: ELISA / EIA, Clinical Diagnostics, Proteomics, Small Molecules, Antibody, Peptide/Protein

Biozol Diagnostica Vertrieb GmbH markets and distributes products for immunology, cell biology, molecular biology and biochemistry, such as antibodies, recombinant proteins, ELISA/EIA, detection kits, biochemicals and further reagents for cell culture, flow cytometry, immunohistology and cytogenetics. The company represents almost 40 different worldwide known suppliers in Germany. Biozol offers additionally different types of services such as free product search.

Bristol-Myers Squibb GmbH & Co. KGaA

PHARMA & CHEMICAL INDUSTRY

Bristol-Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com.



Contact:
Dr. Bernd Winterhalter

Arnulfstr. 29
D-80636 München
Phone: +49 (0) 89 12142-0
Fax: +49 (0) 89 12142-392
E-Mail: info@b-ms.de
Internet: www.b-ms.de

BSL-BIOSERVICE Scientific Laboratories GmbH

CRO

Keywords: Clinical Research, Analysis, Pharmacology, Medical Writing, Toxicology, Pharmacokinetics

Since 1984, BSL BIOSERVICE is world-wide active as an CRO that concentrates on biological trials of pharmaceuticals, biologics, chemicals, medical devices and cosmetics. The internationally accepted approach of the institute with its various accreditations and certifications (GLP, GMP, DIN EN ISO 17025, FDA approved) guarantees high-quality services. Areas of expertise include e.g. ADME and Metabolism, Bioassays, Cell-Based Immunoassays and Immuno-toxicological Investigations, Clinical Sample Services, Toxicology, Pharmacology, Microbiology and Analytics BSL BIOSERVICE also offers comprehensive services for REACH. BSL BIOSERVICE is also active in the development of alternative test methods to animal experiments.



Contact:
Dr. Alexander Werner

Behringstr. 6/8
D-82152 Planegg
Phone: +49 (0) 89 899650-0
Fax: +49 (0) 89 899650-11
E-Mail: info@bioservice.com
Internet: www.bioservice.com

Cambrex GmbH

CMO

Cambrex is a top innovator entirely focussed on GMP custom manufacturing of small molecules (APIs and intermediates) for the pharmaceutical industry worldwide. 900 employees, turnover 250 million US dollar per year. Services: custom manufacturing from preclinic to launch of API, route selection, R&D, scale up, documentation, full scale production, chiral synthesis, chiral amines, microwave chemistry, cytotox compounds, hydrogenation, nitration, azide chemistry, high energy chemistry, full GMP documentation, stability studies, FDA and EMEA approved sites. Cambrex has successfully produced many APIs in preclinical, clinical and after launch volumes for European and US customers. Half of our business is here in Europe. We are locally present.



Contact:
Peter Berg

Gebrüder-Batscheider-Str. 4a
D-82041 Oberhaching
Phone: +49 (0) 89 666290-60
Fax: +49 (0) 89 666290-75
E-Mail: peter.berg@cambrex.com
Internet: www.cambrex.com



Contact:
Dr. Tobias Polifke

Eggenwatt 12
D-88138 Weißensberg
Phone: +49 (0) 8389 929399-0
Fax: +49 (0) 8389 929399-9
E-Mail: info@candor-bioscience.de
Internet: www.candor-bioscience.de

CANDOR Bioscience GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Clinical Diagnostics, ELISA / EIA, Chip / Array Technology, Toxicology

CANDOR – The Technology Solution Provider for Optimising your Immunoassays
CANDOR Bioscience provides services and products for optimising and stabilising immunoassays. Due to optimisation you can significantly improve the reliability of results. We are supplier and service provider for diagnostics, GLP laboratories and pharmaceutical industry. CANDOR provides for every application the optimal solution.

The innovative LowCross buffer® reduces cross reactivities, interference and matrix effects which are characteristic for blood, serum and tissue specimen. All products are available in bulk quantities to manufacturers of test kits. For pharmaceutical research and diagnostics we develop and validate ELISA according to relevant guidances (e.g. FDA). CANDOR is DIN EN ISO 9001:2000 certified.



We make it visible.

Contact:
Dr. Richard Ankerhold

Kistlerhofstr. 75
D-81379 München
Phone: +49 (0) 89 909000-800
Fax: +49 (0) 89 909000-820
E-Mail: info@zeiss.de
Internet: www.zeiss.de/microdissection

Carl Zeiss Microlimaging GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Clinical Research, Clinical Diagnostics, Microscopy, Tissue Engineering / Cell Culture, Analysis

Carl Zeiss Microlimaging GmbH offers a broad range of modern and innovative microscope systems and solutions for different fields such as biotechnology, biomedical and clinical research as well as routine and industrial applications. Carl Zeiss Microlimaging employs about 1,750 staff worldwide and has its direct sales force in 130 countries. The company's headquarter is in Jena. At its Munich site Carl Zeiss Microlimaging is focusing on software development, systems for laser microdissection and its application as well as digital slide and automation technology. In addition, in Munich the company is maintaining a unique facility hosting a modern application center and an up-date laboratory for biomedical and clinical research, molecular analysis and imaging. Practical courses, workshops and training are held on a regular base and customer services are offered.



Contact:
Aart Brower

Joseph-Wild-Str. 20
D-81829 München
Phone: +49 (0) 89 451519-010
Fax: +49 (0) 89 451519-019
E-Mail: info@celgene.de
Internet: www.celgene.de

Celgene GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Drug Development, Small Molecules, Hematology, Drug Delivery, Oncology

Celgene is a globally acting biopharmaceutical company, founded in New Jersey (USA) in 1986. Celgene is mainly active in developing and distributing drugs in oncology and immunotherapy. Since 2006, Celgene operates a German subsidiary in Munich-Riem. For further information visit: www.celgene.de

cellasys GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Devices, Chip / Array Technology, Pharmacokinetics, Drug Development, Tissue Engineering / Cell Culture, Toxicology

cellasys offers system solutions for online analysis of living cells. These include services as research and development, production and maintenance of cell based assays. Furthermore we are consultant for development of applications, data analysis and data interpretation.



Contact:
Joachim Wiest

Karlstr. 96
D-80335 München
Phone: +49 (0) 89 2000110-74
Fax: +49 (0) 89 2000110-76
E-Mail: wiest@cellasys.com
Internet: www.cellasys.com

CellMed AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Diabetics, CNS, Peptide/Protein, Cell Therapy, Drug Delivery, Drug Development

CellMed is developing encapsulated cellular systems for the delivery of therapeutic substances right in the patient. CellMed uses proprietary encapsulation technology and a cell line based on mesenchymal stromal cells. The cells are designed to secrete the desired proteins or peptides. These systems are produced according to GMP and are currently in clinical trials for the treatment of stroke. The engineered peptide here is a proprietary version of GLP-1 with specific anti-apoptotic properties.

For a second version of the GLP-1 AstraZeneca has an option to exclusively license that version for the treatment of diabetes and obesity.

A "pure" bead product for cosmetic dermatology has been developed and will be introduced to the market by Merz.



Contact:
Dr. Peter Geigle

Industriestr. 19
D-63755 Alzenau
Phone: +49 (0) 6023 9181-0
Fax: +49 (0) 6023 9181-33
E-Mail: info@cellmed.de
Internet: www.cellmed.de

Centronic GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Clinical Research, Clinical Diagnostics

Centronic GmbH is a german manufacturer, with a certified Quality Management System according EN ISO 9001:2000 and EN ISO 13485:2003, and distributor of a big range of high qualitative clinical chemistry reagents in fluid and lyophilised form for the determination of enzymes, electrolytes, substrates, lipids and proteins. The product range is completed by Latex reagents, controls-calibrators and our registered additive for waterbaths Prothermal. The products are distributed worldwide.

Our team consist of highly engaged scientists from different special fields with an experience of many years in the area of clinical chemistry.



Contact:
Dr. Johannes Betz

Am Kleinfeld 11
D-85456 Wartenberg
Phone: +49 (0) 8762 724300
Fax: +49 (0) 8762 724312
E-Mail: info@centronic-gmbh.com
Internet: www.centronic-gmbh.com



Contact:
Dr. Katrin Freund

Landsberger Straße 94
D-80339 München
Phone: +49 (0) 89 895570-0
Fax: +49 (0) 89 895570-15
E-Mail: info@cephalon.com
Internet: www.cephalon.de

Cephalon GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Pain, Oncology, Neurology, Hematology, CNS

Cephalon GmbH is the German affiliate of the biopharmaceutical company Cephalon Inc. headquartered in Frazer, Pennsylvania. Cephalon GmbH markets and promotes drugs for the treatment of epilepsy, Parkinson's Disease, narcolepsy, bipolar disorders, breakthrough cancer pain and leukemia with its own sales forces in Germany and Austria.



Contact:
Dr. Anna Niebling

Waldstrasse 22
D-82049 Pullach
Phone: +49 (0) 89 74442700
Fax: +49 (0) 89 79367571
E-Mail: aniebling@chemdiv.com
Internet: www.chemdiv.com

ChemDiv, Inc.

CRO

Keywords: CNS, Neurology, Drug Development, Medicinal Chemistry, Pain, Clinical Research, Pharmacology

ChemDiv, a global Contract Research Organization (CRO), offers Integrated Discovery outSourceTM solutions that cover a complete range of disciplines from medicinal chemistry to clinical development needed to bring new drugs from target to market. With successful 20 years business record and over 500 research associates, the company puts forward unique translational expertise to help accelerate its partners R&D programs. ChemDiv provides Proof of Concept data in less time and at a fraction of the costs typically seen in the industry with keeping the high quality standards, all of which plays a critical role in mitigating risks associated with full scale clinical development.



Contact:
Dr. Andrea Kofler

Mühlenstr. 1
D-83064 Raubling
Phone: +49 (0) 8035 9849-28
Fax: +49 (0) 8035 9849-30
E-Mail: kofler@chrombios.com
Internet: www.chrombios.com

ChromBios GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Founded in 1998, ChromBios is focused on the field of Molecular Cytogenetics (fluorescence in situ hybridisation, FISH). The company's aims are to provide service and products for chromosome analysis tailored to the needs of the customers. We offer "FISH service" such as chromosome analysis with "chromosome painting", mapping of clones, characterisation of cancer cell lines and animal models in genome research. We especially focus on multi colour karyotyping human tumour cells and other transformed cell lines (for example for patent applications). ChromBios also offers multi colour chromosome painting of mouse cells to identify translocations in mouse tumours and to characterise mouse ES cells. Apart from human and mouse, we also provide service in the characterization of chromosomes from other animal model species including rat, hamster, cat, and various live stock animals.

ChromoTek GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Clinical Diagnostics, Proteomics, Peptide/Protein

ChromoTek GmbH, a biotech spin-off from the LMU Munich founded in 2008, aims to establish Chromobodies® (highly efficient functional binding reagents for a multitude of immuno-logical and biochemical applications) as superior substitutes for conventional antibodies in areas like proteome analysis, target screening/validation, cell sorting and live cell HCA. On the basis of its technology (patent pending) the team of 5 biologists around CEO Ulrich Rothbauer develops novel analytical and preparative solutions for the biomolecular research market. It has successfully launched the GFP-Trap®, the best commercially available pull-down reagent for GFP and/or GFP fusion proteins.



Contact:
Dr. Ulrich Rothbauer

Großhadernerstr. 2
D-82152 Martinsried
Phone: +49 (0) 89 23526927
Fax: +49 (0) 89 218074236
E-Mail: u.rothbauer@chromotek.com
Internet: www.chromotek.com

Cibitest GmbH & Co. KG

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Devices, Chip / Array Technology, ELISA / EIA

CibiTest was founded in 2000 with the scientific goal to develop a new generation of on-site diagnostic rapid tests, resulting in a test format which combines highest sensitivity of a fluorescent label with a rapid and simple dipstick assay. Based on this technology, CibiTest offers its customers the possibility to develop and market rapid tests in areas which were not accessible so far due to the missing technological link. CibiTest's technology uncovers opportunities in the huge human diagnostics and industrial diagnostics sectors, where the need for highest sensitivities limited the possibilities of on-site testing up to now. The membership in a group of analytical companies offers CibiTest an excellent scientific and economical basis and makes it an ideal partner for diagnostic companies that are ready to take the next step in developing the next generation of on-site rapid tests.



Contact:
Dr. Johannes Bonenberger

Boschstr. 3
D-89231 Neu-Ulm
Phone: +49 (0) 731 98557-30
Fax: +49 (0) 731 98557-31
E-Mail: info@cibitest.de
Internet: www.cibitest.de

Clinical Trial Care GmbH

CRO

Keywords: Rheumatology, Pain, Nephrology, Metabolic Diseases, Dermatology, Monitoring, Clinical Research

Clinical Trial Care GmbH founded in 2001 is a CRO located in the southwest of Munich (Krailling) and provides the full scope of clinical and biometric services required for the conduct of clinical trials of phase II-IV, post marketing surveillance as well as non-interventional or epidemiologic studies. The very experienced, flexible and successful team ensures expert support and a responsive commitment. The CRO is headed by Dr. Christa Sommerburg and Andreas Behr (Geschäftsführer) with a long standing history of clinical research.



Contact:
Dr. Christa Sommerburg

Pionierstr. 2
D-82152 Krailling
Phone: +49 (0) 89 8638933-10
Fax: +49 (0) 89 8638933-99
E-Mail: christa.sommerburg@clinical-trial-care.de
Internet: www.clinical-trial-care.de



Contact:
Dr. Hans Wolf

Dachauer Str. 37
D-80335 München
Phone: +49 (0) 89 5455 8355
Fax: +49 (0) 89 5574 43
E-Mail: germany@clintec.com
Internet: www.clintec.com

ClinTec GmbH

CRO

Keywords: Cardiovascular Diseases, Neurology, Drug Development, Oncology, Clinical Research, Medical Writing, Regulatory Affairs

ClinTec International is a privately owned full service global Clinical Research Organization covering more than 30 developed and emerging countries. It was founded in 1997 by Dr Rabinder Buttar, the company's President & CEO. In 2007, the Global Clinical Research Centre of Excellence was established in Munich recruiting a functional unit of thirty professionals from the former European headquarters of an international pharmaceutical company. It is the global home for standards, tools and industry best-practice in the following functions: Regulatory Affairs, Clinical Research, Data Management & Biostatistics, Medical Writing and Quality Assurance. We are working seamlessly with our clients, understanding their needs and constraints in order to deliver optimal solutions.



Contact:
Dr. Andreas Klostermann

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 3187-2662
Fax: +49 (0) 89 3187-3835
E-Mail: info@conogenetix.de
Internet: www.conogenetix.de

conoGenetix biosciences GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Peptide/Protein, CNS, Pain, Cardiovascular Diseases

conoGenetix biosciences GmbH is a biotechnology company that focuses on the development of peptide-based drugs for the treatment of currently untreatable neurological and cardiovascular disorders. These therapeutics - isolated from complex animal venoms - display the advantage of an extremely high specificity resulting in reduced side effects for the patient. Alliances with academic research groups and a network of co-operators throughout the world enhance the company's capabilities of drug discovery and development.



Contact:
Jürgen Schäfer

Neuhauser Str. 47
D-80331 München
Phone: +49 (0) 89 236650-0
Fax: +49 (0) 89 236650-50
E-Mail: schaefer@conreso.com
Internet: www.conreso.com

Conreso GmbH

CRO

Keywords: Drug Development, Monitoring, Logistics, Clinical Research

Conreso, established in 1990, BVMA member, offers a wide range of clinical research services. Conreso shows an impressive record of successful FDA inspections and significant contributions to important new product licenses in Europe and the USA. Having recruited more than 30,000 patients between 0 and 17 years of age proves the company's unique expertise in pediatric trials. The Hannover Clinical Trial Center, a joint venture of Conreso and the Medizinische Hochschule Hannover, provides Conreso's clients access to the clinical expertise and the comprehensive diagnostic and therapeutic facilities of one of the leading academic medical institutions in Germany. The Conreso Institute of Veterinary medicine provides all types of veterinary studies.

Corimmun GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Peptide/Protein, Cardiovascular Diseases, Inflammation

CORIMMUN is a spin-off from the universities of Würzburg and of Tübingen. The projects are funded by two grants of the Go Bio project of the BMBF. Corimmun is financed by the MIG AG, KfW Bank, Bayernkapital, HTGF and Bio-M. The company is developing new drugs to treat congestive heart failure and atherosclerosis, the most common causes of mortality in developed countries. Two innovative products COR-1 and COR-2 are currently in preclinical development. COR-1 is a peptide drug candidate to prevent the auto-antibody-mediated propagation of heart failure. COR-2 is a biological which prevents foam cell formation in atherosclerotic plaques. The founders and management of Corimmun bring together knowledge and reputation in research and clinical medicine together with biotech experience.



Contact:
Dr. Goetz Münch

Lochhamer Str. 29, Rückgebäude
D-82152 Martinsried
Phone: +49 (0) 89 8565-2010
Fax: +49 (0) 89 8565-2020
E-Mail: info@corimmun.com
Internet: www.corimmun.com

Coriolis PharmaService GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Drug Delivery, Analysis, Antibody, Peptide/Protein, Small Molecules, Vaccines

Coriolis PharmaService is one of the leading, independent service providers in research and development of formulations for biopharmaceutics and analytical methods. An interdisciplinary team of highly qualified scientists with many years of experience develops individual and innovative solutions. Formulation development ranging from early screening of excipients to the final marketed liquid or lyophilized formulation is offered. Aggregate and particle characterization by innovative analytical methods, i.e. AF4, Nanosight® or Micro-flow imaging™ and stability / comparability studies according to the ICH guidelines or lyophilization process development, are just some examples illustrating the outstanding services provided. Individual solutions for biopharmaceuticals.



Contact:
Dr. Michael Wiggenhorn

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 5424498-10
Fax: +49 (0) 89 5424498-22
E-Mail: info@coriolis-pharma.com
Internet: www.coriolis-pharma.com

Cowatec AG

BIOTECH AGRO, FOOD, ENVIRONMENT

Cowatec AG, based in Burglengenfeld in Bavaria, specialises in hi-tech biogas plants for the efficient generation of energy. Its range of services covers the planning, construction and operation of new plants, as well as the project optimisation of existing biogas projects.



Contact:
Dr. Richard Bulka

Schmidmühlener Str. 53
D-93133 Burglengenfeld
Phone: +49 (0) 9471 3075-0
Fax: +49 (0) 9471 3075-10
E-Mail: welcome@cowatec.com
Internet: www.cowatec.com



Contact:
Dr. Michael Schäffer

Am Klopferspitz 19a
D-82152 Martinsried
Phone: +49 (0) 89 700 760 - 170
Fax: +49 (0) 89 700 760 - 222
E-Mail: schaeffer@crelux.com
Internet: www.crelux.com

CRELUX GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: 3 D Structural Analysis

CRELUX specializes in tailor made protein crystallography and fragment based discovery services. We have solved hundreds of complex structures for Pharma and biotech companies worldwide, and are advancing innovations in protein expression to promote the availability of high quality crystallizable protein. Our Off-the-Shelf portfolio of readily available proteins grants turn around times of customer compound/target complex structures within weeks. Crystallography services from cloning to high resolution complex structure are provided under individual agreements following our customer's needs. Based on novel screening technologies we are offering end-to-end fragment based discovery services.



Contact:
Dr. Tobias Schmidt

Hainbuchenring 4
D-82061 Neuried
Phone: +49 (0) 89 895577-77
Fax: +49 (0) 89 895577-99
E-Mail: tschmidt@pharmanet.com
Internet: www.pharmanet.com

CRO-PharmaNet Services GmbH

CRO

Keywords: Devices, Medical Writing, Monitoring, Logistics, Clinical Research, Analysis, Drug Development

PharmaNet Development Group, a global, drug development services company, provides clinical development services including consulting, Phase I and bioequivalence clinical studies, Phase II-III clinical development programs, Phase IIIb-IV surveys, registries, and programs, as well as bioanalytical laboratory services through its subsidiaries Anapharm, Anapharm Europe, Keystone Analytical, and Taylor Technology.



Contact:
Dr. Ulrich Delvos

Grillparzerstr. 14
D-81675 München
Phone: +49 (0) 89 2000-14210
Fax: +49 (0) 89 2000-14279
E-Mail: info@curacyte.com
Internet: www.curacyte.com

Curacyte AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Peptide/Protein, Multi organ failure, Cardiovascular Diseases, Drug Development

Curacyte AG and its US subsidiary Apex Bioscience, Inc. are focussed on the clinical development of a hospital therapeutic based on human haemoglobin. Hemoximer (PHP, pyridoxalated haemoglobin polyoxyethylene) is currently examined in a multi-European, placebo-controlled Phase III trial in patients suffering from distributive shock.

DABIO Gesellschaft für Auftragsforschung mbH

CRO

Keywords: Rheumatology, Respiratory Diseases, Pain, Ophthalmology, Oncology, Hepatology, Dermatology, Cardiovascular Diseases, Allergy, Drug Development

DABIO is a privately owned, independent CRO founded in 1994. DABIO provides a wide range of cost effective services as an external R&D partner for pharma and biotech companies. DABIO's qualified staff has many years of industrial experiences. We provide full or partial services for clinical trials phase II-IV, post marketing surveillances and phase I trials in cooperation with different partners. Our services include concept and protocol development, trial administration and monitoring, data management, biometrics and medical writing according to ICH-GCP guidelines and national law. DABIO provides special services such as pharmacoconomics, expert reports, publications, organization of meetings and online solutions for EDC.



Contact:
Dr. Heike Wöhling

Haringstr. 19
D-85635 Höhenkirchen
Phone: +49 (0) 8102 8950 6
Fax: +49 (0) 8102 8950 89
E-Mail: info@dabio.com
Internet: www.dabio.com

DAIICHI SANKYO DEUTSCHLAND GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Drug Development, Antibiotics

DAIICHI SANKYO is a global pharmaceutical company that focuses on researching and marketing innovative medications. The company was created in 2005 through the merger of two traditional Japanese enterprises, Daiichi and Sankyo. With net sales of nearly € 5.9 billion in fiscal year 2008, DAIICHI SANKYO is one of the world's 20 leading pharmaceutical companies. The company's world headquarters is in Tokyo, and its European base is located in Munich. DAIICHI SANKYO has affiliates in 12 European countries and has been one of the strongest Japanese pharmaceutical companies located in Europe since it set up European production facilities and marketing offices in 1990. The company's research activities focus on the areas of cardiovascular diseases, hematology, diabetes, anti-infectives and cancer. Its aim is to develop medications that are "best" in their class or to create new classes of pharmaceutical drugs.

For more information, please visit: www.daiichi-sankyo.eu



Contact:
Olaf Lamberz

Zielstattstr. 48
D-81379 München
Phone: +49 (0) 89 7808-0
Fax: +49 (0) 89 7808-202
E-Mail: service@daiichi-sankyo.eu
Internet: www.daiichi-sankyo.eu

Definiens AG

BIOTECH BIOINFORMATICS

Keywords: Analysis, Toxicology, Oncology, Microscopy, Automation, 3 D Structural Analysis, Drug Development

Definiens is the number one Enterprise Image Intelligence company for analyzing and interpreting images on every scale - from microscopic cell structures to satellite images. Based on human cognitive perception processes, Nobel laureate Prof. Gerd Binnig developed the Definiens Cognition Network Technology® to extract intelligence from images. Definiens enables Life Science organizations to analyze and interpret vast numbers of images accurately and consistently. By automating image analysis processes, Definiens improves the measurement of cell assays, the examination of tissue samples and the interpretation of non-invasive imaging, enabling high-content screening and digital pathology.



Contact:
Eva Tietz

Trappentreustr. 1
D-80339 München
Phone: +49 (0) 89 231180-0
Fax: +49 (0) 89 231180-90
E-Mail: etietz@definiens.com
Internet: www.definiens.com

DelphiTest GmbH

Contact:

Dr. Frank Pfannenschmid

Unter den Schwibbögen 23
D-93047 Regensburg
Phone: +49 (0) 941 2986615
Fax: +49 (0) 941 6963846
E-Mail: info@delphitest.de
Internet: www.delphitest.de

DelphiTest GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Laboratory, Clinical Diagnostics, Genomics, PCR, Analytical Chemistry

The company's core technology capitalizes on the revolutionary development of DNA analysis, DNA sequencing and DNA fragment analysis.

Delphitest GmbH focussed on family relationship testing especially for private customers but also for courts, lawyers, medical doctors, youth welfare offices and embassies. We developed new techniques and tests, e.g. paternity tests for dogs, sibling tests etc. In addition, we offer genetic tests for hereditary diseases like Chorea Huntington, Alzheimers Disease or Canavan Syndrome and a genetic blood group test.

Delphitest provides its high level of competence in DNA techniques to scientific partners like universities, hospitals or pharmaceutical companies in Europe.



Contact:

Dr. Ulf Henseling

Seeschafter Str. 27
D-82393 Iffeldorf
Phone: +49 (0) 8856 803605
Fax: +49 (0) 8856 803607
E-Mail: DiaServe@t-online.de
Internet: www.diaserve.de

DiaServe Laboratories GmbH

BIOTECH DEVICES & REAGENTS

DiaServe is a primary manufacturer of human and animal blood derived raw materials for diagnostic industry. Based on this raw materials DiaServe also offers tailor-made in vitro controls/calibrators for medical laboratories.

The company was established in 1997 with a mission to identify, develop and manufacture in vitro diagnostics mainly on OEM basis for diagnostic manufacturers and clinical laboratories.



Contact:

Dr. Franz Kerek

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 856625-55
Fax: +49 (0) 89 856625-56
E-Mail: info@donatur.de
Internet: www.donatur.de

DoNatur GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Rheumatology

DoNatur GmbH develops new therapeutics from herbal extracts with traditionally confirmed therapeutic efficiency. The comprehensive analysis of the genuine extracts, the isolation and structural characterization of the active substances and the test of their pharmacological activities constitutes the main competence of the company. Over the last years DoNatur has successfully developed a new immunomodulatory acting natural substance which has been proved highly efficacious for the therapy of rheumatic diseases.

Dr. Nibler & Partner

CRO

Keywords: Drug Development, Devices, Clinical Research, Pharmacology, Medical Writing

Legal requirements for pharmacovigilance are continuously rising. The fulfillment turns out to be a major burden for small and medium sized enterprises.

We provide a complete pharmacovigilance full-service solution:

- 24-hours availability for receipt of adverse event reports by phone, fax or e-mail
- Literature screening and -review ■ Data entry and MedDRA coding ■ Follow-up by medically qualified personnel (MD, RN) ■ Scientific assessment by experienced physicians ■ Authority reporting either electronically or on paper ■ SUSAR reporting ■ Preparation of periodic reports: PSUR and ASR ■ Preparation and maintenance of risk management plans ■ Implementation and optimization of your pharmacovigilance system ■ SOP preparation or revision ■ Audits and guidance through inspection



Contact:
Dr. Reinhard Nibler

Fürstenriederstr. 105
D-80686 München
Phone: +49 (0) 89 56823726
Fax: +49 (0) 89 92185265
E-Mail: mail@dr-nibler.de
Internet: www.dr-nibler.de

e.gene Biotechnologie GmbH

BIOTECH BIOINFORMATICS

Keywords: Pharmacogenomics, Genomics

e.gene Biotechnologie GmbH is a service provider in microbial genomics and pharmacogenomics.

We perform for our academic and industrial customers complete microbial genome analyses from genome sequencing to annotation and pathway reconstruction.



Contact:
Dr. Hans-Peter Klenk

Poeckinger Fussweg 7a
D-82340 Feldafing
Phone: +49 (0) 8157 9963-164
Fax: +49 (0) 8157 9963-162
E-Mail: info@egene-biotech.de
Internet: www.egene-biotech.de

ELLA Biotech GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Fine Chemicals / Reagents, Clinical Research, Antisense/Nucleotides, Genomics, RNAi & Antisense

Our focus is the synthesis of special oligoribonucleotides for selected projects in diagnostics, chip technologies, genesynthesis and further topics – following quality standards which you would appreciate and expect in your own lab. The guidelines for the synthesis standards can be defined by our customers themselves. Through our validated technology platform, our experienced interdisciplinary team and our resolute attitude towards the highest quality in our products we offer tangible advantages to our customers and partners.



Contact:
Dr. Peter Frischmann

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 70939316
Fax: +49 (0) 89 70939440
E-Mail: info@ellabiotech.com
Internet: www.ellabiotech.com



Contact:
Petra Willnauer

Walter-Gropius-Str. 17
D-80807 München
Phone: +49 (0) 89 5506988-0
Fax: +49 (0) 89 5506988-88
E-Mail: willnauerp@ebsi.com
Internet: www.emergentbiosolutions.com

Emergent Product Development Germany GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Infectious Diseases, Vaccines

Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and therapeutics that assist the body's immune system to prevent or treat disease. Emergent's marketed product, BioThrax® (Anthrax Vaccine Adsorbed), is the only vaccine licensed by the U.S. Food and Drug Administration for the prevention of anthrax infection. Emergent's development pipeline includes programs focused on anthrax, botulism, tuberculosis, typhoid, hepatitis B and chlamydia. To learn more visit www.emergentbiosolutions.com and www.biorthrax.com.



Contact:
Kathrin Zahn


Walter-Gropius-Str. 17
D-80807 München
Phone: +49 (0) 89 5506988-0
Fax: +49 (0) 89 5506988-88
E-Mail: zahnk@ebsi.com
Internet: www.emergentbiosolutions.com

Emergent Sales and Marketing Germany GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Infectious Diseases, Vaccines

Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and therapeutics that assist the body's immune system to prevent or treat disease. Emergent's marketed product, BioThrax® (Anthrax Vaccine Adsorbed), is the only vaccine licensed by the U.S. Food and Drug Administration for the prevention of anthrax infection. Emergent's development pipeline includes programs focused on anthrax, botulism, tuberculosis, typhoid, hepatitis B and chlamydia. To learn more visit www.emergentbiosolutions.com and www.biorthrax.com.



Contact:
Dr. Franz X. Welser

Hebbelstr. 61
D-85055 Ingolstadt
Phone: +49 (0) 841 3796013
Fax: +49 (0) 841 8817185
E-Mail: info@empgenetech.com
Internet: www.empgenetech.com

EMP Genetech

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Drug Development, Tissue Engineering / Cell Culture, Clinical Diagnostics, Peptide/Protein

EMP Genetech conducts development and production of recombinant proteins as a service provider for research departments in industry and academia. For production HEK293 (hn embryonic kidney) cells are being used. These cells are distinguished for the expression of glycosilated, correctly processed and modified proteins. The expressed proteins show excellent bioactivity compared to other expression systems.

The biomolecules are produced in serum free culture medium of safe origin. EMP Genetech offers all working steps from cloning of the GOI to chromatographic purification of the produced protein.

There are developed stable cell lines of high productivity. These are cultivated as suspension cell cultures in stirred bioreactors usually in a continous mode. The expression product is purified from cell supernatant or cell extract by classical column chromatographic methods.

The bioactivity will be analysed by enzymatic or cell assays.

Entelechon GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Antibody Production Service, Genomics, PCR, Chip / Array Technology

Entelechon, founded in 1999, is an internationally operating biotech service provider specialized in synthetic biology. Entelechon integrates a strong DNA synthesis platform for oligos and genes, in-house bioinformatics software development and molecular biological services.

Entelechon provides workflows centered on synthetic biology concepts, such as library screening, protein engineering and creation of artificial metabolic networks. Its bioinformatics expertise focuses on gene optimization and combinatorial biology.

The company maintains a network comprised of strategic partnerships with academic institutions and companies. Among Entelechon's long term customers are major international pharma and biotech players, as well as internationally renowned universities.



Contact:
Christiane Proll

St.-Veit-Weg 2
D-93051 Regensburg
Phone: +49 (0) 941 9468360
Fax: +49 (0) 941 9468366
E-Mail: info@entelechon.com
Internet: www.entelechon.com

EpiCept GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Drug Development, Hematology, Immune Therapy, Pain

EpiCept GmbH is a subsidiary of EpiCept Corp. (Tarrytown, NY) which is a specialty pharmaceutical company that focuses on fulfilling unmet medical needs in cancer treatment and pain management. The Company possesses an approved cancer product and a deep and balanced pipeline of nine clinical product candidates.

EpiCept Corp. is listed on both the NASDAQ National Market and the OME Stockholm Exchange, under the symbol "EPCT".



Contact:
Uschi Lang

Goethestr. 4
D-80336 München
Phone: +49 (0) 89 680872-0
Fax: +49 (0) 89 680872-20
E-Mail: info@epicept.de
Internet: www.epicept.com

EpiGene GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Agrobiotechnology, Genomics

EpiGene GmbH, founded in 1999, is a genomics-based research and development company focusing on applications in plant protection. The core competencies comprise the molecular characterization of plant-pathogen interactions and the development of high throughput systems for molecular diagnostics of involved genetic factors. In addition, research efforts include investigations of the mode of action of plant protective agents at the molecular level and the identification of mutations or differentially expressed genes in pathogens as potential new targets.



Contact:
Dr. Friedrich G. Felsenstein

Hohenbachernstr. 19-21
D-85354 Freising
Phone: +49 (0) 8161 4990-80
Fax: +49 (0) 8161 4990-89
E-Mail: Friedrich.Felsenstein@EpiLogic.de
Internet: www.epigene.de



Contact:
Dr. Friedrich G. Felsenstein

Hohenbacherstr. 19-21
D-85354 Freising
Phone: +49 (0) 8161 4990-80
Fax: +49 (0) 8161 4990-89
E-Mail: Friedrich.Felsenstein@EpiLogic.de
Internet: www.EpiLogic.de

EpiLogic GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Agrobiotechnology, Genomics

EpiLogic is a new European wide operating company involved in product development based on genomic analysis of fungal pathogens propagated by wind in agricultural crops (at present: cereals and vine). Pathogen analysis of virulence and fungicide sensitivity are used as decision support for breeding, choice of cultivar and fungicide management to ensure sustainable agriculture. A genotype bank of several pathogens is currently being set up to offer high quality inoculum for selection in laboratory, greenhouse and field. Additionally, methods are under development for analysing and culturing new pathogens.



Contact:
Dr. Elke Krämer

Thomas-Dehler-Str. 27
D-81737 München
Phone: +49 (0) 89 62731-0
Fax: +49 (0) 89 62731-499
E-Mail: elke.kraemer@essex.de
Internet: www.essex.de

Essex Pharma GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Drug Delivery, Allergy, Cardiovascular Diseases, CNS, Dermatology, Hepatology, Oncology

Essex Pharma is the German country operation of the US.-based Schering-Plough (S-P) Corporation, a global health care company, leading in research of pharmaceutical and health care products with a strong position in biotechnology. S-P spent 2.9 billion US \$ on R&D in 2007. Essex Pharma markets a broad range of innovative drugs for the following therapeutic fields: allergology, anesthesia, cardiovascular, CNS, dermatology, hepatology, immunology, women's health and oncology. Essex Pharma supplements its range by partnerships and licensing of new biotech products, i.e. infliximab, an immune modulating agent for the treatment of Crohn's disease, colitis ulcerosa, rheumatoid and psoriatic arthritis.



Contact:
Felix Raslag

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 12 59 81-0
Fax: +49 (0) 89 12 59 81-19
E-Mail: info@eticur.de
Internet: www.eticur.de

eticur) GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

eticur) is headquartered in the IZB in Martinsried and cooperates with the Department of Transfusion Medicine and Haemostaseology of the University Hospital of Erlangen. Based on the idea that umbilical cord blood contains multipotent adult stem cells, the cord blood is prepared and stored for potential later use. These cells might in future play an important role in therapies including regenerative medicine. Our priority is to grant the most secure storage, highest quality and extensive testing by highly qualified personnel. eticur) grants the storage of stem cells following the highest quality-standards of the Federal Board of Physicians and the Institute for Sera and Vaccine (Paul-Ehrlich-Institute).

Eurofins Medigenomix GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Agrobiotechnology, Genomics, Pharmacogenetics, Clinical Research, Clinical Diagnostics, Pharmacogenomics

Since foundation in 1998 Eurofins Medigenomix has evolved into a recognized reliable outsourcing partner for the biopharmaceutical industry and academic institutions for high fidelity DNA sequencing incl. GLP sequencing and molecular biological techniques. It expanded successfully with services for DNA forensics, animal and plant breeding, food authenticity testing and for Pharma/Pharmacogenetics, e.g. genotyping, DNA/RNA preparation, polymorphism screening, mutation analysis, expression analysis, exclusive marker set for the general identification of responder/non-responder in the scope of clinical studies. Medigenomix is certified according to ISO 9001 and ISO 17025 and audited by pharmaceutical clients for GLP.



Contact:
Dr. Brigitte Obermaier

Anzinger Straße 7a
D-85560 Ebersberg
Phone: +49 (0) 8092 8289-200
Fax: +49 (0) 8092 8289-201
E-Mail: info@medigenomix.de
Internet: www.medigenomix.de

Eurofins MWG Operon

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Genomics, Antisense/Nucleotides, Automation, PCR, Small Molecules

Eurofins MWG Operon, founded in 1990 and member of the Eurofins Group, is an international provider of genomic services established around the core business lines DNA sequencing, oligonucleotide, siRNA and gene synthesis. The companies main mission is focussed on customer convenience and high quality services in industrial scale for the life science industries and academic research institutions around the world.



Contact:
Dr. Jutta Huber

Anzinger Straße 7a
D-85560 Ebersberg
Phone: +49 (0) 8092 8289-0
Fax: +49 (0) 8092 21084
E-Mail: info@mwdna.com
Internet: www.eurofinsdna.com

FermCom Bio-VNT – Biologische Verfahrenstechnik und Netzwerk-Technologie

BIOTECH DEVICES & REAGENTS

Keywords: Monitoring, Devices

FermCom Bio - VNT is a research and development company focused on biotechnology and network applications. FermCom Bio - VNT is in development of an innovative in-situ online-analysis system by using a high-technology bioreactor. With the help of the device for classification of biomolecules in liquid there will be new technologies brought together to a new biosensor system "Multisensor-MiniLab". The use of bio-chips allows to miniaturize online real-time-analysis. In cooperation with appropriate high-tech partner companies FermCom Bio - VNT creates a national / international network via Internet / Intranet for data tele-transfer. International patent-applications (PCT) are the cornerstone of the company's strategy. FermCom's field of activity is development a new compact system for non-invasive process-monitoring in the area of biotechnology, fermentation- and environment-analytics.



Contact:
Albert Stumpf

Aubinger Str. 30
D-82166 Gräfelfing
Phone: +49 (0) 89 895300-24
Fax: +49 (0) 89 895300-25
E-Mail: info@fermcom.de
Internet: www.fermcom.de



Contact:
Martin Krauss

Heimeranstr. 35
D-80339 München
Phone: +49 (0) 89 893119-0
Fax: +49 (0) 89 893119-20
E-Mail: martin.krauss@fgk-cro.de
Internet: www.fgk-cro.de

FGK Clinical Research GmbH

CRO

Keywords: Clinical Research, Drug Development

FGK Clinical Research GmbH is a Europe-based full service Contract Research Organization offering the complete range of clinical development and consulting services to pharmaceutical, biotechnology, and medical device companies. FGK headquarters are in Munich, with more than 60 highly-skilled and experienced employees working on local and global projects, covering clinical studies Phases I to IV and post-marketing studies. In addition, FGK has subsidiaries in the UK and Czech Republic, and further subsidiaries are planned. FGK has extensive experience in all major therapeutic areas and clinical research fields allowing it to effectively design, manage, and analyze development programs and clinical trials.



Contact:
Dr. Edgar J. Fenzl

Heimeranstr. 35
D-80339 München
Phone: +49 (0) 89 893119 22
Fax: +49 (0) 89 893119 20
E-Mail: edgar.fenzl@fgk-rs.com
Internet: www.fgk-rs.com

FGK Representative Service GmbH

CRO

Keywords: Drug Development, Clinical Research

FGK Representative Service GmbH was founded in order to meet legal requirements of sponsor companies which do not have a subsidiary within the European Union and Switzerland, for the purpose of performing clinical research projects in this region. Such a "legal representative" for clinical drug trials or "authorized representative" for medical device trials fulfills the obligation that the sponsor companies must be established or represented in the European Union according to Clinical Trials Directive 2001/20/EC. FGK represents in all member states of the EU for drug and medical device trials to enable submissions of regulatory applications to the European authorities and ethics committees. FGK also represents for all applications in drug authorizations and orphan drug designations.



Contact:
Dr. Christian Schetter

Frankfurter Ring 193a
D-80807 München
Phone: +49 (0) 89 30659-611
Fax: +49 (0) 89 30659-616
E-Mail:
christian.schetter@fresenius-biotech.com
Internet: www.fresenius-biotech.com

Fresenius Biotech GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Oncology, Gene Therapy, Cell Therapy, Antibody, Immune Therapy, Hematology, Drug Development

Fresenius Biotech GmbH - a subsidiary company of the Fresenius Health Care Group - is focused on the development, marketing and commercialization of biopharmaceuticals in the fields of oncology and transplantation medicine. Our current research and development activities are primarily concentrated on the clinical development of immunotherapeutic products based on innovative antibody technologies.

FRIZ BioChem Gesellschaft für Bioanalytik mbH

BIOTECH DEVICES & REAGENTS

Keywords: Clinical Diagnostics, Devices, Infectious Diseases, Chip / Array Technology

FRIZ BioChem develops and produces highly reliable user-friendly and inexpensive biochip systems for applications in medical diagnostics, food testing and pharmaceutical research. Key products are DNA-chips with direct electrical read-out where SNPs (single nucleotide polymorphism) can unambiguously be detected and time-consuming labeling of the target-DNA is no longer necessary. This enables a broad range of simple and fast analyses making the system ideal for biological medical studies.

The company's proprietary combination of micro arrays, electrical detection and semiconductor technology opens the way to compact multiplex analyses directly at a PC without the expensive instrumentation commonly needed.



Contact:
Thomas Kratzmüller

Floriansbogen 2-4
D-82061 Neuried
Phone: +49 (0) 89 72 44 09-0
Fax: +49 (0) 89 72 44 09-10
E-Mail: info@frizbiochem.de
Internet: www.frizbiochem.de

GE Healthcare Europe GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Fine Chemicals / Reagents, Devices, Analytical Chemistry, Genomics, Proteomics

GE Healthcare Life Sciences provides a broad range of products and services for biomolecule separations at all scales. Chief products include:

■ ÄKTAdesign™ chromatography systems and BioProcess™ media ■ Filtration systems and devices ■ Wave Bioreactor™ and mixers ■ Cell separation for isolating and purifying cells, viruses, and sub-cellular particles ■ Fast Trak™ BioPharma Services.

Our products are used in the manufacture of the majority of all FDA-approved biopharmaceuticals on the market. GE Healthcare Life Sciences is a part of GE Healthcare, a General Electric company with more than 42,000 employees, providing transformational medical technologies that are shaping a new age of patient care.



Contact:
Michael Kaleja

Oskar-Schlemmer-Str. 11
D-80807 München
Phone: +49 (0) 7667 833-559
Fax: +49 (0) 7667 833-616
E-Mail: michael.kaleja@ge.com
Internet: www.gelifesciences.com

GENEART AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Combinatorics, Genomics

GENEART is the global leader in gene synthesis and one of the worldwide leading specialists in the area of Synthetic Biology. GENEART's service portfolio ranges from the optimization and production of synthetic genes according to DIN EN ISO 9001:2008, to the generation of gene variants or complex gene libraries and the production of cell lines, to the development and production of DNA and protein based drug candidates. GENEART services are utilized for the production and development of improved drugs and industrial enzymes. In Synthetic Biology, GENEART supports its customers with technologies for the construction of genetically altered bacteria, which produce or degrade complex biopolymers such as plastic or petroleum for example. GENEART AG in Regensburg (Germany) and the subsidiaries GENEART Inc. in Toronto (Canada) and GENEART Inc. in San Francisco (USA) employ about 180 people. GENEART is listed at Frankfurt Stock Exchange (FSE: G6A).



Contact:
Dr. Karoline Stürmer

Josef-Engert-Str. 11
D-93053 Regensburg
Phone: +49 (0) 941 9427-60
Fax: +49 (0) 941 94276-711
E-Mail: info@geneart.com
Internet: www.geneart.com



Contact:
Dr. Peter Haberl

Lena-Christ-Str. 50
D-82152 Martinsried
Phone: +49 (0) 89 8951102-0
Fax: +49 (0) 89 8951102-15
E-Mail: peter.haberl@genedata.com
Internet: www.genedata.com

Genedata Bioinformatik GmbH

BIOTECH BIOINFORMATICS

Genedata is a bioinformatics company that specializes in developing software systems for the comprehensive analysis of genomes, transcriptomes, proteomes, metabolomes, and biochemical compounds. By working closely with key partners, the company combines its extensive product portfolio with expert scientific consulting services to offer tailor-made solutions for specific applications and multiple therapeutic areas. The company's solutions are key for moving the focus of life science research from high-throughput data acquisition to high-content data interpretation. Founded in 1997 as a spin-off from Novartis, the company is headquartered in Basel (Switzerland) with branch offices in Munich (Germany), San Francisco (USA), Boston (USA), and Tokyo (Japan).



Contact:
Dr. Hildegard Haas

Schwanthalerstr. 60
D-80336 München
Phone: +49 (0) 89 54 34 48 0
Fax: +49 (0) 89 54 34 48 20
E-Mail: info@genedia.de
Internet: www.genedia.de

Genedia AG Biotec Services and Products

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Medicinal Chemistry, Genomics, Antisense/Nucleotides

Genedia AG Biotec Services and Products is a provider of DNA testing services including private DNA paternity testing, legal DNA paternity testing as well as other relationship testing services (full or half sibling testing, grandparents testing, aunt or uncle testing, 1st cousin testing, maternity testing as well as twin testing). An other area is DNA genealogy and anthropology, which includes ancestral origin DNA population test, Y-Chromosome Analysis, mt-DNA analysis. The forensic area includes DNA identification and banking services forensic testing services especially stain analysis. DNA molecular testing of diseases (Factor V and II, MTHFR, CFTR-Mutation). DNA testing of animals.



Contact:
Dr. Albert Röder

Am Neuland 1
D-82347 Bernried
Phone: +49 (0) 8158 9223-0
Fax: +49 (0) 8158 9223-35
E-Mail: a.roeder@genelux.de
Internet: www.genelux.de

Genelux GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Clinical Diagnostics, Drug Delivery, Immune Therapy, Oncology

Genelux Corp., San Diego, CA, US, was founded in 2001. Its assets are built on its founder's experience on genetically modified light-emitting bacteria, viruses and mammalian cells: Luminescent or fluorescently labelled microorganisms, when injected into tumor bearing mice, specifically colonize tumors plus metastases and can be imaged. They grow and replicate within the tumors. Tumors are remitted. These scientific results should enable diagnosis and treatment of cancer, combining *in vivo* imaging (diagnostics) with bacteria/virus induced tumor regression (therapy), and should add a potent theragnostic alternative to existing therapies and diagnostics. Genelux GmbH, Bernried, Germany, was established mid 2004 and aims to translate the scientific results into commercial services and products.

Genetic ID (Europe) AG

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: ELISA / EIA, Genomics, PCR, Analysis, Laboratory, Transgenic Plants, Agrobiotechnology

Genetic ID is a global leader in testing for the presence of genetically modified organisms (GMOs) in food and agricultural products. In addition Genetic ID also offers Allergen screening.

Founded in 1996, Genetic ID Inc. maintains global headquarters in USA, as well as premier testing laboratories in Japan and Germany, offices in Brazil, and the Global Laboratory Alliance of affiliated laboratories and representatives spanning five continents.

We develop technologies that address all aspects of the GMO-testing segment and provide all clients with the technology, services and information they need to operate in the increasingly high-tech global marketplace.



Contact:
William F. Thompson

Am Mittleren Moos 48
D-86167 Augsburg
Phone: +49 (0) 821 747 76-30
Fax: +49 (0) 821 747 76-39
E-Mail: info-europe@genetic-id.com
Internet: www.genetic-id.de

Genetix GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Devices, Automation, Chip / Array Technology, Genomics, Antibody, Cell Therapy

Genetix, a business unit of Leica Microsystems, provides scientists and clinicians with solutions for imaging and image analysis in the life science and clinical markets.

In research, pharmaceutical and biotherapeutic development, Genetix systems continue to establish industry standards in areas such as picking microbial colonies for genomic studies or screening and selection of mammalian cell lines. Other systems use imaging platforms to monitor cell growth, evaluate cellular response and quantify tissue biomarkers.



Contact:
Dr. Miguel Jimenez

Max-Planck-Str. 4
D-85609 Dornach bei München
Phone: +49 (0) 89 18918-1180
Fax: +49 (0) 89 18918-2180
E-Mail: miguel.jimenez@genetix.com
Internet: www.genetix.com

Genewake GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Genomics, Clinical Diagnostics, Pharmacogenomics, Oncology

GeneWake GmbH focuses on contract research in the vast field of biomarker analysis for oncology. We specialize in biomarker prescreening for patient stratification to ensure the best possible care for cancer patients. By employing bioinformatical algorithms based on knowledge in pathway structure and microarray data from public sources, it is possible to limit biomarker screening to analysis on a low-density scale. This is not only cost efficient, but also more easily interpreted compared to high-density methods like whole genome microarrays. Samples can be anything from fresh frozen or paraffin embedded tissue to whole blood. A typical output of a study would be a short list of 10-20 potential biomarkers, that are highly likely to carry changes on the DNA or protein level.



Contact:
Dr. Robert Löwe

Lindwurmstr. 23
D-80337 München
Phone: +49 (0) 89 96977010
Fax: +49 (0) 89 548629243
E-Mail: robert.loewe@genewake.com
Internet: www.genewake.com



Contact:
Karl Blank

Bayerstr. 85a
D-80335 München
Phone: +49 (0) 89 599766 0
Fax: +49 (0) 89 599766 55
E-Mail: info@genomatix.de
Internet: www.genomatix.de

Genomatix Software GmbH

BIOTECH BIOINFORMATICS

Keywords: Genomics

Genomatix Software GmbH is a computational biology company headquartered in Munich, Germany. Founded in 1997, Genomatix pioneered the analysis and understanding of eukaryotic gene regulation.

Genomatix offers integrated solutions and databases for genome annotation and regulation analysis.

Genomatix' product portfolio contains solutions for:

■ Literature and pathway mining ■ Transcription factor analysis ■ Genome annotation integrating a wide variety of transcript sources and a special focus on regulatory regions ■ Analysis technology for high throughput genomic technologies (microarrays and next generation sequencing)

Recently Genomatix focuses on Next Generation Sequencing data analysis offering turnkey-systems with purpose built hardware for in-house installation.



Contact:
Dr. Andrea Kücherer-Ehret

Fraunhoferstr. 17
D-82152 Martinsried
Phone: +49 (0) 89 899890-0
Fax: +49 (0) 89 899890-90
E-Mail: info@gilead-sciences.de
Internet: www.gilead.com

Gilead Sciences GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Gilead Sciences is dedicated to providing accelerated solutions for patients and the people who care for them. The evolution of Gilead - from a promising bio-pharmaceutical company to a leader in the international development and commercialisation of medicines for life-threatening infectious diseases (viral, fungal and bacterial infections) - is testament to what the company has achieved through disciplined science, visionary thinking and diversified planning. Gilead's headquarter is based in Foster City, California with additional operations in San Dimas, California. Sales and marketing organisations are located in the following cities: Athens, Greece; Cambridge, UK; Lisbon, Portugal; Madrid, Spain; Istanbul, Turkey; Munich, Germany; Paris, France; Dublin, Ireland; Milano, Italy.



Contact:
Dr. Christian Hautmann

Lessingstr. 14
D-80336 München
Phone: +49 (0) 89 209 120-0
Fax: +49 (0) 89 209 120-30
E-Mail:
c.hautmann@gkm-therapieforschung.de
Internet: www.gkm-therapieforschung.de

GKM Gesellschaft für Therapieforschung mbH

CRO

Keywords: CRO/CMO, Clinical Research, Logistics, Monitoring, Medical Writing, Analysis, Pharmacovigilance

GKM Gesellschaft für Therapieforschung mbH is a privately owned full service Contract Research Organisation for designing and conducting clinical trials phase II-IV as well as post-marketing-surveillances.

Since 1981, GKM is a much valued partner for many pharmaceutical, biotech and medical device companies. GKM provides flexible services with expert knowledge and dedication to your Projects according to ICH-GCP and international guidelines for research projects.

25 years experience: Cost-effective quality combined with the latest standards and technologies.

■ Concept ■ Statistical planning ■ Study material ■ Regulatory services
■ Site recruitment ■ Monitoring ■ Clinical trial management
■ Quality assurance ■ Data management ■ Medical coding / writing
■ Statistical analysis

GlaxoSmithKline GmbH & Co. KG

PHARMA & CHEMICAL INDUSTRY

GlaxoSmithKline is a leading pharmaceutical company with biotech developments in the area of vaccines and biopharmaceuticals. A cooperation with Human Genome Sciences Inc. has led to the sequence and functional analysis of a large number of genes which are the basis of ongoing developments. Besides GSK has signed a collaboration agreement with the psychiatry of the University of Munich (Ludwig-Maximilian-University, LMU) to establish a genotyping platform (GRC, Genetic Research Centre) focusing on common diseases with complex genetic background.



Contact:
Claudia Kubacki

Theresienhöhe 11
D-80339 München
Phone: +49 (0) 89 360 440
Fax: +49 (0) 89 360 448000
E-Mail: service.info@gsk.com
Internet: www.gsk.com

Harrison Clinical Research Deutschland GmbH

CRO

Keywords: Cardiovascular Diseases, CNS, Metabolic Diseases, Pain, Nephrology, Oncology, Clinical Research, Monitoring

Harrison Clinical Research is an independent ISO 9001 certified CRO founded in 1987 in Munich with offices in UK, Belgium, Israel, Spain, Italy, France, Austria, Poland, Ukraine, Russia, USA and partners in Asia and Australia. Our team comprises more than 300 research professionals. We offer all services required for the clinical development and registration of new pharmaceutical products/medical devices: International project management, monitoring, data management, statistics, medical writing, auditing, training and outsourcing. Apart from conduct of standard Phase I studies, our Phase I/Ia clinic is specialised on proof-of-concept studies in special patient populations and efficacy studies in various indications. For more information please visit www.harrisonclinical.com.

Harrison
Clinical
Research

Harrison

Contact:
Nancy Meyerson-Hess

Albrechtstr. 43
D-80636 München
Phone: +49 (0) 89 126 680-0
Fax: +49 (0) 89 126 680-2444
E-Mail: Nancy.Meyerson-Hess
@harrison-cro.com
Internet: www.HarrisonClinical.com

Hematris Wound Care GmbH

MEDTECH

Keywords: Devices

Hematris Wound Care GmbH develops, manufactures and markets products in the area of wound care. Our major initial focus is the marketing of hemostatic products to control bleeding.

We are experts in the field of hemostasis and wound healing. Our vision is to build up an attractive company together with our investors in this business area.



Contact:
Dr. Dr. Stefan Bertsch

Lena-Christ-Str. 31b
D-85521 Ottobrunn
Phone: +49 (0) 89 6008761-0
Fax: +49 (0) 89 6008761-24
E-Mail: bertsch@hematris.de
Internet: www.hematris.de



Contact:

Dr. Katja Rosenkranz

Agnes-Pockels-Bogen 1
D-80992 München
Phone: +49 (0) 89 4111842-0
Fax: +49 (0) 89 4111842-09
E-Mail: katja.rosenkranz@hepawash.com
Internet: www.hepawash.com

Hepa Wash GmbH

MEDTECH

Keywords: Hepatology, Devices

The Hepa Wash GmbH is a medical device company developing a new liver assist device for the treatment of patient with life-threatening liver disease. Main features of Hepa Wash's extracorporeal technology are its highly efficiency albumin-dialysis and its innovative albumin regeneration circuit. Hepa Wash is dedicated to developing a therapy that's several times more effective than currently available treatments and to significantly increase the survival rate and quality of life of patients with life-threatening liver disease.



Contact:
Kurt Martin

Postfach 1351
D-85767 Unterföhring
Phone: +49 (0) 89 95001711
Fax: +49 (0) 89 9612087
E-Mail: Kurt.Martin@hepacult.de
Internet: www.hepacult.de

hepacult GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Analytical Chemistry, Drug Development, Tissue Engineering / Cell Culture, Clinical Research, Toxicology, Analysis

hepacult develops and markets cell culture technology based on human liver cells and other human organs. The cell culture technology is used to prognose the metabolism of novel drugs and for the in vitro simulation of liver dysfunctions. With their cutting edge cell and tissue products hepacult provides to the scientific community and pharmaceutical industry an outstanding in vitro test system coming close to the human in vivo conditions. Animal experiments can be replaced to a large extent. Results gained during the preclinical stage with hepatocytes show a better prognostic value. Partially even the cost-intensive clinical experiments on humans and related risks to humans can be reduced.



Contact:
Dr. Carsten Brockmeyer

HEXAL AG
Keltenring 1 + 3
D-82041 Oberhaching
Phone: +49 (0) 89 613670-0
Fax: +49 (0) 89 613670-147
E-Mail: carsten.brockmeyer@sandoz.com
Internet: www.sandoz.com

Hexal AG / Sandoz Biopharmaceuticals

BIOTECH

Keywords: 3 D Structural Analysis, Drug Development, Pharmacokinetics, Peptide/Protein, Clinical Research

Sandoz - HEXAL develops Biosimilars at its Biopharmaceutical Development Center in Oberhaching. Biosimilars are approved versions of existing Biopharmaceuticals whose patents have expired. Sandoz - HEXAL is a pioneer in the development of Biosimilars. Following the Sandoz launch of the world's first ever Biosimilar - human growth hormone Omnitrope® in 2006 - and the launch of the first Biosimilar version of a major anaemia medicine Epoetin alfa HEXAL® / Binocrit® in 2007, the approval of our third Biosimilar, Filgrastim, in February 2009 represented a major step in biosimilar development. In October 2008 Hexal Biotech ForschungsGmbH merged with Hexal AG and is now part of Sandoz Biopharmaceuticals with approx. 45 employees on site in Oberhaching.

HTI bio-X GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Devices, Automation

HTI bio-X GmbH is a innovative company and is focussing on products and customer service for biotechnological and pharmaceutical laboratories as well as Life Science industry. We develop products from the simple lab device to complex automated solutions. Our service is focused on engineering tasks and technical support, project management, technical and management consulting. Our current product portfolio covers consumables and instruments (e.g. cleavage machines) for DNA-synthesis as well as for microarray techniques (e.g. hybridization chambers). We also provide instruments for the dosage of powder as well as a complete robotic platform and devices for sample preparation and DNA extraction. Our biomagnetic workstation X-Tract facilitates all kinds of magnetic beads applications.



Contact:
Ditte Heimberg

Anzinger Str. 7
D-85560 Ebersberg
Phone: +49 (0) 8092 2092-0
Fax: +49 (0) 8092 2092-28
E-Mail: info@hti-bio-x.com
Internet: www.hti-bio-x.com

Hyglos GmbH

BIOTECH

Keywords: Proteomics, Infectious Diseases, Peptide/Protein, Clinical Diagnostics

Hyglos' core competency is to exploit the principles of bacteriophage biology and the expert use of the proprietary phage-protein technology for diagnostics, therapeutic and research applications. Hyglos' products and services are supplied to well known pharmaceutical and biotech companies as well as research institutes. Hyglos product portfolio includes EndoTrap®, EndoGrade®, Reagents for food diagnostics, Bacteria Capture Kits Furthermore, Hyglos offers customized services using state-of-the-art technology; Endotoxin Detection Service, Endotoxin Removal Service, From Gene to Protein Service.

Hyglos GmbH is certified according to ISO 9001:2008 and ISO 13485:2003 + AC:2007.



creative bioscience solutions

Contact:
Dr. Ingrid Wanninger

Josef-Engert-Str. 11
D-93053 Regensburg
Phone: +49 (0) 941 94262-0
Fax: +49 (0) 941 94262-20
E-Mail: inquiry@hyglos.de
Internet: www.hyglos.de

i.DRAS GmbH international Drug Regulatory Affairs Services

CRO

Keywords: Drug Development, Analytical Chemistry, Small Molecules, Analysis, Medical Writing, Pharmacology, Toxicology

i.DRAS is a consultancy company for international drug regulatory affairs. i.DRAS offers strategic support and services for human and veterinary medicinal products from the preclinical/early clinical development stages to the first submission of the MA dossier throughout post marketing activities, covering the whole product life cycle. Services provided cover new and established drug substances and the corresponding drug products, including herbal and biological/biotechnological medicinal products. If requested i.DRAS takes over the project management for complex projects with further partners who may be assigned through us or our clients. Furthermore, i.DRAS provides and organises in-house training and education, covering all topics related to the services offered by i.DRAS.



Contact:
Prof. Dr. Markus Veit

Fraunhoferstr. 18b
D-82152 Martinsried
Phone: +49 (0) 89 856536-50
Fax: +49 (0) 89 856536-66
E-Mail: info@i-dras.com
Internet: www.i-dras.com



Contact:
Simon Herzog

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 800 00 11 11 28
Fax: +49 (0) 800 00 11 11 29
E-Mail: sherzog@ibidi.de
Internet: www.ibidi.de

ibidi GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Devices, Nanobiotechnology, Tissue Engineering / Cell Culture, Chip / Array Technology, Microscopy

ibidi develops and distributes cell culture biochips, so called μ -Slides. The Slides are made for the analysis of cells and biomolecules. The parallel cultivation, staining and imaging of cells inside the carriers allows various applications as immunofluorescence, chemotactical analysis, perfusion assays and the simulation of blood vessels for adhesion and migration studies. The read out for ibidi's optically high-end cell culture systems is performed via microscopy. So far, the μ -Slide family consists of 10 different types/ geometries. The volume inside these carriers is minimized ranging from 10 μ l up to 1 ml. The high optical quality of the μ -Slides allows microscopical cell investigations via phase contrast or DIC, fluorescence as well as confocal microscopy.



Contact:
Jens-Peter Wartmann

Frankfurter Ring 193a
D-80807 München
Phone: +49 (0) 89 3246330
Fax: +49 (0) 89 3241684
E-Mail: idea@idea-ag.de
Internet: www.idea-ag.de

IDEA AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Delivery, Drug Development, Small Molecules, Dermatology, Bone / Joint Diseases, Inflammation, Pain, Rheumatology, Clinical Research

IDEA AG develops therapeutics using self-optimising carriers for targeted and non-invasive delivery of drugs. The proprietary carrier, Transfersome®, is typically applied on the skin and can be engineered to achieve high drug concentration at or near the site of application, diminish local or systemic adverse side effects, and increase drugs potency. These benefits can transform established agents into superior, and newly patented, products. The Company leads the development of physically targeted therapeutics with focus on pain and dermatology. IDEA independently develops deep peripheral pain therapeutics comprising NSAIDs (Diractin®), and new dermatological products with improved risk/benefit profile on behalf of TDT Ltd, which is controlled by IDEA's main institutional shareholder.



Contact:
Dr. Merold Müller

Lise-Meitner-Straße 30
D-85354 Freising/Weihenstephan
Phone: +49 (0) 8161 206962
Fax: +49 (0) 8161 9363876
E-Mail: info@ikinowo.com
Internet: www.ikinowo.com

IKINOWO GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Analytical Chemistry, Aptamer Technology, Chip / Array Technology, Proteomics, Oncology

The main goal of the *IKINOWO GmbH* is to develop diagnostic tools for human diseases and cell profiling concerned with ribonuclease, expression defects and codon usage.

IKINOWO GmbH has been funded by the german government:

Federal Ministry of Education and Research (BMBF) in the framework of the program „EXIST SEED“ promoting business start ups from university research.

IMGM Laboratories GmbH

your partner for genomic services

BIOTECH PRECLINICAL SERVICES

Keywords: PCR, Genomics, Chip / Array Technology, Pharmacogenetics, Analysis, Laboratory

IMGM Laboratories was founded in 2001 and provides advanced genomic services tailored to the needs of customers coming from pharma, academia and biotech. We cover the areas of [RNA services], [DNA services], [Bioinformatics] and [Consulting].

IMGM is accredited according to DIN EN ISO/IEC 17025, is fully accredited for gene expression analysis (microarrays and real-time PCR) and is an Agilent Certified Service Provider (CSP) for Gene Expression Microarrays.

At IMGM Laboratories, we combine state-of-the-art technology with complex data analysis to deliver meaningful results in an easy-to-understand format.

For more information on our service portfolio, please visit www.imgm.com.



Contact:
Dr. Ralph Oehlmann

Lochhamer Str. 29
D-82152 Martinsried
Phone: +49 (0) 89 8955784-0
Fax: +49 (0) 89 8955784-1
E-Mail: info@imgm.com
Internet: www.imgm.com

immatics biotechnologies GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Oncology, Immune Therapy, Vaccines, Peptide/Protein, Proteomics, Genomics, Drug Development

immatics biotechnologies is a clinical-stage biopharmaceutical company developing rationally designed therapeutic vaccines that are active against cancer. immatics' lead product, IMA901 has completed a Phase II trial in renal cell carcinoma. immatics' pipeline also includes IMA910, in Phase II for colorectal cancer, and IMA950 which is being developed for glioma.

immatics' technology platform rapidly generates defined therapeutic cancer vaccines which are based on multiple tumour-associated peptides (TUMAPs) with the ability to specifically stimulate the immune system against cancer cells. These vaccines - comprising multiple peptides confirmed to be naturally presented by real tumour tissue - offer the prospect of greater effectiveness than existing cancer vaccine approaches. immatics' products are 'drug like' with stable, off-the-shelf formulations and robust easily scalable manufacturing. immatics is based in Tuebingen and Munich, Germany, and has raised more than € 54 million (US\$ 72million) in private equity in two financing rounds.



immatics

Contact:
Dr. Bettina Kipp

Fraunhoferstr. 18b
D-82152 Martinsried
Phone: +49 (0) 89 309041-0
Fax: +49 (0) 89 309041-55
E-Mail: info@immatics.com
Internet: www.immatics.com



Contact:
Wolfgang Mayer

Karlstrasse 46
D-80333 München
Phone: +49 (0) 89 5432177-89
Fax: +49 (0) 89 5432177-92
E-Mail: info@immumed.de
Internet: www.immumed.de

Immumed GmbH Gesellschaft für angewandte Immunologie

BIOTECH PRECLINICAL SERVICES

Keywords: Clinical Diagnostics, Inflammation, ELISA / EIA, Analysis, Laboratory

Applied Immunology - Testing Services

We offer testing services for human, mouse or rat samples:

- Analysis of cytokines, chemokines and phosphoproteins
- Cell-characterization ■ Cell-separation ■ Cytotoxicity

Our team is specialized in measuring multiplex-parameter analysis with Luminex-Technology in various samples like serum, cell cultures, saliva, urine. We perform every application for flow-cytometry analysis, for example cell phenotyping, intracellular cytokine detection or cytotoxicity assays as well as positive or negative selection of cells with magnetic-bead technology.



Contact:
Dr. Matthias Reinhard

Rudolf-Diesel-Str. 8a
D-97267 Himmelstadt
Phone: +49 (0) 9364 810-610
Fax: +49 (0) 9364 810-613
E-Mail: info@immunoglobe.com
Internet: www.immunoglobe.com

immunoGlobe Antikörpertchnik GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Laboratory, Antibody Production Service, Antibody

immunoGlobe® GmbH is a privately owned company, founded in 1997. Core competences are 1) the manufacturing of novel research antibodies, 2) full service custom antibody production and purification, as well as 3) marketing of own and licensed antibodies through a global network of OEM partners, wholesalers, and distributors.

Specialisations:

Through sophisticated antigen design and purification schemes immunoGlobe® has particularly specialised in the generation of highly specific polyclonal rabbit antibodies against: ■ phosphorylation sites ■ neo-epitopes ■ isoforms and mutants differing in as few as a single amino acid.

As an option, these polyclonal approaches may directly lead over to rabbit monoclonal projects.



Contact:
Dr. Andrea Seidel

Schatzbogen 52
D-81829 München
Phone: +49 (0) 89 7263718-0
Fax: +49 (0) 89 21758349
E-Mail: info@implen.de
Internet: www.implen.de

Implen GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Devices, Automation, Chip / Array Technology, Genomics, Nanobiotechnology, Proteomics

Implen GmbH is a leading supplier for system solutions for the analysis and processing of small volumes. We develop and distribute key technologies to optimize processes needed for molecular biological as well as cytogenetic applications. Together with our partners we combine customized complete-solutions and bring them to the market worldwide.

IMR Partner International GmbH

CRO

IMR Partner GmbH is a contract research organization located in Munich and Jena. We provide specialized services for the development of pharmaceuticals and medical devices.

■ Supervision of clinical studies by MD's ■ Consultancy ■ Conduct of the clinical part of Phase II-IV studies (principal investigator, site management)



Contact:

Ilka Rother

Lärchenstr. 3
D-82166 Gräfelfing
Phone: +49 (0) 89 89665425
Fax: +49 (0) 89 82084607
E-Mail: info@imr-partner.de
Internet: www.imr-partner.de

Inamed Research GmbH & Co. KG

CRO

Keywords: Drug Delivery, Clinical Research, Monitoring, Medical Writing, Respiratory Diseases



Inhalation medicine is our expertise. Inamed Research was founded in 1998 as a spin off from the GSF. You profit from more than 30 years of our experience in aerosol bio-physics and aerosol technology and from our large network of experts.

Inamed's competence is inhalation therapy with regard to clinical trials from phase I to IV and inhalation device testing. One of our specialties is the use of radioactive labeled drugs to determine lung deposition in scintigraphy trials, investigating mucociliary clearance and the analysis of the breathing pattern.

In the division device testing, we characterize devices, not only with regard to particle size, output and flow, but also in realistic simulations, to establish the performance of the device when a patient is using it.

Contact:
Dr. Thomas Meyer

Robert-Koch-Allee 29
D-82131 Gauting
Phone: +49 (0) 89 89 35 69 0
Fax: +49 (0) 89 89 35 69 22
E-Mail: request@inamed.eu
Internet: www.inamed.eu

Infors GmbH

BIOTECH DEVICES & REAGENTS

Infors is specialised in marketing and maintenance of fermenters and shakers. As a subsidiary of Infors AG in Basel, Switzerland, it not only sees itself as a trading and service company but also cooperates with researchers in order to develop new equipment used in the field of microbiology and cell culture.



Contact:
Dr. Burkhard J. Feigel

Dachauer Str. 6
D-85254 Eisingen
Phone: +49 (0) 8135 8333
Fax: +49 (0) 8135 8320
E-Mail: infors.de@infors-ht.com
Internet: www.infors-ht.com



Contact:
Susanne Imsel

Fraunhoferstr. 13
D-82152 Martinsried
Phone: +49 (0) 89 8565-2300
Fax: +49 (0) 89 8565-2305
E-Mail: info@ingenium-pharmaceuticals.com
Internet: www.ingenium-ag.com

Ingenium Pharmaceuticals GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Medicinal Chemistry, Inflammation, Cardiovascular Diseases, Neurology, Pharmacology

Ingenium Pharmaceuticals GmbH, founded in 1998, is a subsidiary of Probiot drug (Halle/S. and Martinsried, Germany). Probiot drug is a privately held biopharmaceutical company focused on the development of innovative small molecule drugs. Probiot drug is pioneering an industrialized approach for making innovative targets pharmacologically accessible. Its core competence is the elucidation of the structure, biochemistry, and biology as well as the pathophysiology of regulatory peptides and enzymes modifying the activity of specific proteins and pathways. Based on this expertise, the Company is developing inhibitors and ligands targeting key enzymes such as proteases and kinases. The most promising compounds are then developed by Probiot drug as drug candidates for the treatment of major diseases such as Alzheimer's disease or chronic inflammatory disorders. In Alzheimer's disorder, Probiot drug's expertise in metabolic enzymes has led to the discovery of an entirely new mechanism of action which is involved in the seeding of the typical depositions found in the brain of AD patients and also explains their neurotoxicity.



Contact:
Prof. Dr. Toni Lindl

Balanstr. 6
D-81669 München
Phone: +49 (0) 89 48777-4
Fax: +49 (0) 89 48777-2
E-Mail: info@I-A-Z-zellkultur.de
Internet: www.I-A-Z-zellkultur.de

Institut für angewandte Zellkultur Dr. Toni Lindl GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Tissue Engineering / Cell Culture, Antibody Production Service

The Institut für angewandte Zellkultur Dr. Toni Lindl offers services in the area of cell culture and tissue culture, training in cell culture work, distribution of cell lines, consulting in cell culture, molecular biology, genetic engineering and development of monoclonal antibodies and in vitro processes. The core competences cover cell culture services and genetic engineering with a product range of recombinant human interleukin-2 and human monoclonal antibodies against rabies. Partnerships are sought with university research institutes in immunology and virology, where know-how in cell culture and in vitro technologies can be transferred.



Contact:
Dr. Frank Becker

Lochhamer Str. 29a
D-82152 Martinsried
Phone: +49 (0) 89 895572-80
Fax: +49 (0) 89 895572-81
E-Mail: info@intana.de
Internet: www.intana-bioscience.de

Intana Bioscience GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Drug Development, Microscopy, Antibody, Peptide/Protein, Small Molecules

Intana Bioscience GmbH, founded 2008, is a privately owned service provider company. Understanding the selectivity profile and the binding characteristics of a candidate drug has been shown to be essential for downstream optimization. Intana Bioscience GmbH offers interaction analysis based on a single molecule sensitive spectroscopic approach called fluorescence cross correlation spectroscopy (FCCS). FCCS can be applied in cellular lysates to determine the binding and rate constants of biomolecular interaction and represents a highly efficient approach to develop selective inhibitors for targeted therapies. Customers benefit from short assay development time, in depth interaction analysis and assay conditions that mimic the natural environment of a drug.

INTERLAB central lab services – worldwide GmbH

CRO

Keywords: Analytical Chemistry, Clinical Diagnostics, Logistics, Clinical Research

INTERLAB is an independent central laboratory supporting clinical trials for pharmaceutical and biotechnology companies covering Europe, North and South America, Australia, Africa and Asia. The international head office is in Munich, Germany. INTERLAB performs routine and esoteric testing on a daily basis: over 25.000 samples daily: clinical chemistry, hematology, endocrinology, genetics, PCR, microbiology, virology, immunology, serology, histopathology, cytology, toxicology, drug assays, incl. LC-MS/MS. Additional services: professional project managers, flexible data management and transfer, cost-effective shipment logistics worldwide, EN 45,000, ISO 9001 and EC/ISO/EN 15189 (17025).



Contact:
Dr. Hermann Schulz

Bayerstr. 53
D-80335 München
Phone: +49 (0) 89 741393-0
Fax: +49 (0) 89 741393-39
E-Mail: CEO.Schulz@INTERLAB.de
Internet: www.INTERLAB.de

IRIS Biotech GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Agrobiotechnology, Peptide/Protein, Drug Development, Drug Delivery, Medicinal Chemistry, Combinatorial Chemistry, Natural Compounds

1. Biocatalysis (immobilised enzymes, enzyme carriers, unusual and innovative enzymes for modern biocatalytic synthesis of fine chemicals, optical resolution of racemic mixtures; lipases and esterases for food industry and biodiesel production)
2. Starting Materials for Peptide Synthesis, Peptidomimetic and Medicinal Chemistry (Protected Amino Acids, Coupling Reagents, Linkers, Resins)
3. Reagents for PEGylation (improving solubility and pharmacokinetic properties of biopharmaceuticals and organic drug molecules)
4. Reagents for Life Science Research (Enzyme Substrates, Special Proteins, Natural Products, with biological & pharmacological activity, Carbohydrates Derivatives)
5. Contract Manufacturing of unusual derivatives with one or several chiral centres.



Contact:
Dr. Thomas Bruckdorfer

Waldershofer Str. 49-51
D-95615 Marktredwitz
Phone: +49 (0) 9231 9619-73
Fax: +49 (0) 9231 9619-99
E-Mail: info@iris-biotech.de
Internet: www.iris-biotech.de

KantarHealth GmbH

CRO

Keywords: Oncology, Clinical Research, Logistics, Monitoring, Medical Writing, Analysis, Pharmacovigilance

KantarHealth GmbH Clinical Research conducts phase I-IV clinical trials as well as NIS world-wide. Our operations span local agencies in over seventy countries in Europe. KantarHealth GmbH combines more than 25 years of CRO expertise in drug research with the development of innovative web-based applications in project and data management (InTrial and InDrums). Our services include: protocol and CRF design, eCRF solutions, feasibility and site selection, investigators training, handling and completion of legal and ethical requirements, monitoring and site management, project management, implementation of risk management programs, data management, medical coding, quality assurance, statistical planning and analysis, medical writing.



Contact:
Siegfried Freytag

Landsberger Str. 338
D-80687 München
Phone: +49 (0) 89 5600-1421
Fax: +49 (0) 89 5600-1590
E-Mail: siegfried.freytag@kantarhealth.com
Internet: www.tns-healthcare.de



Contact:
Dr. Dieter Seitz-Tutter

Stefan-George-Ring 6
D-81929 München
Phone: +49 (0) 89 99 39 13-0
Fax: +49 (0) 89 99 39 13-160
E-Mail: info.muc@kendle.com
Internet: www.kendle.com

Kendle GmbH

CRO

Keywords: Allergy, Diabetics, Oncology, Clinical Research, Monitoring, Medical Writing, Pharmacology

Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing drugs to market for the benefit of patients worldwide. As one of the world's largest global providers of Phase I-IV services, we offer experience spanning more than 100 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges. Please find more information about Kindle at www.kendle.com



Contact:
Dr. Andreas Jenne

Am Klopferspitz 19a
D-82152 Martinsried/München
Phone: +49 (0) 89 4613363-0
Fax: +49 (0) 89 4613363-20
E-Mail: info@kinaxo.com
Internet: www.kinaxo.de

KINAXO Biotechnologies GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Genomics, Proteomics, Metabolic Diseases, Drug Development, Small Molecules, Inflammation, Oncology

KINAXO offers a unique technology tool box for drug mode-of-action analysis, cellular target profiling, target deconvolution, drug repositioning and biomarker identification. KINAXO maintains several collaborations with leading pharmaceutical companies, such as Bayer, Roche, Boehringer Ingelheim and Johnson & Johnson.



Contact:
Dr. Klaus Hellmann

Geyerspergerstr. 27
D-80689 München
Phone: +49 (0) 89 580082-0
Fax: +49 (0) 89 580082-15
E-Mail: info@klifovet.com
Internet: www.klifovet.com

KLIFOVET AG

CRO

Keywords: Logistics, Monitoring, Medical Writing, Analysis, Clinical Research

KLIFOVET is the provider of high quality services for the Animal Health Industry and Animal Nutrition Industry in Europe regarding the registration and marketing of products. Strategic advice on licensing products, regulatory affairs consultancy, but also full CRO for conducting efficacy studies in any animal species is our business. We are in command of well organized logistics, a highly motivated team, a comprehensive net of co-operators and skilled investigators throughout Europe and US. We can handle large multinational projects as well as run studies locally, in Europe or globally according to the demanding standards of FDA, EMA and/or the client. We perform this efficacy studies, field safety studies, marketing studies and palatability studies for veterinary medicinal products and feed additives.

kmbs

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Genomics, PCR

kmbs is a small enterprise working as service partner for e. g. Conservation Biologists, Zoologists, Phylogeneticists, Taxonomists and Molecular Biologists to clear up specimens' identities by means of molecular/genetic analyses (PCR, DNA sequencing, Gene Fragment analysis) for purposes like resolving species relationships, detecting sibling species, delimiting species boundaries, investigating population integrity, a.s.o.

In addition to this we are experienced in making microscopic preparations, but also we are carrying out outdoor services like mapping species inventories or searching for special organisms within a given habitat including the collection of organisms on demand.



Contact:
Michael Miller

Ferdinand-Zwack-Str. 39
D-85354 Freising
Phone: +49 (0) 08161 205957
E-Mail: info@kmbioservices.de
Internet: www.kmbioservices.de

Laboklin GmbH & Co KG – Unternehmensbereich Labogen

BIOTECH THERAPEUTICS & DIAGNOSTICS

Our laboratory provides a complete testing service for veterinary surgeons to meet the diagnostic needs of your practice. You can find all important information and our laboratory profiles and screens (microbiology, haematology, allergy, pathology and genetic testing. Furthermore you can download submission forms or order sample collection material. If you are registered you are able to locate your samples, the stage of investigation and much more.



Contact:
Dr. Elisabeth Müller

Steubenstr. 4
D-97688 Bad Kissingen
Phone: +49 (0) 971-72020
Fax: +49 (0) 971-68546
E-Mail: laboklin@t-online.de
Internet: www.laboklin.de

LEUKOCARE AG

BIOTECH DEVICES & REAGENTS

Keywords: Inflammation, Immune Therapy, Peptide/Protein, Antibody, Clinical Research, New Materials, Clinical Diagnostics

LEUKOCARE is a biotechnology company with its headquarter in Munich. LEUKOCARE has developed a coupling and postcoating technology that stabilizes and protects immobilized functional proteins and other bioactives. In this way functionalized matrices coated with a broad variety of proteins are sterilizable and suitable for storage without major loss of functionality. The biocoating technology enables LEUKOCARE to produce biofunctional coatings for medical devices using standardised procedures under non-aseptic production conditions. This unique platform technology is applicable to a wide range of uses including implant surfaces, wound dressings and stents. LEUKOCARE provides its proprietary sterilizable coating technology to interested partners on a joint development and license basis.



Contact:
Michael Scholl

Baierbrunner Str. 25
D-81379 München
Phone: +49 (0) 89 7801665-0
Fax: +49 (0) 89 7801665-11
E-Mail: info@leukocare.de
Internet: www.leukocare.de



Contact:
Dr. Fritz Huber

Josef-Engert-Str. 9
D-93053 Regensburg
Phone: +49 (0) 941 698091-00
Fax: +49 (0) 941 698091-01
E-Mail: info@lipofit.de
Internet: www.lipofit.de

LipoFIT Analytic GmbH

CRO

Keywords: Agrobiotechnology, Fine Chemicals / Reagents, Pharmacokinetics, Metabolic Diseases, Nephrology, Analysis, Clinical Diagnostics

LipoFIT: NMR analytics for clinical laboratories, the pharmaceutical and agrochemical industry.

For current unsolved analytical challenges, the NMR technology may offer a solution. LipoFIT offers and develops tests based on NMR and tailor made statistical procedures for multi-parameter tests. Examples are:

- Products for safety testing: A precise multi-parametric NMR screening test for detecting nephrotoxicity caused by any substance (e.g. NECs)
- Purity testing of chemical compounds: Distinction of analogues, causing severe auto immune reactions
- Products used in the agrochemical industry: Quality tests of plants and seeds as raw materials and for breeding purposes.

LipoFIT is certified (EN ISO 13485:2003 and ISO 9001:2000) and holds the Statement of GMP Compliance.



Contact:
Dr. Renate Loewe

Mühlweg 2a
D-82054 Sauerlach
Phone: +49 (0) 8104 61620
Fax: +49 (0) 8104 61648
E-Mail: dr.loewe@loewe-info.com
Internet: www.loewe-info.com

Loewe Biochemica GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Agrobiotechnology, ELISA / EIA

LOEWE is committed to the development and production of high quality reagents for the detection of plant diseases caused by bacteria, fungi, nematodes, and viruses. Furthermore we offer contract testing services for all kinds of crops and ornamentals (ELISA techniques, Immuno Fluorescence Antibody Assays, Blotting, and PCR).



Contact:
Dr. Ludwig Deml

Josef-Engert-Str. 9
D-93053 Regensburg
Phone: +49 (0) 941 944-4636
Fax: +49 (0) 721 151 397 812
E-Mail: info@lophius.de
Internet: www.lophius.de

Lophius Biosciences GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

The Lophius Biosciences GmbH, which was founded in the year 2002, is a spin-off of the Institute for Medical Microbiology and Hygiene and the Department of Internal Medicine I, University of Regensburg, Germany.


The core business of Lophius is R&D for innovative diagnostic and therapeutic products in T-cell immunology and immunotherapy.

Lophius offers clinical sample-testing services based on a broad repertoire of immunological routine assays. In addition, Lophius uses its proprietary technology for the highly sensitive detection and characterization of active T cells.

medicomp GmbH

CRO

medicomp GmbH was founded in 1985 and has developed ever since into a full service CRO. We offer a wide range of services for phase I-IV trials, PMS and medical devices: medical and biometrical planning, protocol and CRF design, project management, data management, monitoring, statistical analysis and medical writing. medicomp is a member of the Bundesverband Medizinischer Auftragsinstitute (BVMA), which implies regular independent system audits. Furthermore, medicomp is a founding member of Pharmaceutical Service Network (PSN), a network of independent European CROs, which allows us to offer services for studies conducted on a European scope in collaboration with our partners.



Contact:

Dr. Michael Gierend

Fraunhoferstr. 17

D-82152 Martinsried

Phone: +49 (0) 89 895286-0

Fax: +49 (0) 89 895286-66

E-Mail: medicomp@medicomp-cro.de

Internet: www.medicomp-cro.de

medicore International AG / MediCliPha Ltd

CRO

Keywords: Drug Development, Clinical Research, Monitoring, Medical Writing

medicore International AG was founded in 1992 and is a contract research organisation (CRO) with services for biotech- and pharmaceutical companies. Recently, a close cooperation was formed with MediCliPha Ltd. The full-service concept includes consultations in drug development (from the active principle to marketing approval), clinical trials (phase II to IV, phase I in co-operation), data management, biostatistics, quality assurance (audits of different type), expert reports (pharmacology/ toxicology and clinical), medical writing, marketing surveillance studies, regulatory affairs, medical information and drug safety. Both companies offer full service packages or a modular approach. The reputation is based on competent staff, on GCP-conformance, on strict keeping timelines and budget.

MediCliPha Ltd

Contact:

Prof. Dr. Peter Schlieper

Bergstr. 7

D-86926 Greifenberg

Phone: +49 (0) 8192 9336-0

Fax: +49 (0) 8192 9336-17

E-Mail: info@medicore.de

Internet: www.medicore.de

MediGene AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Autoimmune Diseases, Dermatology, Immune Therapy, Drug Development, Oncology

MediGene AG is a publicly listed (Frankfurt, Prime Standard: MDG, TecDax) biotechnology company located in Martinsried/Munich, Germany, with subsidiaries in Oxford, UK and San Diego, USA. MediGene is the first German biotech company to have drugs on the market which are distributed by partner companies. It has several drug candidates in clinical development and possesses innovative platform technologies. MediGene focuses on clinical research and development of novel drugs with focus on oncology.



Contact:

Dr. Nadja Wolf

Lochamer Str. 11

D-82152 Martinsried

Phone: +49 (0) 89 85 65 29 0

Fax: +49 (0) 89 85 65 29-20

E-Mail: medigene@medigene.com

Internet: www.meditgene.com



Contact:
Katrín Stedtler

Gmunder Strasse 53
D-81379 München
Phone: +49 (0) 89 8955718-0
Fax: +49 (0) 89 8955718-100
E-Mail: K.Stedtler@medpace.com
Internet: www.medpace.de

Medpace Germany GmbH

CRO

Keywords: Clinical Research, Cardiovascular Diseases, Metabolic Diseases, Oncology, Monitoring

Medpace, established in 1992, is a full-service Contract Research Organization (CRO), who partners with leading pharmaceutical and biotech organizations to bring promising new drugs to market. Medpace combines comprehensive regulatory consulting with efficient clinical trial management to provide sponsors with exceptional support in drug development. Proven leaders in medical and scientific research monitor every project. Medpace physicians have first-hand experience working with regulatory agencies to successfully guide projects through the complexities of the regulatory process. The medical expertise and regulatory guidance provided by Medpace leads to reduced costs and increased efficiencies for our valued customers.



Contact:
Dr. Horst H. Langenbahn

Olschewskibogen 7
D-80935 München
Phone: +49 (0) 89 354 998-0
Fax: +49 (0) 89 354 998-99
E-Mail: office@MedPharmTec.de
Internet: www.MedPharmTec.de

MedPharmTec-Services

CRO

MedPharmTec-Services is a Pharmaceutical Contract Service Organisation providing expert assistance in drug development, clinical research (phase II through IV), medical information, regulatory affairs and drug safety to pharmaceutical and biotechnology companies. Our clinical research services range from protocol planning, CRF design, trial management, monitoring and auditing up to data management, biometrics and report writing. Further areas of MedPharmTec-Services' activities include medical information, i.e. medical and scientific translations, proof-reading, writing/designing of brochures, publications and scientific literature searches as well as consulting and services in terms of regulatory affairs and drug safety.



Contact:
Dr. Bernhard Ladstetter

Am Feld 32
D-85567 Grafing
Phone: +49 (0) 8092 7008-0
Fax: +49 (0) 8092 7008-99
E-Mail: bernhard.ladstetter@merck.de
Internet: www.merck.de

Merck Serono Institute of Drug Metabolism and Pharmacokinetics

PHARMA & CHEMICAL INDUSTRY

Keywords: Small Molecules, Antibody, Pharmacokinetics, ELISA / EIA, Drug Development

The Institute of Drug Metabolism and Pharmacokinetics (DMPK) is located in Grafing near Munich and is part of Global Research of Merck Serono, Geneva. The institute was established in 1969 and has grown considerably over the years. Currently 80 people are working at Grafing. The scope of the Institute of DMPK includes ADME studies of NCEs and NBEs in laboratory animals during drug discovery and development phases. Support is given to toxicology (toxicokinetics) and to clinical R&D by providing bioanalytical data and information about the metabolism in humans. The institute is equipped with state of the art instruments (e.g. LC-MS/MS, NMR, biacore, phosphor-imaging systems) and laboratories for radiolabelling of drugs with various radioisotopes (e.g. C-14, H-3, J-125).

metabion

BIOTECH DEVICES & REAGENTS

Keywords: Genomics, Proteomics, Antibody Production Service, RNAi & Antisense, Analysis, PCR

metaBIO is one of the globally leading suppliers of custom nucleic acids renowned for its focus on reliable supplies of consistently high quality products and services. Founded in 1997 in Munich/Martinsried, metabion keeps on expanding its product portfolio from the production of a wide range of synthetic DNA and RNA oligonucleotides according to customers' needs to the supply of standard life science products. Successfully translating highest quality standards into daily practice is the core of metabion's business philosophy and key to its popularity at the same time. Careful evaluation and implementation of new and promising technologies and products are complementing metabion's progressive and innovative approach within a healthy and sound business setup.



Contact:
Dr. Andreas Berghammer

Lena-Christ-Str. 44
D-82152 Martinsried
Phone: +49 (0) 89 899363-0
Fax: +49 (0) 89 899363-11
E-Mail: metabion@metabion.com
Internet: www.metabion.com

Metronomia Clinical Research GmbH

CRO

Keywords: Drug Development, Oncology, Clinical Research, Logistics, Monitoring, Medical Writing

Metronomia Clinical Research, is a mid-size European CRO with special focus on biostatistical, data management and e-clinical full-service offers. Since more than 15 years Metronomia's mission statement is to combine cutting-edge e-clinical technologies and innovative but accepted study designs in order to improve drug development. A pronounced customer orientation, flexibility and cost-effectiveness – these are Metronomia's attributes highlighted most frequently by our customers. Studies in a wide range of indications were successfully performed, specialities being oncology, transplantation, dermatology, pulmonology, immunology, cardiology and CNS. E-clinical trials are run with clin case, one of the top EDC systems, with an outstanding performance, flexibility and user friendliness.



Contact:
Dieter Meyer

Paul-Gerhardt-Allee 42
D-81245 München
Phone: +49 (0) 89 829265-100
Fax: +49 (0) 89 829265-099
E-Mail: info@metronomia.net
Internet: www.metronomia.de

MICROBIONIX GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Infectious Diseases, Analysis, Clinical Research

MICROBIONIX specializes in the development of Multiplex Assay Systems. The basis of all our applications is Luminex "xMAP-Technology", a bead-based multiplex platform technology for rapid and cost-efficient analysis. Furthermore, MICROBIONIX offers Multiplex Testing Services for analytes relevant to biomarker studies, hormone-analytic, cellular signal transduction and pathways:

- Quantification of Cytokines, Chemokines and Growth Factors ■ Activity Assays for Protein-Kinases ■ Activity State Assays for Signalling Proteins
- Binding-Assays for Transcription Factors ■ Immunglobulin Isotyping
- MMP-Analysis



Contact:
Dr. Erwin Soutschek

Floriansbogen 2-4
D-82061 Neuried
Phone: +49 (0) 700 50 50 2002
Fax: +49 (0) 700 50 50 2003
E-Mail: info@microbionix.com
Internet: www.microbionix.com



Contact:
Dr. Günter Müller

Am Neuland 3
D-82347 Bernried
Phone: +49 (0) 8158 9981-0
Fax: +49 (0) 8158 9981-10
E-Mail: info@microcoat.de
Internet: www.microcoat-biotechnologie.de

MicroCoat Biotechnologie GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Clinical Diagnostics, ELISA / EIA, PCR, Analytical Chemistry

Founded in 1992, MicroCoat is a biotechnology company focused on the field of Immune- and Nucleic acid-Diagnostics.

The major work areas are

- Coating of various biological reagents (streptavidin; antibodies; nucleic acids; and others) on solid phases (e.g. microtiterplates, tubes, chips)
 - Development and manufacturing of diagnostic assays,
 - Service in the field of Immune and Nucleic acid-Diagnostics like:
measurement of samples, also for clinical trials; method comparison of assays; configuration and handling of "sample panels"; system verification and validation.
- MicroCoat has been certified for EN ISO 13485:2003 (9001/EN 46001).



Contact:
Angela Lucks

Staffelseestr. 2
D-81477 München
Phone: +49 (0) 89 895277-0
Fax: +49 (0) 89 895277-105
E-Mail: info@micromet.de
Internet: www.micromet.de

Micromet AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Antibody, Immune Therapy, Oncology

Micromet puts novel concepts in immunotherapy to work. Using proprietary technologies, the Company is building a strong pipeline of innovative drug candidates for the treatment of cancer, inflammation and autoimmune disease. Two candidates are currently in clinical trials. The Company has established a powerful drug development platform: BiTE™ ("Bispecific T cell engagers"), a unique drug format that leverages the outstanding cytotoxic potential of T cells to precisely eliminate pathogenic cells. In addition, Micromet is exploiting the potential of SCAs (single-chain antibodies) for the development of novel drug candidates. The Company has attracted both top-tier life science investors and corporate partners such as MedImmune, Inc., Enzon Pharmaceuticals, Inc., and Serono.



Contact:
Dr. Erwin Soutschek

Floriansbogen 2-4
D-82061 Neuried
Phone: +49 (0) 89 54801-0
Fax: +49 (0) 89 54801-100
E-Mail: mikrogen@mikrogen.de
Internet: www.mikrogen.de

MIKROGEN GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, ELISA / EIA, Infectious Diseases, Automation, Autoimmune Diseases, Chip / Array Technology

Founded in 1989 MIKROGEN GmbH offers innovative solutions for medical laboratories. The companies scope is the development and production of clinical diagnostic test systems based on recombinant antigens, with the focus on bacterial, viral, parasitic and autoimmune diseases. MIKROGEN's core competencies covers genetic engineering and the scientific quality of research and development, which is reflected in various patent applications and publications in international journals. The key success factors of the company are the consequent customer orientation, the strong product competence and highly skilled employees. MIKROGEN meets ongoing market demands by emphasising its activities on automation and standardisation in the in-vitro diagnostics, to improve processes in medical laboratories.

MLL Münchener Leukämie Labor GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Chip / Array Technology, Genomics, PCR, Hematology, Oncology

MLL Munich Leukemia Laboratory is working as a reference laboratory for the diagnosis of hematologic malignancies focussing on leukemia and lymphoma. All 60 coworkers (physicians, molecular biologists, and technicians) have outstanding reputation in the field of comprehensive diagnostics. In parallel, cytomorphology, cytochemistry, immunophenotyping, cytogenetics, FISH, and molecular genetic techniques such as PCR are performed. The seven day available work-flow is orientated to the clinical needs of patients and physicians. MLL is testing new techniques such as microarrays. We serve as a reference laboratory for German and European leukemia studies and are a SME-member in the European Leukemia Network (ELN). Education programmes are provided for physicians and technicians.



Contact:

Prof. Dr. Dr. Torsten Haferlach

Max-Lebsche-Platz 31
D-81377 München
Phone: +49 (0) 89 99017-0
Fax: +49 (0) 89 99017-111
E-Mail: info@mll-online.com
Internet: www.mll-online.com

Molecular Networks GmbH

BIOTECH BIOINFORMATICS

Keywords: Small Molecules, Molecular Modelling

Molecular Networks offers innovative chemoinformatics software products, consulting, development and research services to increase the quality and productivity of discoveries in chemical, pharmaceutical and biotechnology R&D. Founded in 1997, the company established international business relationships and Molecular Networks' technology is utilized in major industrial and academic discovery laboratories worldwide to design and optimize chemical products and processes. Molecular Networks' product portfolio comprises a variety of software tools, databases and decision support applications for the design and the synthesis of chemical compounds, the prediction of their chemical, physical and biological properties, their chemical reactivity and metabolic or environmental fate.



Contact:

Dr. Oliver Sacher

IZMP, Henkestr. 91
D-91052 Erlangen
Phone: +49 (0) 9131 8156-68
Fax: +49 (0) 9131 8156-69
E-Mail: info@molecular-networks.com
Internet: www.molecular-networks.com

Monitor Zentrale Deutschland

CRO

Monitor Zentrale Deutschland (MZD) a department of Geelen & Geelen GmbH, is a clinical research service provider, located in Grasbrunn near Munich. It started in 1994 as a monitoring service and has become an agency for the recruitment (out- and in-sourcing) of temporary experienced freelance clinical research professionals for the R&D sector (e.g. CRAs, Study Nurses, Project Managers, Medical Writers, Regulatory Affairs and Drug Safety Managers, Clinical Trials Administrators or Coordinators, Data Managers. Besides this Geelen & Geelen is the publisher of the German Magazine of Clinical Research (Deutsche Zeitschrift für Klinische Forschung www.dzkf.de).



Contact:

Dr. Jorge Garcia

Gut Keferloh 1c
D-85630 Grasbrunn b. München
Phone: +49 (0) 89 456729 0
Fax: +49 (0) 89 456729 18
E-Mail: mailto:mzd.de
Internet: www.MZD.de



Contact:
Dr. Claudia Gutjahr-Löser

Lena-Christ-Str. 48
D-82152 Martinsried
Phone: +49 (0) 89 89927-0
Fax: +49 (0) 89 89927-222
E-Mail: info@morphosys.com
Internet: www.morphosys.com

MorphoSys AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Antibody Production Service, Antibody, Dermatology, Infectious Diseases, Oncology, CNS

MorphoSys is one of the world's leading biotechnology companies focusing on fully human antibodies. With its proprietary technologies, MorphoSys is developing the next generation of antibodies not only for research and diagnostics purposes, but also as highly effective and precise therapeutics. HuCAL® (Human Combinatorial Antibody Library) is a very powerful technology for the rapid and automated production of specific antibodies. The most distinctive feature of the library is its unique capability to optimize fully human antibodies to predefined specifications, allowing MorphoSys researchers and their partners to "Engineer the Medicines of Tomorrow". MorphoSys's goal is to establish HuCAL® as the technology of choice for antibody generation in all market sectors.



Contact:
Dr. Jörg Müller

Hauptstr. 68
D-82008 Unterhaching
Phone: +49 (0) 89 665084-52
Fax: +49 (0) 89 665084-54
E-Mail: services.de@m-scan.com
Internet: www.m-scan.com

M-Scan

Mass Spectrometry Consultants and Analysts

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Pharmacokinetics, Proteomics, Antibiotics, Antibody, Peptide/Protein, Small Molecules, Vaccines, Analytical Chemistry

M-Scan is an independent group of companies, offering consulting, analytical and training services, particularly in chromatography and mass spectrometry, for the pharmaceutical and chemical industries. In addition to routine testing, M-Scan, as a specialised problem solving analytical consultancy, provides solutions to the most demanding problems in chemistry and biochemistry. In the Life Science field, M-Scan is expert in the structural characterisation of biomolecules (e.g. Proteins, Antibodies, Oligonucleotides) in compliance with the US FDA definition of a "well-characterised or specified" molecule and ICH Q6B Guidelines. M-Scan is GLP/cGMP certified. M-Scan laboratories are currently equipped with a range of 18 high performance mass spectrometers providing a full range of ionisation procedures.



Contact:
Kurt Leidner

Lindenplatz 1
D-85540 Haar
Phone: +49 (0) 89 4561-1130
Fax: +49 (0) 89 4561-1329
E-Mail: kurt_leidner@msd.de
Internet: www.msd.de

MSD SHARP & DOHME GMBH

PHARMA & CHEMICAL INDUSTRY

Keywords: Cardiovascular Diseases, Dermatology, Diabetics, Respiratory Diseases, Rheumatology, Ophthalmology, Oncology

MSD SHARP & DOHME GMBH is the German subsidiary of Merck & Co., Inc., a research-driven, worldwide acting pharmaceutical company based in the US, which develops, produces and distributes medicines and vaccines in different therapeutic fields. MSD wants to contribute to medical care in order to guarantee and improve access to urgently needed medicines worldwide. Thus, MSD supports numerous poor countries with donations of pharmaceuticals.

For more than 100 years MSD publishes the renowned "MSD-Manual", a standard publication for physicians and pharmacists (www.msd.de/msdmanual/). Medical knowledge and advice for the public is published in the "MSD-Manual Handbuch Gesundheit". MSD Germany has more than 1,200 employees. The company is situated in Haar near Munich.

MSOURCE Medical Development GmbH

CRO

Keywords: Cardiovascular Diseases, CNS, Infectious Diseases, Oncology, Clinical Research, Analysis, Monitoring

As a rapidly expanding ISO 9002 certified full-service CRO organization, MSOURCE has provided a range of clinical development and professional services to the pharmaceutical, biotechnology and medical device industries since 1994. Through a strong focus on client needs, our people, processes and continued emphasis on quality, MSOURCE has built services to address: Clinical Trial Management, Clinical Data Services, Clinical Contract Hire and Quality Assurance Consulting.



A member of TÜV SÜD Group.

Contact:
Christine Wurm

Rüdesheimerstr. 15/3
D-80686 München
Phone: +49 (0) 89 21019-10
Fax: +49 (0) 89 21019-150
E-Mail: cwurm@msource-cro.com
Internet: www.msource-cro.com

multimmune GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Clinical Diagnostics, Antibody, Cell Therapy, Vaccines, Oncology

multimmune is a biopharmaceutical company dedicated to the discovery and development of new products for the treatment of cancer. The company focuses on the development of drug candidates to treat heat shock protein 70 (Hsp70) positive tumors, as surface-bound Hsp70 is a tumor-specific marker expressed on about 50-75% of various cancer entities, e.g. lung, breast, colon, pancreas. Currently, four approaches are being explored to destroy cancer cells: (1) by extracorporeal activation of Natural Killer (NK) cells with a synthetic peptide (ready to go into phase II), (2) by using an antibody against Hsp70 (preclinical), (3) by direct infusion of an Hsp70 peptide (R&D), (4) by inducing tumor specific apoptosis with a serine protease (R&D).



Contact:
Dr. Claus Botzler

Arnulfstr. 197
D-80634 München
Phone: +49 (0) 89 4140-4298
Fax: +49 (0) 89 4140-4299
E-Mail: info@multimmune.de
Internet: www.multimmune.de

Nanion Technologies GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Nanobiotechnology, Devices

Nanion Technologies is a spin-off from the Center for Nanoscience (CeNS) of the Ludwig-Maximilians-University of Munich (LMU). Nanion combines bio- and microtechnology in a company serving the life sciences industry by offering products and services which will dramatically increase the speed and efficiency of the drug discovery process in an important segment of the pharmaceutical market. Nanion bases its business on a proprietary chip technology and will design and develop High Throughput Screening (HTS) systems for ion channel active drugs (ICADs). Ion channels are prime targets for innovative medicines aimed at many important diseases.



Contact:
Dr. Niels Fertig

Erzgiessereistr. 4
D-80335 München
Phone: +49 (0) 89 218997972
Fax: +49 (0) 89 218997960
E-Mail: info@nanion.de
Internet: www.nanion.de



Contact:
Philipp Baaske

Amalienstr. 54
D-80799 München
Phone: +49 (0) 89 21802833
Fax: +49 (0) 89 21802050
E-Mail: info@nanotemper.de
Internet: www.nanotemper.de

NanoTemper Technologies GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Nanobiotechnology, Proteininstabilität, Proteincharakterisierung, Peptide/Protein, Small Molecules

The NanoTemper Technologies GmbH provides services and instruments for the pharmaceutical and biotechnological industry and is also developing products for medical diagnostics. The NanoTemper® Technology "Micro Scale Thermophoresis" allows to probe the affinity, size, stability and conformation of drug candidates/biomolecules in close to real conditions: freely moving in aqueous solutions and especially in biological liquids like cell lysate or blood. For example the affinities of antibodies, aptamers, small molecules, proteins and oligonucleotides can be quantified, as well as the interactions of nanoparticles, microbeads or drug delivery systems with body fluids.



Contact:
Dr. Rainer Paffenholz

Weihenstephaner Str. 28
D-81673 München
Phone: +49 (0) 89 427299-4000
Fax: +49 (0) 89 427299-4010
E-Mail: munich@ndareg.com
Internet: www.ndareg.com

NDA Regulatory Service GmbH

CRO

Keywords: Regulatory Affairs, Pharmacovigilance, Drug Development

NDA is one of the leading Regulatory Affairs consultancies in Europe. With ~85 employees and offices in Sweden, UK and Germany, NDA has successfully provided Regulatory Support throughout Europe for over 10 years. NDA Regulatory Service GmbH in Munich was founded by a core group of regulatory experts from the European headquarter of an international pharmaceutical company. Our consultants are experienced professionals who offer expert knowledge and understanding of European regulations, guidelines and procedures. They are proficient in all regulatory activities associated with small molecules, biologicals and advanced therapies. We are dedicated to guide our clients smoothly through product development and registration in Europe.



Contact:
Dr. Thomas Rohrmeier

Josef-Engert-Str. 9
D-93053 Regensburg
Phone: +49 (0) 941 7853690
Fax: +49 (0) 941 7853699
E-Mail: info@neuroprofile.com
Internet: www.neuroprofile.com

NeuroProfile GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

NeuroProfile is committed to the discovery and development of novel therapeutics for the treatment of Central Nervous System (CNS) diseases. The main objective is the identification and commercialization of novel neuronal drug targets (disease-related genes or proteins) for the most important neurodegenerative diseases Alzheimer and Parkinson and for psychiatric disorders such as schizophrenia and depression. Our targets will be the basics for forthcoming drug generations with new mechanisms of action that not only ameliorate the disease symptoms, but potentially prevent or block progression of the disease. Several patent pending target candidates are run in preclinical validation projects.

NIGU Chemie GmbH

PHARMA & CHEMICAL INDUSTRY

Nigu offers a full range of high-purity guanidine salts for biotechnological applications, which meet the supreme quality standards set by the biopharmaceutical industry. The product group includes several grades of guanidine hydrochloride for separation and purification of recombinant proteins and antibodies.

Guanidine thiocyanate for nucleic acid based diagnostics is another integral part of the portfolio. A typical example is to provide guanidine-salts and recycling of used solutions as a complete package to the biopharmaceutical industry.



Contact:
Dr. Frank Fleischer

Beuthener Str. 2
D-84478 Waldkraiburg
Phone: +49 (0) 8638 962-0
Fax: +49 (0) 8638 962-287
E-Mail: info@nigu.de
Internet: www.nigu.de

NimbleGen Systems GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Clinical Diagnostics, Fine Chemicals / Reagents, Chip / Array Technology, Genomics

NimbleGen Systems, the leading supplier of flexible high-density microarray products and services, is enabling a new era of High- Definition Genomics (SM). NimbleGen uniquely produces high-density arrays of isothermal long oligos that provide superior results for advanced genomic analysis methods such as CGH, ChIP, microbial Comparative Genome Sequencing, and expression tiling. NimbleGen's High-Definition Genomics enables scientists to obtain and integrate complex genomic data sets not previously accessible, providing a much clearer understanding of genome structure and function, and how this relates to biology and medicine.

NimbleGen Systems GmbH is the wholly owned German subsidiary of Nimblegen Systems Inc and the chemistry arm of NimbleGen.



Contact:
Dr. Klaus-Peter Stengele

Beuthenerstr. 2
D-84478 Waldkraiburg
Phone: +49 (0) 8638 98420
Fax: +49 (0) 8638 984211
E-Mail: stengele@nimblegen.de
Internet: www.nimblegen.de

Novartis Consumer Health GmbH

PHARMA & CHEMICAL INDUSTRY

Novartis Consumer Health, located in Munich, merchandises and distributes OTC and prescription drugs for self-medication.



Contact:
Martin Bischof

Zielstattstr. 40
D-81379 München
Phone: +49 (0) 89 7877-0
Fax: +49 (0) 89 7877-250
E-Mail: communications.munich_de@novartis.com
Internet: www.novartis-consumerhealth.de

octapharma

For the safe and optimal use of human proteins

Contact:

Dr. Jana Gäbler

Am Klopferspitz 19/19a
D-82152 Martinsried
Phone: +49 (0) 89 700 769-60
Fax: +49 (0) 89 700 769-61
E-Mail: info-munich@octapharma.com
Internet:
www.octapharma-biopharmaceuticals.com

Octapharma Biopharmaceuticals GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Hematology, Drug Development, Peptide/Protein

Octapharma Biopharmaceuticals GmbH (foundation 1997) is a product-oriented R&D company with 37 employees located in Martinsried. The emphasis of our work is the development of recombinant pharmaceuticals as a modern alternative to plasma products. Our recombinant proteins produced in a human cell line show human-identical properties and improved tolerance in patients compared to hamster cell - derived products is expected. Our recombinant FVIII is already successfully running in Clinical Phase II in patients. Fresenius Kabi and Octapharma Group entered into an Exclusive License, Development and Supply Agreement to develop a HSylated recombinant protein. These combined technologies are intended to generate a therapeutic protein with superior product profile in respect of half-life prolongation - increased quality of life for the patient.

Omegametrix GmbH

Contact:

Adrian Passow

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 55063007
Fax: +49 (0) 89 55063008
E-Mail: info@omegametrix.eu
Internet: www.omegametrix.eu/

Omegametrix GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Prof. W.S. Harris, Sanford University - USA, and Prof. C. von Schacky, University of Munich, invented and defined the HS-Omega-3 Index in 2004. Then, in 2006 Schacky founded Omegametrix GmbH, as a Laboratory, to deal with the ever growing number of research projects, applications and samples. Initially proposed as a risk factor for sudden cardiac death, it now indicates cardiovascular risk as well. First studies have shown its association to life expectancy in general. Other applications, still in development, range from psychiatric diseases to pregnancy and lactation.



Contact:

Prof. Dr. Lutz Eichacker

Adelbergweg 14
D-82234 Wessling
Phone: +49 (0) 8153 908785-3
Fax: +49 (0) 8153 908785-4
E-Mail: info@omx-online.com
Internet: www.omx-online.com

OMX GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Proteomics, Peptide/Protein, Analysis, Devices

The OMX GmbH develops and markets innovative technology and offers mass spectrometry services in proteomics.

Products facilitate new work flows for laboratory routines to yield highest quality results.

The laboratory disposable OMX-S has been established to ease protein sample preparation from polyacrylamide gels. The all in one device OMX-S facilitates a four step protocol in an aqueous buffer to yield highest quality peptides in one hour. Peptides are ready for MALDI- or ESI- based mass spectrometry analysis. With OMX-MS, customers pick a single protein with OMX-S, and send the device by ordinary mail to OMX or to any laboratory to perform the sample preparation and mass spectrometry analysis.

OncoLead GmbH & Co. KG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Clinical Diagnostics, Tissue Engineering / Cell Culture, Cell Therapy, Oncology

OncoLead offers cellular screens designed to accelerate the decision making process for the development of anticancer drugs. Its information driven cell panel screen is to help scientists from all sectors to discover and develop novel and innovative anticancer medicines faster.

OncoLead GmbH & Co. KG

Contact:

Dr. Igor Ivanov

Fraunhoferstr. 20
D-82152 Martinsried
Phone: +49 (0) 89 38012215-0
Fax: +49 (0) 89 38012215-9
E-Mail: request4more@oncolead.com
Internet: www.oncolead.com

origenis GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Combinatorial Chemistry, Medicinal Chemistry, Automation, Combinatorics, Molecular Modelling, Small Molecules

origenis is a contract research organisation offering services in drug design, synthesis, and characterisation. origenis has implemented a novel drug design and discovery platform, MOREsystem® and MolMind®, based on a multi-disciplinary approach, which integrates state of the art

- molecular modelling ■ chemo-informatics ■ innovative chemistry
 - high throughput secondary screening
- into a seamless, fast and cost-effective process.

This interdisciplinary process is built to design and discover promising and novel target focussed compound series, with optimized properties for their pre-defined therapeutic use.

origenis

Contact:

Michael Almstetter

Am Klopferspitz 19a
D-82152 Martinsried
Phone: +49 (0) 89 7801676-0
Fax: +49 (0) 89 7801676-777
E-Mail: info@origenis.de
Internet: www.origenis.de

Orion Clinical Services GmbH

CRO

Keywords: Clinical Research, Monitoring, Medical Writing, Drug Development

ORION Clinical Services is a full-service clinical development organisation performing all aspects of clinical trials internationally. The company is a dynamic, proactive, multicultural CRO, offering a high quality, customised and flexible service. ORION's European operations are managed from offices in the United Kingdom, France and Germany, while North America is managed from the USA, and Australasia from Australia. These central hubs are augmented by regional staff – who are particularly important in providing coverage of central and Eastern Europe.

Founded in 1997, ORION Clinical Services has steadily built a reputation built on quality and reliability.



Contact:

Dr. Jörg Rennecke

Elsenheimerstr. 61
D-80667 München
Phone: +49 (0) 2241 97398 201
Fax: +49 (0) 2241 97398 200
E-Mail: Joerg.Rennecke@orioncro.com
Internet: www.orioncro.com



Contact:
Dr. Christine Unger

Cuvilliéstr. 14a
D-81679 München
Phone: +49 (0) 89 895218-0
Fax: +49 (0) 89 895218-50
E-Mail: christine.unger@os-europe.com
Internet: www.os-europe.com

OSE Oncology Services Europe S.a.r.l.

CRO

Keywords: Clinical Research, Pharmacology, Toxicology, Immune Therapy, Oncology, Cell Therapy, Gene Therapy

OSE is a full service CRO specialised in the field of Oncology. OSE can provide an organically grown international network of international investigator sites and opinion leaders.

From Phase I to Phase IV OSE offers a range of services to assist the pharmaceutical and biotech industries in executing their clinical studies.

Our services include: study planning, medical writing, patient and investigator recruitment, data management, biostatistics, site monitoring, in-house monitoring, project management, study reporting and much more.

OSE has clinical expertise with different drugs like: antibodies, antisense cytotoxics, hormones, radio-sensitizer, small molecules, proteins, vaccines and biologicals.



Contact:
Dr. Axel F. Wenzel

Kreillerstr 65
D-81673 München
Phone: +49 (0) 89 92 20 03-0
Fax: +49 (0) 89 92 20 03-90
E-Mail: office@p-ss-t.de
Internet: www.p-ss-t.de

P.SST Pharma Scientific Services Team

CRO

Keywords: Pharmacovigilance, Regulatory Affairs, Drug Development, Devices, Nutraceuticals, Antibiotics

P.SST is a small international consultancy and service provider for pharmaceutical and related industries. We accompany your drug / medical device development projects with advise and services in:

■ regulatory affairs (from Clinical trials to Marketing authorisation filings, strategies+services including e.g. eCTD, User testing for PILs) ■ drug dev. project management organisation+services, quality management ■ clinical dev. (incl. scientific writing, protocol development, EUDRACT filings, IMPD etc) ■ general services and consultancy ■ training and information provision
P.SST's range includes scientific services for all sections of pharmaceutical, medical and healthcare industry. For support in other countries we established partnerships with local CROs and consultant.



Contact:
Elvira Schecklies

Bürgermeister-Herzog-Str. 5
D-85241 Hebertshausen
Phone: +49 (0) 8131 20709
Fax: +49 (0) 8131 20709
E-Mail: pab.productions@web.de
Internet: www.pabproductions.de

pab productions GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Antibody Production Service

pab productions produces polyclonal antibodies in rabbits and chicken. Immunological test systems, are developed as customer service.

An innovative product line based on renewable resources has been invented

■ microtiterplates from polylactic acid (PLA) especially for peptide coating
■ an innovative immunostick-cuvette-system for ELISA (adhesive and covalent binding) from polyhydroxybutyrate (PHB) ■ adjuvant for immunostimulation from PHB and biomicroparticles for affinity chromatography.

PAKTIS Antibody Service GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Antibody Production Service, Xenotransplantation, Transgenic Animals, Agrobiotechnology

Paktis offers business development services, providing strategic consulting and active management support to diagnostic, material and life sciences companies. This includes business plan evaluation, due diligence services, interim management, corporate development as well as sales and marketing.

We support companies dealing with:

- Special TypiFix® ear tags for farm animals that allow easy and convenient taking of tissue samples for further analyses (Scrapie, Bovine Virus Diarrhea) or for identification of the meat's origin.
- One-step ultra-quick DNA-purification columns (Nexttec).
- Polyclonal antibody production using rabbits.
- Large scale production of industrial proteins with transgenic farm animals (sheep, cattle).



Contact:

Dr. Martin Riffeser

Lise-Meitner-Str. 30
D-85354 Freising
Phone: +49 (0) 8161 141-1160
Fax: +49 (0) 8161 141-1166
E-Mail: info@paktis.com
Internet: www.riffeser-online.de

Patrys GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Antibody, Infectious Diseases, Oncology

Patrys – the natural human antibody based company. Patrys Limited (ASX: PAB) is an Australian public company committed to the development of novel treatments for cancer and other diseases, including the commercialisation of a unique natural human antibody based therapies for the treatment of lung, pancreatic, gastric and colon cancers.

The company has the world-wide and exclusive rights to technologies that have been developed over 25 collective years of research and development and which uniquely allow for the capture, development and production of natural human antibodies for potential therapeutic applications. The technologies, and resulting deep product pipeline, have achieved positive results in animal studies in the treatment of human lung, pancreatic, gastric and colon cancers.

Patrys also currently benefits from the prior establishment of drug development collaborations with three large pharmaceutical companies.

In addition to its internal drug development projects and existing collaborations, the company has also acquired a substantial preferred equity holding in Acceptys, Inc., an American company developing the platform natural human antibody technology for the treatment of infectious diseases, including Hepatitis C, Hepatitis B, Pneumonia and Staph A.

Patrys' commercial strategy is to blend the internal development of lead product candidates while simultaneously benefiting from partnerships and collaborations aimed at developing additional product candidates from the company's deep product pipeline.



Contact:

Dr. Frank Hensel

Friedrich-Bergius-Ring 15
D-97076 Würzburg
Phone: +49 (0) 931 230795-0
Fax: +49 (0) 931 230795-19
E-Mail: info@patrys.com
Internet: www.patrys.com



International Research Organization

Contact:

Birgit Hennecke-Janzer

Landsberger Str. 408

D-81241 München

Phone: +49 (0) 89 9999-7733

Fax: +49 (0) 89 9999-7744

E-Mail: birgit.hennecke-janzer@pfc-cro.com

Internet: www.pfc-cro.com

PFC Deutschland GmbH

CRO

Keywords: Drug Development, Endocrinology, Oncology, Rheumatology, Clinical Research, Monitoring, Medical Writing

PFC Pharma Focus (1992) is a privately owned International Research Organization located in Switzerland (HQ), Germany, Israel and India. Our core competencies are

- Concept Development ■ Clinical Drug Development ■ International Project Management ■ Regulatory & Medical Affairs ■ Quality Assurance (QA) Services ■ Training

The combination of our service portfolio, our flexible & highly trained teams and our structured network enables the adaptation to the specific requirements of each project.



Contact:

Holger Stammer

Hermann-Schmid-Str. 10

D-80336 München

Phone: +49 (0) 89 544 637-0

Fax: +49 (0) 89 544 637-50

E-Mail: pharmalog@pharmalog.com

Internet: www.pharmalog.com

PHARMALOG Institut für klinische Forschung GmbH

CRO

Pharmalog acts as a European full service CRO with an excellent reputation in clinical trials Phase I - IV since 1983. Our staff of 50 colleagues (incl. central field based monitors) conducts clinical and non-interventional trials in Germany and all EU/EEU-countries, using our pool of 9,800 investigators in clinics/ practices. Special advantages: Fast patient recruitment, motivated investigators, local monitors are native speakers. We have performed about 300 clinical trials in all medical indications for medical products/-devices/biotechnology products according to ICH- and FDA-Standards for 50 nat./internat. pharmaceutical companies. We offer full service or modular approach (e.g. monitoring, data management/statistics), reasonable pricing due to short contact ways and low overhead costs.



Contact:

Dr. Peter Sonner

Ingolstädter Str. 20

D-80807 München

Phone: +49 (0) 89 375 0899-0

Fax: +49 (0) 89 375 0899-20

E-Mail: german.office@pharm-olam.com

Internet: www.pharm-olam.com

Pharm-Olam International Deutschland GmbH

CRO

Pharm-Olam International is a multi-national contract research organization offering a wide range of comprehensive, clinical research services to the pharmaceutical, biotechnology and medical device industries.

Our global network, including the emerging markets of Central Eastern Europe, Latin America, and India enables us to recruit patients on-time for even the most challenging studies. By accelerating enrolment, we reduce costs for our sponsors and take trials to the next Phase faster.

From pre-clinical to Phase IV, POI is focused on delivering the highest quality data, achieving targeted enrolment and meeting projected timelines.

Phytochem Referenzsubstanzen GbRmbH

BIOTECH DNA/PROTEIN ANALYTICS

Phytochem develops, produces and markets high purified substances for the pharmaceutical industry, research, analytics and authorities (main focus over 3,000 Natural Compounds). Phytochem synthesizes or isolates also Degradation products and Impurities in remedies or other rare drugs especially for customers needs with best equipment and experience. Lot specific testing is guaranteed. Phytochem products were used as Reference Standards for research and development: (Identity standard Data File: IDF) also for quality control as Primary Standards (Reference Substance Masterfile: RMF) and full documented Method Validation. Additional products and consulting services in the fields of Functional Foods, Dietary Supplements, Food Additives and Cosmetics are new focuses from Phytochem.



Contact:
Hans Rausch

Krumbacherstr. 9
D-89335 Ichenhausen
Phone: +49 (0) 731 97205-45
Fax: +49 (0) 731 97205-46
E-Mail: phytochem@t-online.de
Internet: www.phytochem-standards.de

Pieris AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Peptide/Protein, Drug Development

Pieris AG is a biopharmaceutical company engaged in the discovery and development of Anticalins® for the diagnosis and treatment of life-threatening human disorders. Exploiting extensive know-how in protein engineering as part of a broad intellectual property portfolio, the Company applies a balanced risk business model to the development of its Anticalin® candidates. Recognizing the enormous market potential of protein-based drugs, Pieris is committed to becoming an integrated drug discovery and development company.



Contact:
Rita Fischer

Lise-Meitner-Str. 30
D-85354 Freising/Weihenstephan
Phone: +49 (0) 8161 1411400
Fax: +49 (0) 8161 1411444
E-Mail: info@pieris-ag.com
Internet: www.pieris-ag.com

PIKA Weihenstephan GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Agrobiotechnology, New Materials, Analytical Chemistry, Analysis, PCR

PIKA Weihenstephan was founded in 2000 as a spin-off from the Technical University of Munich-Weihenstephan. Our focus is the fast detection and identification of microorganisms which may occur as spoilers during the production process of beer and beverages, but also in a diversity of other applications. Besides offering analyses for customers, PIKA Weihenstephan is producing and selling enrichment media and kits to be used for fast and specific process control. We are specialists in microbiology, both in conventional and in DNA analyses, especially PCR based methods. All processes at PIKA Weihenstephan are certified according to DIN EN ISO 9001:2008.



Contact:
Dr. Gudrun Vogeser

Hohenwarter Str. 100
D-85276 Pfaffenhofen
Phone: +49 (0) 8441 87948-30
Fax: +49 (0) 8441 87948-31
E-Mail: info@pika-weihenstephan.de
Internet: www.pika-weihenstephan.de



Contact:
Markus Fischer

St. Veit-Weg 2
D-93051 Regensburg
Phone: +49 (0) 941 94683-60
Fax: +49 (0) 941 94683-66
E-Mail: info@polyquant.com
Internet: www.polyquant.com

PolyQuant GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Clinical Research, Genomics, Proteomics

Based on an innovative platform technology for the absolute multiplex quantitation of proteins, PolyQuant offers cost-effective products and services for proteomics and pharma. The technology allows large-scale acquisition of protein levels, which can be leveraged in drug discovery and biomarker validation. The QconCAT technology is particularly well suited for the rapid development of protein assays, which typically takes 12 weeks and less. QconCAT-based reference standards for a wide range of topics, such as disease states or metabolic pathways, are in the pipeline or can be custom designed on request. PolyQuant offers a full protein analytical service from arbitrary samples such as cell extracts or blood serum. Alternatively, protein quantitation products are offered for the implementation of analytical workflows at the customer. A convenient license path exists for adaptation of PolyQuant technologies to large scale customer projects.



Contact:
Dr. Thorsten Klein

Max-Planck-Str. 14
D-86899 Landsberg a. L.
Phone: +49 (0) 8191 428181
Fax: +49 (0) 8191 428175
E-Mail: info@postnova.com
Internet: www.postnova.com

Postnova Analytics GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Devices

Postnova Analytics provides complete analytical solutions for the characterization of proteins, biopolymers, macromolecules and nanoparticles (1000 Da - 10E12 Da, 10 nm - 100 µm). Postnova's products are used by all major global companies and institutions in the field of biotechnology, pharma, polymer and environmental research, e.g. DOW, BASF, Roche, MIT, TUM. Postnova's product portfolio includes systems, supplies and services based on its proprietary patented FFF technology for protein-virus, aggregate characterization, polymer-rubber characterization, nanoparticle characterization and preparative micron particle separation. Postnova has two locations in Landsberg, Germany (headquarters) and Salt Lake City, Utah, USA.

Priaxon AG

PHARMA & CHEMICAL INDUSTRY

Keywords: Proteomics, Drug Development, Drug Delivery, Peptide/Protein, Small Molecules, Oncology

Priaxon is an emerging pharmaceutical company building a pipeline of novel drug candidates in different therapeutic fields, but mainly focusing on protein-protein interactions in oncology and other diseases. The goal is to discover and develop candidates for validated but hard-to-drug targets using two orthogonal drug discovery platforms. In January 2009 a collaboration agreement for the development of mdm2/p53-inhibitors with Boehringer Ingelheim was signed. We open up a new dimension in drug discovery by a unique combination of proprietary chemoinformatic tools with innovative synthetic chemistries. As a result Priaxon rationalizes and accelerates the whole drug discovery process.

Contact:
Dr. Christoph Burdack

Gmunder Str. 37-37a
D-81379 München
Phone: +49 (0) 89 4521308-0
Fax: +49 (0) 89 4521308-22
E-Mail: contact@priaxon.de
Internet: www.priaxon.com

PRIONICS DEUTSCHLAND GmbH

BIOTECH AGRO, FOOD, ENVIRONMENT

Keywords: Clinical Diagnostics, Agrobiotechnology, ELISA / EIA, Infectious Diseases

PRIONICS DEUTSCHLAND GmbH, founded in September 2005, is responsible for the marketing, sales and technical support of innovative tests for the early detection of important zoonotic diseases of production animals. The company provides its customers in Germany and Austria with a portfolio of more than 50 diagnostic kits, accessories and biochemicals.

PRIONICS DEUTSCHLAND offers diagnostic solutions for all major animal disease areas including TSE, BVDV, FMD, TB, ParaTB, CSF, Salmonella, Trichinella and Blue Tongue. The DNA sample collection products from forensiX round out its portfolio. The parent company Prionics AG, Switzerland, is one of the world's leading providers of farm animal diagnostics and a recognized centre of expertise in BSE and prion diseases.



Contact:
Esther Gleede

Am Klopferspitz 19
D-82152 Martinsried/München
Phone: +49 (0) 89 517 39 49-0
Fax: +49 (0) 89 517 39 49-9
E-Mail: info@prionics.de
Internet: www.prionics.de

probior GmbH

BIOTECH DEVICES & REAGENTS

probior distributes products for biotechnology, medicine and pharmacy. We carry a wide selection of high quality reagents and assay kits for High Throughput Screening manufactured by our Japanese partner Dojindo. We offer fast and convenient assay kits for protein labeling, DNA/RNA isolation, cell viability/cytotoxicity and oxidative stress. There are also high-purity reagents available e.g. for cell staining, NO research, diagnostic analysis, and also Self Assembled Monolayer, HPLC reagents, detergents, good's buffer.



Contact:
Dr. Christian Philipp

Ernsbergerstr. 5a
D-81241 München
Phone: +49 (0) 89 5800812-0
Fax: +49 (0) 89 5800812-2
E-Mail: info@probior.com
Internet: www.probior.com

Proteros biostructures GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: 3 D Structural Analysis, Fine Chemicals / Reagents, Small Molecules, Cardiovascular Diseases, Infectious Diseases, Metabolic Diseases, Oncology

Proteros biostructures GmbH is the global leader in X-ray protein structure analysis and structure guided drug design. Proteros collaborates worldwide with more than 60 renowned international life science companies.

Proteros' competitive advantage is the proven capability of producing high-resolution X-ray data and protein-ligand-complexes using its industrialized process and proprietary Free Mounting System™ (FMS™), unique Picodropper™ technology, and a large catalogue of Gallery Structures.

Proteros' Business Unit Screening & Proteins offers high quality, custom made proteins for drug discovery including assay development and screening. Furthermore, this business unit offers services for the detailed kinetic analysis of compound-target interactions.



Contact:
Dr. Torsten Neufeind

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 700761-0
Fax: +49 (0) 89 700761-15
E-Mail: business@proteros.com
Internet: www.proteros.com



Contact:
Dr. Gerhard Müller

Fraunhoferstr. 20
D-82152 Martinsried
Phone: +49 (0) 89 86466807-53
Fax: +49 (0) 89 86466807-69
E-Mail: business@proteros-fragments.com
Internet: www.proteros-fragments.com

Proteros fragments GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Medicinal Chemistry, Small Molecules, Molecular Modelling, 3 D Structural Analysis, Inflammation, Metabolic Diseases, Oncology

Proteros fragments GmbH is a service company specializing in Fragment-Based Lead Generation, addressing pre-clinical research leading towards new chemical entities. The conceptual combination of protein crystallography, a tailor-made compound library in conjunction with unique assay technologies and medicinal chemistry capabilities allows the company to generate novel lead structures for a variety of therapeutically relevant target proteins. Flexible business models, no royalty requirements, and the transfer of Intellectual Property to the customer renders the company an ideal partner of the Pharmaceutical and Biotech Industry in the area of small molecule drug discovery.



Contact:
Dr. Volker Schlüter

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 326051-66
Fax: +49 (0) 89 326051-67
E-Mail: info@qinlab.de
Internet: www.qinlab.de

QinLAB Diagnostik GbR

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Medicinal Chemistry, Automation, Diabetics, Hematology

QinLAB diagnostics was founded in January 2008 as Baier & Dr. Schlüter GbR Vertriebsgesellschaft Life Sciences. Vision of the new company is to establish high-quality in-house laboratory diagnostics in small hospitals, clinics and larger private medical centers (MVZs). An overall lab concept is built that includes the customers' wishes and needs and that result in innovative, economic and patient-friendly diagnostics on a high level. Besides the classical clinical chemistry and drugs-of-abuse assay systems Qinlab develops and offers innovative single test assays which are suitable for the point-of-care (POCT)-market.



Contact:
Dr. Bernhard Schirm

Am Klopferspitz 19a
D-82152 Martinsried
Phone: +49 (0) 89 700763 16
Fax: +49 (0) 89 700763 29
E-Mail: info@quattro-research.com
Internet: www.quattro-research.com

quattro research GmbH

BIOTECH BIOINFORMATICS

quattro research GmbH develops and markets software solutions for the management and analysis of chemical and biological data in drug discovery and development. quattro's suite of products contains solutions for registering new chemical substances, for managing biological assay data, for stock management particularly for research laboratories, and an electronic laboratory notebook. The efficiency of the quattro products is a result of the integrated Chemistry Engine, which facilitates work with chemical structures in all areas of the software package. The quattro's suite has been developed under realistic conditions, in close collaboration between quattro research's developer team and scientists in the laboratory. In addition to the quattro's suite, quattro research also offers its customers consultancy services and specific system solutions to manage chemical and biological data.

QUINTILES GmbH

CRO

Keywords: Monitoring, Medical Writing, Clinical Research

Quintiles' Product Development, Commercialization and Novaquest Development divisions help improve healthcare worldwide by providing a broad range of professional services, information and partnering solutions to the pharmaceutical, biotechnology and healthcare industries. Headquartered near Research Triangle Park, North Carolina, Quintiles has about 17,000 employees in offices in 50 countries and is the world's leading pharmaceutical services organization. For more information visit the company's Web site at www.quintiles.com.



Contact:
Stefan Schöffel

Mühlweg 2
D-82054 Sauerlach
Phone: +49 (0) 8104 8980 13
Fax: +49 (0) 8104 8980 99
E-Mail: stefan.schoeffel@quintiles.com
Internet: www.quintiles.de

QUINTILES Consulting

CRO

Quintiles is a leading international consultancy and CRO offering comprehensive services to the worldwide medical device industry. Our services include regulatory affairs, quality assurance, standards, pricing and reimbursement, authorized representation, clinical trial management, languages and labeling, etc. These services are provided by highly experienced, locally based consultants coming from competent authorities, notified bodies, European Commission, and the health care industry. They have academic qualifications in medicine, pharmacy, chemistry, law, engineering, languages, business management, etc. Many of the consultants are among the top EC experts on certain issues and have contributed to the development of the European directives and guidelines in such areas as vigilance, drug/device borderline issues, classification, and animal and human origin materials. Quintiles key strength is being able to understand the issues of small and start up companies, the needs of large multinational corporations, and to provide a customized approach to both. Quintiles offices are in B, D, F, I, S, UK and AUS. Quintiles is represented in 30 countries.

QUINTILES Consulting

Contact:
Dr. Konstantin von Martius

Zuccalistr. 19
D-80639 München
Phone: +49 (0) 89 1767 82
Fax: +49 (0) 89 1767 73
E-Mail: kvmartius@t-online.de
Internet: www.quintiles.com

R&D Biopharmaceuticals GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Natural Compounds, Small Molecules

R&D-Biopharmaceuticals is a biopharmaceutical company focusing on the pre-clinical and clinical development of unique small molecules deriving from natural products for diseases with unmet medical need. The Company has exclusive access to the natural product class of the Tubulysins discovered by Prof. Höfle and Prof. Reichenbach from the Gesellschaft für Biotechnologische Forschung in Braunschweig and to proprietary second generation Epothilones, a highly promising new drug class for the treatment of cancer. The Company is pursuing an active partnering strategy for further development of these compound classes. They are suited especially for conjugation and targeting approaches.



Contact:
Dr. Wolfgang Richter

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 70 07 64 90
Fax: +49 (0) 89 70 07 64 99
E-Mail: wolfgang.richter@rdbiopharma.de
Internet: www.rdbiopharma.de



Contact:
Dr. Karoline Meures

Ottostr. 3
D-80333 München
Phone: +49 (0) 89 20244497-0
Fax: +49 (0) 89 20244497-9
E-Mail: meures@radpharm.com
Internet: www.radpharm.com

RadPharm Europe GmbH

CRO

Keywords: Drug Development, Clinical Research, Oncology

RadPharm is an imaging core lab, managing the complete imaging segment of clinical trials for the global pharmaceutical, biotechnology and medical device industries. Our expertise spans Phase I through IV and all major therapeutic areas. We are specialized in oncology trials but also do cardiovascular, musculoskeletal, CNS and medical device studies. Our radiologists, nuclear physicians and medical oncologists interpret data from all major modalities, including CT, MRI, X-ray, SPECT, Ultrasound, PET and PET/CT in a centralized and independent way. We assist in planning, tracking and implementation of studies and provide medical expertise, regulatory know-how and validated technologies.



Contact:
Ulrike Haase

Ketteler-Str. 3-11
D-97222 Rimpar
Phone: +49 (0) 9365 8826-0
Fax: +49 (0) 9365 8826-99
E-Mail: info@rapidbiomed.de
Internet: www.rapidbiomed.de

RAPID Biomedical GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Clinical Research, Devices, Bone / Joint Diseases, Cardiovascular Diseases, CNS, Oncology

RAPID Biomedical GmbH is specialised in the development of probeheads for MRI and NMR spectroscopy. The company cooperates with research institutes, hospitals and MR system manufacturers worldwide. Our products include 1H MR coils for clinical studies at all magnetic field strengths and for all organs. We supply multi-nuclear MR-probeheads for combined MRI and MRS in clinical and basic science investigations. This development has been extended to a 7 T whole body scanner.

Our recent work concentrates on multi array coils for parallel MRI both for human as well as for animal studies.

Our sister company RAPID MR International, LLC (www.rapidmri.com), situated in Columbus, Ohio, is contact partner for customers from the United States, Canada and South America.

Whenever you need an optimised MRI coil for your application, please contact us and we will come up with a proposal.



Contact:
Dr. Albrecht Pfahler

Münchner Freiheit 18
D-80802 München
Phone: +49 (0) 89 33039921-0
Fax: +49 (0) 89 33039221-30
E-Mail: info@remark-pharma.de
Internet: www.remark-pharma.de

REMARK GmbH Pharmaservices & Consulting

CRO

Keywords: Drug Development, Clinical Research, Medical Writing

REMARK is a privately owned pharma services and consulting company founded in 1999. Quality and speed are the decisive factors in the success of a company involved in the healthcare market. To reach your goals our business unit Clinical Research offers the following services:

■ Strategic Consulting ■ Project Management ■ Quality Assurance ■ Pharmacovigilance Services ■ Training / Coaching ■ Medical Writing ■ Due Diligence
Together with our unit Pharma Marketing, REMARK bridges the gap between development and marketing.

For more information visit our web site at www.remark-pharma.com

Retro-Tech GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Infectious Diseases, Devices, Automation, Natural Compounds, Xenotransplantation, Small Molecules

Retro-Tech focuses on technology and product development based on magnetic beads (core technology) for diagnostics of retroviruses (HIV, HTLV, MLV, Hepatitis, other) and therapy of viral diseases (AIDS, Leukemia, Hepatitis, Autoimmune), with special focus on retroviral enzymes (reverse transcriptase, integrase), receptors (CD4, chemokine) and regulatory proteins. Services offered include Biosafety & Quality testing of bio-pharmaceuticals, organs, cell banks, blood products, antiviral drug screening by cellular and biochemical assays, toxicity testing, kinetic and inhibition studies on mechanism of action. The products currently offered are retroviral diagnostic kits, reagents & accessories, e.g. assay kits for reverse transcriptase (RTA), magnetic bead separation and handling devices.



Contact:

Dr. Ortwin Faff

Carl-von-Linde-Str. 40
D-85716 Unterschleißheim
Phone: +49 (0) 89 321419-60
Fax: +49 (0) 89 321419-59
E-Mail: info@retrotech-online.de
Internet: www.retrotech-online.de

Ridom GmbH

BIOTECH BIOINFORMATICS

Ridom supplies highly customized and therefore extremely user-friendly software for DNA sequence-based diagnostics.

The company was started in January 2003 by research scientists who still have close links to the University. Therefore, the company's motto is "from scientists for scientists". As a highly specialized company, which is owned by the founders, Ridom reacts flexible and fast to their customers needs. Major products are Ridom SeqSphere and Ridom StaphType.



Contact:

Jörg Rothgänger

Sedanstr. 27
D-97082 Würzburg
Phone: +49 (0) 931 4173329
Fax: +49 (0) 931 4173348
E-Mail: info@ridom.de
Internet: www.ridom.de

Ritter GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Devices, Automation, ELISA / EIA, Genomics, PCR, Pharmacogenetics, Proteomics

As a very productive brand-supplier, Ritter provides over 40 years of know-how in developing and producing fine high-precision plastic parts.

Ritter produces in accordance to the local quality standards only in own production plants. The company is DIN ISO 9001:2000 certified and works according the DIN EN ISO 13485:2003.

The 200 employees are engaged to provide packaging solution for construction chemicals (cartridges), laboratory and medical products (liquid handling systems), products for dialysis and robotic systems.



Contact:

Kerstin Lenke

Kaufbeurer Str. 55
D-86830 Schwabmünchen
Phone: +49 (0) 8232 5003-0
Fax: +49 (0) 8232 5003-10
E-Mail: info@ritter-online.de
Internet: www.ritter-medicalcare.de



Contact:

Barbara Jopp-Heins

Nonnenwald 2

D-82377 Penzberg

Phone: +49 (0) 8856 60-0

Fax: +49 (0) 8856 60-3896

E-Mail: barbara.jopp-heins@roche.com

Internet: www.roche.de

Roche Diagnostics GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Clinical Diagnostics, Automation, ELISA / EIA, PCR, Antibody, Peptide/Protein

Roche Diagnostics GmbH is part of Roche, Basel, Switzerland. Roche is one of the world's leading research-focused healthcare groups for pharmaceuticals and diagnostics and supplies products and services for the detection, prevention, diagnosis and treatment of disease. Roche is a world leader in in-vitro diagnostics, the leading supplier of medicines for cancer and transplantation and a market leader in virology. At Penzberg, Roche operates one of the largest biotechnology facilities in Europe. Diagnostics research develops innovative reagents and test systems for the life science market but also for diagnosis, patient stratification and therapy monitoring. Pharmaceutical research has broad experience in research, development and production of therapeutic human proteins and focuses on new protein projects.



Contact:

Dr. Roland Kreutzer

Fritz-Hornschnuh-Str. 9

D-95326 Kulmbach

Internet: www.roche-kulmbach.de

Roche Kulmbach GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Respiratory Diseases, Oncology, Metabolic Diseases, Inflammation, Antisense/Nucleotides, Drug Development

Roche Kulmbach GmbH is Roche's Center of Excellence for the discovery and development of a new class of therapeutics based on the principle of RNA interference (RNAi). RNAi is a natural process to selectively silence endogenous genes and is mediated by Small Interfering RNAs (siRNAs). Roche Kulmbach GmbH uses synthetic siRNAs to specifically silence disease-associated genes. This universal approach is applied to develop novel therapeutics for the treatment of oncological, respiratory and metabolic diseases.



Contact:

Iris Margraf

Fraunhoferstr. 15

D-82152 Martinsried

Phone: +49 (0) 89 8565 1800

Fax: +49 (0) 89 8565 1819

E-Mail: info@sciltechnology.com

Internet: www.sciltechnology.com

Scil Technology GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Drug Delivery, Peptide/Protein, Bone / Joint Diseases

Scil Technology develops products for bone and cartilage regeneration in dental and orthopaedic indications. Scil's products consist of growth-stimulating biomolecules (protein-based growth factors) and biomaterials being completely biodegradable and biocompatible. These innovative products are tailor-made to meet the specific requirements of each target indication and will be applied locally to induce or enhance tissue regeneration. In the dental field, Scil Technology develops products for dental bone augmentation, periodontal disease and dental implantology. Orthopaedic products are developed for spinal fusion, trauma, cartilage defects and osteoarthritis.

Sension GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Antibody, Autoimmune Diseases, ELISA / EIA, Clinical Diagnostics

Sension develops immunoassays and rapid test systems for on-site analysis. The tests find broad applications in the fields of food analysis, environmental analysis, medical diagnostics, reproductive management in agriculture, and in the monitoring of samples for mold.

Also technologies for label production to prevent products from counterfeiting are realized.

Sension is realizing own product developments, but also performs R&D developments for partners and customers and specifically focus on the specific needs required.



Contact:

Dr. Marcus Meyr

Am Mittleren Moos 48

D-86167 Augsburg

Phone: +49 (0) 821 455799-0

Fax: +49 (0) 821 455799-22

E-Mail: info@sension-gmbh.de

Internet: www.sension-gmbh.de

SequiServe GmbH

BIOTECH DNA/PROTEIN ANALYTICS

SequiServe offers the following custom services in molecular biology: DNA-sequencing (plasmids, PCR-products, BACs, PACs, primer-walking).



Contact:

Eva Metzger

Bahnhofstr. 30

D-85591 Vaterstetten

Phone: +49 (0) 8106 8887

Fax: +49 (0) 8106 301565

E-Mail: service@sequiserve.de

Internet: www.sequiserve.de

SERVIER Deutschland GmbH

PHARMA & CHEMICAL INDUSTRY

Keywords: Diabetics, CNS, Cardiovascular Diseases, Bone / Joint Diseases, Clinical Research, Drug Development

Following its international success, SERVIER Deutschland GmbH has established an independent branch in Munich since 1996. SERVIER is one of the very dynamic pharmaceutical companies in Germany, experiencing a growth-rate in double figures on average. The reason for this is not only the approved and merchandised drugs but also new, innovative products. The success of the new drugs is supported by the SERVIER Forschung und Pharma-Entwicklung GmbH (also in Munich), which manages many different projects throughout the German-speaking region.



Contact:

Horst Stemmer

Elsenheimer Str. 53

D-80687 München

Phone: +49 (0) 89 57095-01

Fax: +49 (0) 89 57095-126

E-Mail: info@de.netgrs.com

Internet: www.servier.de



Contact:
Dr. Udo Sticher

Eschenstr. 5
D-82024 Taufkirchen
Phone: +49 (0) 89 6513-1504
Fax: +49 (0) 89 6513-1399
E-Mail: udo.sticher@sial.com
Internet: www.sigma-aldrich.com

Sigma-Aldrich Chemie GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Genomics, Proteomics, CNS, Antibody, Small Molecules, Knock Out, PCR

Sigma-Aldrich is a leading Life Science and High Technology company. Our biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. We have customers in life science companies, university and government institutions, hospitals and in industry. Sigma-Aldrich operates in 36 countries and has over 7,600 employees providing excellent service worldwide.



Contact:
Dr. Franz Kerek

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 856625-55
Fax: +49 (0) 89 856625-56
E-Mail: kerek@sinatur.net
Internet: www.sinatur.net

SiNatur GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Diabetics, Metabolic Diseases

SiNatur owns the patent rights for the structure, preparation and medicinal applications Sub-Nano-Silicic Acid (SNSA). This recently discovered SNSA is the first biologically active form of silicic acid and of silicon generally. The substance is a potent inhibitor of P-type ATPases and of certain Protein-Phosphatases with IC₅₀ in the nanomolar range.

Due to the ubiquitous presence of Si in living organisms the discovery of the first biological active form of this element will have a broad scientific and practical impact.

SiNatur is developing medicinal applications of SNSA first of all in the therapy of diabetes and of gastric hyperacidity.



Contact:
Dr. Lars Behrend

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 7009619-99
Fax: +49 (0) 89 7009619-98
E-Mail: info@sirion-biotech.de
Internet: www.sirion-biotech.com

SIRION BIOTECH GmbH

BIOTECH DEVICES & REAGENTS

Keywords: RNAi & Antisense, Knock Out, Gene Transfer

SiNatur owns the patent rights for the structure, preparation and medicinal applications Sub-Nano-Silicic Acid (SNSA). This recently discovered SNSA is the first biologically active form of silicic acid and of silicon generally. The substance is a potent inhibitor of P-type ATPases and of certain Protein-Phosphatases with IC₅₀ in the nanomolar range.

Due to the ubiquitous presence of Si in living organisms the discovery of the first biological active form of this element will have a broad scientific and practical impact.

SiNatur is developing medicinal applications of SNSA first of all in the therapy of diabetes and of gastric hyperacidity.

Sloning BioTechnology GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Automation, Genomics, PCR, Proteomics

Sloning BioTechnology GmbH is a Biotech company in the vicinity of Munich, Germany, which has developed a novel way of synthesising double-stranded DNA molecules (gene constructs). Based on a library of standardised, double-stranded building blocks, gene constructs are synthesised on a fully automated robotic platform. Purely research driven in the past, the company has successfully entered the market in 2006 as a service provider of customised genes and high quality SlonoMax mutant libraries.

Sloning's mission is to industrialise the synthesis of artificial genes to unlock the huge potential of genome data for drug development and production applications.



Contact:
Dr. Heinz Schwer


Zeppelinstr. 4
D-82178 Puchheim
Phone: +49 (0) 89 809095-0
Fax: +49 (0) 89 809095-50
E-Mail: info@sloning.de
Internet: www.sloning.com

SMARTEC IngenieurBüro

MEDTECH

Keywords: Tissue Engineering / Cell Culture, PCR, Chip / Array Technology, Automation, Devices

Smartec IngenieurBüro is your competent partner for individual system approaches and instrument development in the biological laboratory. Smartec IngenieurBüro convinces with know-how within the ranges biotechnology, analytics, genetic engineering, micro technology as well as micro fluidic. Smartec IngenieurBüro solves tasks of instrumentation for molecular and immunological process engineering. Smartec IngenieurBüro supports you from the idea to all stages of the product. Smartec IngenieurBüro offers complete solutions, consisting of mechanics, optics, electronics, as well as firm- and software of a hand. Smartec IngenieurBüro consists of engineers and physicists which are predominantly settled in the ranges Research and Development (R&D) of bioanalytic systems.



Contact:
Dipl. Ing. Ulrich Schubert

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 854665-13
Fax: +49 (0) 89 854665-15
E-Mail: ulrichschubert@smartecbio.de
Internet: www.smartecbio.de

Spherotec GmbH

BIOTECH PRECLINICAL SERVICES

Keywords: Drug Development, Oncology, Tissue Engineering / Cell Culture

Spherotec is a biotech company using 3D cell-culture systems that have similar properties to micrometastases in cancer patients. On this basis, Spherotec offers pharmaceutical and biotech companies the opportunity to conduct functional tests of drug candidates for oncology in close to real conditions. This permits the early identification of promising substances and gives a broad profile of the effects of substances. The process also allows the definition of the kinds of tumors for which a substance or a combination of substances has the best clinical efficacy.



Contact:
Dr. Peter Frost

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 21908740
Fax: +49 (0) 89 70956263
E-Mail: pfrost@spherotec.com
Internet: www.spherotec.com



Contact:
Dr. Michael Sigmund


Landsberger Str. 23/25
D-82110 Germerring
Phone: +49 (0) 89 8006500
Fax: +49 (0) 89 800650555
E-Mail: michael.sigmund@cro-sss.eu
Internet: www.cro-sss.eu

SSS International Clinical Research GmbH

CRO

Keywords: Hematology, Cardiovascular Diseases, Oncology, Respiratory Diseases, Monitoring, Medical Writing, Clinical Research

SSS International Clinical Research provides cost-effective, high quality, comprehensive, and internationally integrated services to develop and commercialize the products of our clients throughout Europe in the pharmaceutical and biotechnology industries. From experienced project planning and clinical trials management to innovative web-based monitoring tools and expert consulting, our products and services have been proven for more than a decade and through many successful projects. From Phase II dose-finding studies to Phase IV post-marketing studies, and everything in between, we offer a broad range of therapeutic expertise to meet your clinical trial needs. We have the international experience and local presence to promote your success.



Contact:
Prof. Dr. Peter Buckel

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 30905068-0
Fax: +49 (0) 89 30905068-68
E-Mail: info@supremol.com
Internet: www.supremol.com

SuppreMol GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Autoimmune Diseases, Rheumatology, Drug Development, Antibody, Peptide/Protein

SuppreMol is developing Biological Medicines based on a new Therapeutic Principle with the potential to significantly improve the Quality of Life of Patients suffering from Autoimmune Diseases which affect more than 3% of the worldpopulation.

SuppreMol is promoting its lead product for the treatment of orphan drug indications bridging to block buster markets of Systemic Lupus Erythematosus and Rheumatoid Arthritis.

SuppreMol is a spin-off company out of the laboratory of Nobel laureate Robert Huber of the Max-Planck-Institute of Biochemistry in Martinsried, Germany, where the "proof of principle" of sFcR in animals has been shown.

Syntacoll GmbH

Contact:
Claudia Schlak

Donaustr. 24
D-93342 Saal/Donau
Phone: +49 (0) 9441 68600
Fax: +49 (0) 9441 686030
E-Mail: info@syntacoll.de
Internet: www.innocoll.de

Syntacoll GmbH

PHARMA & CHEMICAL INDUSTRY

Syntacoll is the manufacturing division of Innocoll, Inc. and produces clinical supply or commercial product to its marketing partners and to Innocoll's two other divisions, Innocoll Technologies and Innocoll Pharmaceuticals. Using proprietary manufacturing processes, Syntacoll converts raw collagen material and incorporates medicinal compounds yielding finished pharmaceutical product in the form of a sponge or membrane. This system forms the basis of Innocoll's lead collagen-based technology, CollaRx. The sponge or membrane product format is a unique way to locally deliver a wide variety of medicinal compounds and is fully biodegradable and resorbable. The sponge and the membrane formats can be implanted at the time of surgery or applied topically to a chronic, acute or traumatic wound. Delivering drug locally to the site of action has a number of benefits, including the safe delivery of higher doses than could be achieved through systemic routes and avoidance of systemic side effects.

TILL Photonics GmbH

BIOTECH DEVICES & REAGENTS

Keywords: Devices, Automation, Microscopy

TILL Photonics develops and markets opto-electronic instrumentation for fluorescence microscopy as used in fundamental research, applied science and diagnostics. The equipment, which is based on several patents for confocal and conventional fluorescence microscopes, is developed in collaboration with the Biolmaging Zentrum (BIZ) at the Ludwig-Maximilians-Universität in Munich. TILL Photonics also collaborates with several leading German research institutions. The majority of TILL's customers are found in the fields of neurobiology, cell biology, biomedicine and pharmacology.



Contact:
Marion Schädler

Lochhamer Schlag 21
D-82166 Gräfelfing
Phone: +49 (0) 89 89 56 62-0
Fax: +49 (0) 89 89 56 62-101
E-Mail: info@till-photonics.com
Internet: www.till-photonics.com

TopLab GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Proteomics, Analysis

TopLab GmbH was founded in 1994 by three scientists as a private spin off of the Max-Planck-Institute for Biochemistry in Martinsried and the Gene Center of the University of Munich. The leading idea for TopLab was to offer a technology platform with bioanalytical tools to the pharmaceutical industry and to public institutes as partner for outsourcing projects. TopLab is one of the leading companies in the field of proteomics, combining the extensive know-how of its experienced scientists with its highly specialised state of the art infrastructure. Services are offered to both public research institutes and to the pharmaceutical and biotechnology industry. In addition to absolute confidentiality, TopLab guarantees the highest possible analytical precision and reliability, no matter whether single analyses or big proteome projects are concerned. The contracts, which are customer-oriented and flexible, make it possible for all property rights that may arise during specific projects to remain with the customer.



Contact:
Dr. Elfriede Müller

Fraunhoferstr. 18a
D-82152 Martinsried
Phone: +49 (0) 89 856512-83
Fax: +49 (0) 89 856512-86
E-Mail: info@toplаб.de
Internet: www.toplab.de

TRION Pharma GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Antibody, Immune Therapy

TRION Pharma develops a new class of trifunctional antibodies (triomab®) for highly effective cancer treatments. Two state-of-the-art production plants allow cost-effective large-scale manufacture according to international GMP standards. The efficacy of the triomab® antibodies in terms of tumour elimination and induction of a polyclonal humoral and cellular anti-tumour immunity has been proven in animal models and in clinical trials. In spring 2009, Removab® (catumaxomab) received EU approval for the intraperitoneal treatment of malignant ascites in patients with EpCAM-positive carcinomas. It is marketed by TRION's partner Fresenius Biotech. Several Triomab® antibodies are currently under development.



Contact:
Brigitte Stempfer

Frankfurter Ring 193a
D-80807 München
Phone: +49 (0) 89 324 266-0
Fax: +49 (0) 89 324 266-199
E-Mail: mail@trionpharma.de
Internet: www.trionpharma.com



Contact:
Brigitte Stempfer

Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 700766 0
Fax: +49 (0) 89 700766 11
E-Mail: mail@trionresearch.de
Internet: www.trionresearch.com



Contact:
Dr. Ulrike Uhrig

Martin-Kollar-Str. 17
D-81829 München
Phone: +49 (0) 89 451030-0
Fax: +49 (0) 89 451030-30
E-Mail: ulrike.uhrig@certara.com
Internet: www.tripos.com



Contact:
Michaela Stein

Fraunhoferstr. 22
D-82152 Martinsried
Phone: +49 (0) 89 8103-9100
Fax: +49 (0) 89 8103-9199
E-Mail: information@u3pharma.com
Internet: www.u3pharma.com

TRION Research GmbH

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Drug Development, Antibody Production Service, Immune Therapy

TRION Research GmbH, founded in 1998, is a Biotech research company and a strategic partner of TRION Pharma GmbH focusing on the generation of novel Triomab® antibody candidates and the support of non-clinical and clinical development of Triomab® antibodies. The company offers Immunomonitoring Service, special antibody conjugation support, additional analytical service in tumor biology and further analytical support for reagent control to investigators, study sponsors and CROs.

The core competences of the company are:

- Immunomonitoring and logistical support for clinical and non-clinical studies
- Supply of purified antibodies (labeled and unlabeled)
- Development of immunological assays

Tripos International

BIOTECH BIOINFORMATICS

Keywords: 3 D Structural Analysis, Combinatorial Chemistry, Medicinal Chemistry, Molecular Modelling

Tripos International is a global leader in innovative scientific solutions that enable life science researchers to improve the efficiency of their molecular discovery efforts. Established in 1979, Tripos was the first company to bring scientific computational drug discovery capabilities to the pharmaceutical, chemical and food design industries, and today helps a broad range of companies and research facilities accelerate the identification and optimization of new compounds that have the potential to become new products in the drug, food, flavoring and fragrance markets. Headquartered in St. Louis, Missouri, Tripos International serves more than 1,000 customers spanning over 46 countries. Tripos is wholly owned by Vector Capital, a San Francisco-based private equity boutique.

U3 Pharma GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Antibody

U3 Pharma GmbH, based in Martinsried near Munich, Germany, is a leader in targeted cancer drug development. Established in July 2001, the company has produced a pipeline of novel targeted therapeutics based on the ground-breaking discoveries made by its founder - Professor Axel Ullrich. In May 2008, U3 Pharma was bought by DAIICHI SANKYO Co. Ltd., one of the top 20 leading pharmaceutical companies worldwide and No. 3 in Japan. Being part of this global environment, U3 Pharma is striving to provide patients around the world with innovative antibody-based therapeutics.

Vaecgene Biotech GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Clinical Diagnostics, Proteomics, Drug Development, Immune Therapy, Infectious Diseases, Oncology

Vaecgene focuses on the research and development of novel therapeutics and in vitro diagnostics. Core competence and proprietary technology are the development of viral vectors that helped Vaecgene to establish a broad portfolio including individual drugs for immunological treatment of tumors and infectious diseases. Recently, Vaecgene has developed a new intelligent technology, AMIDA, for functional proteomics for fast and efficient identification and validation of tumor markers for early detection of cancer. In addition, the company offers services related to Epstein-Barr Virus.

The company has also extensive experience in monitoring and quantitating the immune competence in patients and non-human primates.



Contact:
Dr. Reinhard Zeidler

Marchioninistr. 25
D-81377 München
Phone: +49 (0) 89 709 92 96
Fax: +49 (0) 89 709 92 25
E-Mail: info@vaecgene.de
Internet: www.vaecgene.de

vasopharm GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

vasopharm is a pharmaceutical company dedicated to the discovery and development of novel therapeutics for the treatment of cerebro- and cardiovascular diseases and their consequences. The company is focused on the development of therapeutics which permits steering the bioavailability of biological NO, covering the entire NO/cGMP signal cascade and its functional counterpart NOX. vasopharm's drug candidate VAS203 represents a completely new class of NOS modulators targeting cerebral vessels and cerebral tissue, thus preventing life threatening rises in intracranial pressure after a traumatic brain injury.

www.vasopharm.com



Contact:
Christian Wandersee

Friedrich-Bergius-Ring 15
D-97076 Würzburg
Phone: +49 (0) 931 359099-0
Fax: +49 (0) 931 359099-12
E-Mail: office@vasopharm.com
Internet: www.vasopharm.com

vermicon AG

BIOTECH AGRO, FOOD, ENVIRONMENT

vermicon AG offers solutions for microbiology. The company develops and markets products and services for the detection and analysis of microorganisms. Additionally the company offers microbiological consulting. Its approach is new and non-conventional. Our portfolio comprises: The products - our detection systems for industrial and private customers. The services - extensive analyses for microbiology. Microbiological consulting - the unique link between microbiology and consulting. The power of the technology portfolio combined with a strong and innovative team consisting of microbiologists and chemists allows us to explore completely new and exciting ways.



Contact:
Barbara Roderus

Emmy-Noether-Str. 2
D-80992 München
Phone: +49 (0) 89 1 58 82-0
Fax: +49 (0) 89 1 58 82-100
E-Mail: info@vermicon.com
Internet: www.vermicon.com



Contact:
PD Dr. Fritz Thümmler

Lise-Meitner-Str. 30
D-85354 Freising-Weihenstephan
Phone: +49 (0) 8161 1411211
Fax: +49 (0) 8161 1411212
E-Mail: info@vertis-biotech.com
Internet: www.vertis-biotech.com

vertis Biotechnologie AG

BIOTECH DNA/PROTEIN ANALYTICS

Keywords: Chip / Array Technology, Genomics, PCR, Analysis

VERTIS was established in 2000 as a spin off from Technical University Munich-Weihenstephan, Germany. The company offers highest quality and fast turn-around molecular biology services in the field of functional genomics. VERTIS has developed an innovative technology platform which significantly accelerates gene discovery projects.

VERTIS products and services can be broadly grouped into the following categories:

- cDNA synthesis ■ Full-length cDNA cloning ■ cDNA library construction
- Cloning and analysis of small non-coding RNA (sncRNA, the prototype of which is microRNA) ■ Profiling of gene expression using novel ultra high throughput MPSS DNA sequencing technology



Contact:
Christian Sacher

Sembdnerstr. 5
D-82110 Germerring
Phone: +49 (0) 89 800 777-60
Fax: +49 (0) 89 800 777-88
E-Mail: verum@verum.de
Internet: www.verum.de

VERUM.de GmbH

CRO

Keywords: Cardiovascular Diseases, Clinical Research, CNS, Dermatology, Diabetics, Oncology, Respiratory Diseases

VERUM is a CRO highly specialised in monitoring in Central and Eastern Europe, with experienced and well established monitoring units in the Czech Republic (since 1992), Hungary, Romania and in the Ukraine (all since 1996). VERUM also cover Slovakia and Kazakhstan. All 26 CRAs are highly educated (23 MDs), well trained and permanently employed. A long tradition combined with an excellent relationship to authorities and a broad experience from some 50 international projects guarantee the smooth conduct of a trial and high quality of the data. Client related key functions like reporting, contracting or invoicing as well as project and quality management are provided by the German head offices. The 40 Europe wide employees of VERUM have handled trials with up to 1200 patients per study. In addition to its core business, monitoring in CEE and performing of audits, VERUM offers a full CRO service to the client via an established network (PSN), including monitoring in Western Europe and all data management and statistics services.



Contact:
Dr. Ludwig Furtmayr

Behringstr. 11
D-82152 Planegg-Steinkirchen
Phone: +49 (0) 89 899336
Fax: +49 (0) 89 8599949
E-Mail: viramed@viramed.de
Internet: www.viramed.de

Viramed Biotech AG

BIOTECH DEVICES & REAGENTS

Keywords: Clinical Diagnostics, ELISA / EIA, Infectious Diseases

Based on 20 successful years on the German IVD-Market, Viramed Biotech AG produces and markets IVD-Products, based on its proprietary research and development. The company focuses on Westernblot-, Stripe- and Elisa-test kits for serological screening and confirmation of infectious and autoimmune diseases. The major products are Westernblot tests for Borrelia sp., Yersinia, Helicobacter p., Epstein-Barr-Virus, Bordetella pertussis, ENA and autoimmune liver diseases. New analytics based on purified and recombinant antigens are under development. The development of antigens and test kits for specific analytics are offered as service. The company aims to intensify export of existing products worldwide and appreciates further distribution contacts.

ViroLogik GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Infectious Diseases

ViroLogik develops innovative drugs for treatment of viral diseases with a focus on Hepatitis C, HIV and Influenza.

ViroLogik devised a novel strategy to overcome the formation of drug-resistance. The approach aims at the inhibition of highly conserved host cell factors mandatory for viral replication. This is in contrast to many current drugs that target fast changing viral proteins and, hence, are prone to formation of drug resistance. ViroLogik obtained a licence for a highly promising drug candidate and owns a broad panel of patents and patent applications. Comprehensive partnerships with leading research institutions, hospitals and pharmaceutical companies secure access to valuable expertise, networks and resources.



VIROLOGIK GmbH

Contact:

Karl Appelmann

Henkestr. 91

D-91052 Erlangen

Phone: +49 (0) 9131 974434-0

Fax: +49 (0) 9131 974434-43

E-Mail: info@virologik.com

Internet: www.virologik.de

vivoPharm Europe Ltd

CRO

Keywords: Metabolic Diseases, Drug Development, Bone / Joint Diseases, Oncology, Medical Writing, Pharmacology, Toxicology

vivoPharm is a contract research organisation (CRO) based in Australia. It offers integrated preclinical services to the biotechnology and pharmaceutical industries, which include in vitro and in vivo efficacy, safety, toxicology (GLP), pharmacodynamic and pharmacokinetic analyses.

The company's advanced animal facilities, laboratories and corporate headquarters are located in Adelaide, Australia. Its European office is based in Munich, Germany. vivoPharm works closely with its clients to develop a flexible experimental design to best serve each customer's individual needs.

vivoPharm operations are GLP compliant and meet the highest industrial standards, acknowledged by customers worldwide.



Contact:

Dr. Katja Wosikowski

Grillparzerstr. 25

D-81675 München

Phone: + 49 (0) 89 552797-590

Fax: + 49 (0) 89 552797-599

E-Mail: info@vivopharm.eu

Internet: www.vivoPharm.eu

Wacker Chemie AG

PHARMA & CHEMICAL INDUSTRY

Keywords: Antibody Production Service, Fine Chemicals / Reagents

WACKER is a globally active chemical company headquartered in Munich, Germany. With a wide range of state-of-the-art specialty products, WACKER is a leader in numerous industrial sectors. Its products are required in countless high-growth end-user sectors such as photovoltaics, electronics, pharmaceuticals and household/personal care products.

WACKER's operations are divided among following business divisions: WACKER SILICONES, WACKER POLYMERS, WACKER FINE CHEMICALS, WACKER POLYSILICON and SILTRONIC. The Group operates 22 production sites worldwide, supplying over 3,500 products to more than 3,500 customers in over 100 nations. The company is represented by subsidiaries and sales offices in over 28 countries across Europe, the Americas and Asia - including a strong foothold in China.



Contact:

Rachela Mohr

Hanns-Seidel-Platz 4

D-81737 München

Phone: +49 (0) 89 6279-0

Fax: +49 (0) 89 6279-1770

E-Mail: info@wacker.com

Internet: www.wacker.com



Contact:
Katja Arnold

Grillparzerstr. 10
D-81675 München
Phone: +49 (0) 89 41 31 38-0
Fax: +49 (0) 89 41 31 38-99
E-Mail: investors@wilex.com
Internet: www.wilex.com

Wilex AG

BIOTECH THERAPEUTICS & DIAGNOSTICS

Keywords: Drug Development, Antibody, Small Molecules, Oncology

WILEX AG is a publicly quoted (Frankfurt: Prime Standard) biopharmaceutical company based in Munich. Its focus is on developing drugs with a low side effect profile and targeted treatment of different types of cancer and diagnostic agents for specific detection of tumours. The antibody candidates REDECTANE® and RENCAREX® are undergoing Phase III registration trials. MESUPRON®, the first uPA-inhibitor worldwide in clinical development, is in Phase II trials in two indications. The MEK inhibitor WX-554 is in a Phase I trial, and a further four oncology projects are in preclinical development. WILEX aims within a few years to be able to finance its research and development programmes from its operating cash flow.



Contact:
Nicole Czesak

Deutschherrnstr. 15-19
D-90429 Nürnberg
Phone: +49 (0) 911 926800
Fax: +49 (0) 911 9268039
E-Mail: wn@winicker-norimed.de
Internet: www.winicker-norimed.de

Winicker Norimed GmbH

MEDIZINISCHE FORSCHUNG

Winicker Norimed, established in 1993, is a full service Contract Research Organization, located in Southern Germany in the center of Nuremberg. Our highly skilled personnel has many years of professional experience in clinical research and consists of physicians, life scientists, psychologists, statisticians and other specialists with medical background. Our reputation is based on professionalism, personal commitment and an efficient client-oriented cooperation. We deliver quality by exclusively working according to internationally accepted standards, Good Clinical Practice and by following our or our clients' Standard Operating Procedures. Winicker Norimed offers a full range of services in clinical research, from planning through reporting. We manage and conduct phase II-IV clinical trials, non-interventional trials, epidemiological studies and registers.



Contact:
Ilka Rother

Lärchenstr. 3-3a
D-82166 Gräfelfing
Phone: +49 (0) 89 89665425
Fax: +49 (0) 89 82084607
E-Mail: info@x-pert-med.de
Internet: www.x-pert-med.de

X-Pert Med GmbH

CRO

Keywords: Clinical Research

X-pert Med GmbH is a family owned CRO and SMO with its main offices in Munich, Germany and a subsidiary in Jena, Germany. We offer the following services:

CRO-Services related to the conduct and organization of clinical studies with a focus on services requiring an M.D. SMO-Conduct of clinical studies as an investigator (Phase I-IV) in Munich and Jena.

At present we cover the following treatment areas: General internal medicine, Diabetology, Endocrinology, Neurology, Psychiatry, Pain, Orthopedics, Surgery, Physical therapy and Rehabilitation, Cardiology, Dermatology and Urology.

Xvir Therapeutics GmbH

BIOTECH THERAPEUTICS & DIAGNOSTICS

Xvir Therapeutics GmbH was founded in 2004 and is focusing on the clinical development of novel cancer therapies for the treatment of various solid tumors, and in particular of drug-resistant or radiation-resistant tumors. Such cancer therapies are based on the use of oncolytic adenoviruses restoring drug sensitivity and radiation-sensitivity, respectively, of the tumors. Experimental evidence for the efficacy of Xvir's therapeutic approach has been provided in several animal studies. Xvir's therapeutic approach is covered by proprietary patents and patent applications, respectively.



Contact:

Dr. Per Sonne Holm

Sonnenstr. 8

D-80331 München

Phone: +49 (0) 89 99317446

Fax: +49 (0) 89 51556413

E-Mail: info@xvir.com

Internet: www.xvir.com

Zentrum für Humangenetik und Laboratoriumsmedizin Dr. Klein und Dr. Rost GbR

MEDTECH

Keywords: Pharmacogenetics, Oncology

Full range of quality genetic diagnostics for more than 200 diseases and the most comprehensive services in the diagnosis, prevention and management of hereditary disorders and birth defects affecting the fetus, the newborn, as well as children, adolescents and adults.

DNA- and RNA- based testing in molecular genetics (mutation scanning, genotyping), classic and molecular cytogenetics, immunogenetics (HLA high resolution typing, immunoprofiling), pharmacogenetics, molecular oncology and paternity testing.

Continuing development of new tests and implementation of state-of-the-art technologies such as array-CGH, microchips and single cell analyses.

The laboratory is accredited according to the international standards DIN EN ISO/IEC 17025 und DIN EN ISO 15189.

ZENTRUM FÜR HUMANGENETIK
UND LABORATORIUMSMEDIZIN
Dr. Klein und Dr. Rost



Contact:

Dr. Hanns-Georg Klein

Lochhamer Str. 29

D-82152 Martinsried

Phone: +49 (0) 89 895578-0

Fax: +49 (0) 89 895578-78

E-Mail: info@medizinische-genetik.de

Internet: www.medizinische-genetik.de



Contact:
Dr. med. Christine Günther

Max-Lebsche-Platz 30
D-81377 München
Phone: +49 (0) 89 7009608-0
Fax: +49 (0) 89 7009608-79
E-Mail: cg@apceth.com
Internet: www.apceth.com

Apceth GmbH & Co. KG

APPLIED CELL THERAPY

Keywords: Tissue Engineering / Cell Culture, Oncology, Cardiovascular Diseases, Gene Therapy, Cell Therapy, Gene Transfer

Apceth is dedicated to the development of innovative cell and gene therapies for the treatment of non-malignant and malignant diseases based on human stem cells in the context of the "advanced therapeutic medicinal product" (ATMP)-regulation. Apceth has established unique cultivation protocols for GMP-grade expansion of human mesenchymal stem cells intended for clinical use. Apceth will also provide services for the manufacturing and characterization of somatic cell therapies. The company was founded in 2007 by scientists and private investors and started to operate in 2009. Currently, Apceth employs 18 scientists and technicians. The facility is located very close to the Klinikum Grosshadern in Munich and the Biotech-Area. The production facilities include clean-room areas (B- and C-areas) and QC-laboratories for the GMP-grade production and characterization of the cell products as well as S2-laboratories for gene-therapy concepts.



Contact:
Dr. Andre Koltermann

Staffelseestraße 6
D-81477 München
Phone: +49 (0) 89 710661-0
Fax: +49 (0) 89 710661-122
E-Mail: info.crd@sud-chemie.com
Internet: www.sud-chemie.com

Süd-Chemie AG

CHEMICAL INDUSTRY AND INDUSTRIAL BIOTECHNOLOGY

Keywords: Industrial Biotechnology, Bio-Catalysis, Bio-Refining, Bio-Fuels, Second Generation Bio-Ethanol, Cellulosic Bio-Ethanol, Enzymatic Hydrolysis

Süd-Chemie is a global leading specialty chemicals company. The common denominator of all Süd-Chemie products is the efficient use of natural resources to enhance the quality of life for humans and the environment. Key markets served by its Adsorbents Division include the consumer goods, packaging and foundry industries, as well water treatment. Products manufactured by the Catalysts Division offer solutions for the chemical, petrochemical and refinery industries, for energy storage, hydrogen production and off-gas purification. The main focus of Süd-Chemie's industrial biotechnology activities is on bio-catalysis and bio-refining. The company develops energy-efficient processes for the manufacture of biomass-based chemicals and fuels. Süd-Chemie has for instance developed a process which uses enzymatic hydrolysis followed by fermentation to produce second generation cellulosic bio-ethanol from wheat straw or other agricultural production residue.



Contact:
Prof. Dr. Arne Skerra

Lise-Meitner-Straße 30
D-85354 Freising-Weihenstephan
Phone: +49 (0) 8161 53730-90
Fax: +49 (0) 8161 53730-99
E-Mail: info@xl-protein.com
Internet: www.xl-protein.com

XL-protein GmbH

BIOTECH THERAPEUTICS

Keywords: Peptide/Protein, Drug Development, Plasma Half-Life Extension

XL-protein is a biopharmaceutical company utilizing its proprietary 'PASylation' technology to develop second generation biopharmaceuticals with prolonged plasma half-life. PASylation of therapeutic proteins allows less frequent and lower dosing combined with better tolerability, also opening perspectives for follow-on products of approved biopharmaceuticals. 'PASylation' – the genetic fusion with conformationally disordered polypeptide sequences composed of the amino acids Pro, Ala, and Ser – provides a superior way to attach a solvated random chain with large hydrodynamic volume to a biologically active protein. Thus, its typically rapid clearance via kidney filtration can be retarded by one to two orders of magnitude while the PAS moiety is biochemically inert and easily degradable.

Your business contact to Bavaria

www.invest-in-bavaria.com

www.bayern-international.com

Biotech Incubators in Bavaria



The background of the image features a dark blue gradient with several lighter blue triangles overlaid. These triangles are oriented at various angles, creating a sense of depth and movement. Some triangles overlap, while others are positioned to reveal the darker blue areas behind them.

www.biotech-bavaria.de